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The expansion of blood vessel networks by angiogenesis is critical for matching blood 
supply to the metabolic demands of growing tissues. In adult tissues, blood vessels and the 
endothelial cells (ECs) that make them generally remain in a quiescent state. However, the 
reactivation of angiogenesis is a hallmark of a number of diseases including cancer and 
vision-threatening eye diseases. In the case of eye disease, angiogenesis results in abnormal 
vascular growth that damages the retina. This abnormal angiogenesis often occurs in 
response to retinal hypoxia that can arise as a result of excessive retinal vessel regression. 
Understanding the mechanisms by which blood vessels both grow and regress is therefore 
important for understanding how vascular diseases arise in the eye. In this thesis, I have used 
in vivo mouse models of normal and pathological angiogenesis in the retina to examine the 
molecular and cellular mechanisms that control blood vessel growth and regression.  
In the first part of my thesis, I investigated the role of the histone acetyltransferase 
HBO1 in retinal blood vessel growth. Through its histone acetyltransferase activity, HBO1 
promotes transcriptionally permissive chromatin and is necessary for cells to change their 
gene expression patterns, particularly during development. I found that HBO1 was required 
for the expression of genes and pathways that are upregulated by ECs undergoing 
angiogenesis. ECs lacking HBO1 failed to undergo directed migration during angiogenesis, 
resulting in reduced blood vessel production both in the normal retina and in a model of 
pathological retinal vessel growth.  
In the second part of this thesis, I examined the role of EC apoptosis in disease-
causing blood vessel regression using a model of ischaemic retinopathy. In this model, vessel 
regression associated with EC apoptosis results in retinal ischaemia, causing a hypoxic 
response that drives abnormal vessel growth similar to that seen in human eye diseases. I 
found that blocking EC apoptosis did not prevent vessel regression or the onset of retinal 
ischaemia. Nonetheless, it completely prevented the loss of ECs from ischaemic areas of the 
retina. These preserved ECs were capable of rapidly reassembling into a functional vessel 
network that reduced hypoxia and the subsequent pathological vascular response. Vessel 
reassembly was not impeded by neutralising VEGFA, suggesting that it is not dependent on 
high levels of VEGFA produced by the ischaemic retina. 
Overall, my studies provide new insight into the mechanisms of blood vessel growth 
and regression and may potentially open new therapeutic avenues for preventing abnormal 
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1 Literature Review 
Chapter 1: Literature Review 
1.1 Blood vascular system  
The blood vasculature is a tubular network that facilitates the circulation of blood, for the 
distribution of oxygen and nutrients to and removal of waste and metabolic by-products 
from almost all tissues in the body. This is achieved by a hierarchical and diverse network of 
blood vessels. This system comprises arteries that carry oxygenated blood from the heart and 
then branch into smaller arterioles that feed into capillary beds. The small diameter and low 
flow pressure in capillaries facilitate the efficient diffusion of oxygen into tissues. From there, 
capillaries empty into venules and then veins that carry oxygen-depleted blood back to the 
heart. This is reversed in the lung circulation, where pulmonary arteries carry oxygen-
depleted blood from the right heart to the lung and the pulmonary veins carry oxygenated 
blood from the lung to the left atrium. The lymphatic system is a parallel vascular system 
that plays a crucial role in tissue fluid homeostasis, lipid absorption and the immune system 
(Vaahtomeri et al., 2017). The focus of this thesis will be on the blood vascular system. All 
blood vessels are lined by endothelial cells (ECs) that are exposed to the vessel lumen and 
regulate the exchange of cells and molecules between the blood and tissues. ECs are a 
heterogeneous cell population with distinct molecular, phenotypic and morphological 
characteristics. These characteristics match the function of ECs to the specialised needs of 
the tissue in which they reside (Augustin & Koh, 2017, Potente & Makinen, 2017). A 
continuous, tight layer of endothelium with low permeability exists within arteries, veins and 
capillaries to maintain barrier function such as in the brain and retina.  In contrast, specialised 
capillary networks in tissues involved in filtration or absorption, such as the kidney glomeruli 
and intestine, are fenestrated to increase fluid and molecular exchange (Augustin & Koh, 
2017, Jourde-Chiche et al., 2019). Blood vessels are surrounded by perivascular mural cells 
that stabilise and support vascular function. Differences in mural cell coverage reflect vessel 
function. Large calibre vessels like arteries and veins have layers of vascular smooth muscle 
cells to maintain pressure and prevent vessel rupture, whereas low-pressure capillaries are 
covered with pericytes that regulate processes like permeability and vasodilation. For 
example the 1:1 ratio of pericytes to ECs in the central nervous system forms the tight, 
protective blood-brain barrier compared to the lower ratios found in other organs (Armulik 
et al., 2010, Daneman et al., 2010).  
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1.2 The development and growth of blood vessel networks  
The principle role of the blood vasculature is metabolic support for tissues. Blood vessel 
networks expand to meet the metabolic demands of rapidly growing or otherwise hypoxic 
tissues. The blood vasculature develops by two main processes: vasculogenesis and 
angiogenesis. 
 
1.2.1 Vasculogenesis gives rise to the first vessels 
The cardiovascular system is one of the earliest organ systems to form during embryogenesis 
and perturbations in its development results in early embryonic lethality (Carmeliet et al., 
1996, Gale et al., 2004). Blood vessel development begins shortly after gastrulation with the 
specification of blood vessel precursors from mesoderm that is positive for Flk1 (encoding 
VEGFR2), which is the major signalling receptor for vascular endothelial growth factor A 
(VEGFA) (Yamaguchi et al., 1993). VEGFA is a hypoxia-induced, potent stimulator of 
vessel growth. Flk1+ progenitors aggregate and differentiate into ECs to form the first 
vessels - the dorsal aortae, cardinal veins and yolk sac plexus that together with the heart 
make up the primitive circulatory system (Swift & Weinstein, 2009, Walls et al., 2008). This 
assembly of blood vessels in the absence of pre-existing vessels is defined as vasculogenesis. 
The crucial role of VEGFA signalling in vascular development is highlighted by loss of 
function mouse mutants. Flk1–/– embryos are embryonic lethal with failed vasculogenesis 
and blood island formation (Shalaby et al., 1997, Shalaby et al., 1995). In addition, loss of a 
single allele of Vegfa results in defects in vessel development and mid-gestation embryonic 
lethality (Carmeliet et al., 1996, Ferrara et al., 1996). While vasculogenesis is needed to 
establish the first vessels, it is quickly replaced by angiogenesis, which accelerates vessel 
expansion and continues as the predominant method of vessel network expansion through 
later development and postnatal life.  
 
1.2.2 Angiogenesis expands existing vessel networks 
Hypoxia is caused by the imbalance between oxygen supply and demand, which triggers the 
expansion of existing vessel networks in order to increase blood supply until balance is 
restored. The sprouting growth of new vessels from pre-existing vessels is termed 
angiogenesis and is dependent on the proliferation, migration and differentiation of ECs 
(Betz et al., 2016). This is the major mechanism for new vessel growth; although there are 
other mechanisms by which pre-existing vessels can expand vessel networks (e.g. 
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intussusception (De Spiegelaere et al., 2012)). Angiogenesis is a multi-step process that begins 
with the emergence of a nascent, blind-ended, non-perfused vessel sprout. These sprouts 
grow into the avascular, hypoxic tissue, eventually anastomosing with other vessel sprouts to 
establish continuous new vessels (Betz et al., 2016). The vessel network initially formed by 
angiogenesis is immature and uniform requiring extensive remodelling to establish a 
functional, hierarchical and highly efficient conduit for blood flow. Remodelling includes the 
selective pruning of inefficient vessel segments, changing vessel diameter, recruitment of 
perivascular support cells and stabilisation of endothelial junctions (Betz et al., 2016, 
Szymborska & Gerhardt, 2018).  
 
1.3 Angiogenesis in disease 
Physiologic hypoxia occurs as tissues grow or their metabolic needs change with 
development or maturation. As such, angiogenesis is uncommon in adults and is instead only 
found at sites of tissue turnover, such as female reproductive organs (Goede et al., 1998, 
Modlich et al., 1996). However, hypoxia can be due to pathological causes such as vessel 
blockages, leading to ischaemia, or tissue hypertrophy, such as in heart failure or cancer. The 
hardwired response of the vasculature to hypoxia drives expansion of the vascular network, 
which in some cases can lead to an abnormal angiogenic process, responsible for disease.   
 
1.3.1 Vessel growth during tumourigenesis 
As with the expansion of tissues in development, tumours must grow their vascular network 
to obtain sufficient blood supply. The tumour vasculature has been recognised as a potential 
therapeutic target for almost fifty years (Folkman, 1971) and anti-angiogenic therapies 
became plausible with the identification and sequencing of VEGFA (Ferrara & Henzel, 
1989). Monoclonal antibodies targeting human VEGFA were developed and were shown to 
decrease the growth of animal tumours and patient-derived xenografts (Borgstrom et al., 
1996, Kim et al., 1993, Warren et al., 1995), highlighting the central role of this cytokine in 
angiogenesis. The first human anti-VEGFA agent developed was bevacizumab (Hurwitz et 
al., 2004), which was approved by the U.S. Food and Drug Administration (FDA) in the 
treatment of cancer in 2004. Additional anti-VEGFA agents including suntinib and 
aflibercept have since been developed and approved for a number of cancers (Ferrara & 
Adamis, 2016, Raymond et al., 2011, Van Cutsem et al., 2012). Anti-VEGFA therapy has 
shown improvement in survival in patients in a range of cancer types, although cancer growth 
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is usually only delayed by a few months owing to both inherent and acquired resistance 
(Ferrara & Adamis, 2016). Systemic administration of anti-VEGFA agents also have class-
specific adverse effects including hypertension, thromboembolism and proteinuria that can 
limit their use (Jayson et al., 2016). 
 
1.3.2 Biphasic retinal vascular disease 
Vaso-proliferative eye diseases are a leading cause of vision loss across all age groups 
worldwide. These are characterised by aberrant blood vessel growth in various vascular beds 
that supply the eye and cause diseases including retinopathy of prematurity (ROP), 
proliferative diabetic retinopathy (PDR) and age-related macular degeneration (AMD), 
among others (Miller et al., 2013) (Figure 1.1). ROP and PDR are examples of biphasic retinal 
vascular diseases, that are characterised by abnormal growth of the retinal vasculature in 
response to retinal ischaemia (Miller et al., 2013). The first phase of disease involves a loss 
of vascular function that results in tissue hypoxia. This induces pro-angiogenic factors that 
then drive the second phase of the disease, which produces abnormal, vision-threatening 
vascular growth often referred to as neovascularisation (Figure 1.1 and Figure 1.2). The 
neovascular lesions grow abnormally on the surface of the retina and can grow into the 
vitreous body of the eye, where they can leak, causing the vision threatening aspects of these 
disease, namely vitreous haemorrhage, fibrosis and tractional retinal detachment 
(Campochiaro, 2015). 
 
ROP affects preterm babies born prior to the retinal vasculature being fully developed 
(Hartnett, 2015), due both to lack of exposure to growth cues provided in utero (Hellstrom 
et al., 2003) and by suppression of factors required for vessel growth (Claxton & Fruttiger, 
2003). At birth, the underdeveloped, avascular regions of the retina become hypoxic, leading 
to neovascularisation in response to upregulation of factors such as VEGFA and 
erythropoietin (Sato et al., 2009). Immature retinal vasculature is highly sensitive to oxygen 
levels and vessel loss induced-ROP also occurs in preterm babies given excessive 
supplemental oxygen (Hellstrom et al., 2013).  
 
PDR is the leading cause of blindness in working age people in industrialised nations. While 
not all diabetes patients develop diabetic retinopathy, all are at risk and PDR currently affects 
over 20 million people with diabetes worldwide (Lechner et al., 2017, Stitt et al., 2016). 
Hyperglycaemia can cause vascular dysfunction and capillary loss in the retina that manifests 
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as diabetic retinopathy. Widespread death of pericytes, ECs and smooth muscle cells from 
the retinal microvasculature contributes to progressive capillary dropout that causes areas of 
focal ischaemia (Gardiner et al., 1994, Mizutani et al., 1996). Over time, accumulating vessel 
damage and areas of ischaemia leads to upregulation of pro-angiogenic factors such as 
VEGFA and erythropoietin that eventually cause progression to the neovascular phase of 
disease (Aiello et al., 1995, Pierce et al., 1995, Watanabe et al., 2005).  
 
While AMD is not a biphasic retinal vascular disease, it is nonetheless caused by abnormal 
vessel growth in the eye and is the leading cause of blindness in developed countries (Wong 
et al., 2014). AMD has two forms, wet and dry AMD, with only the wet form being caused 
by abnormal vessel growth. While wet AMD is less common than the dry form, it is 
associated with a worse vision prognosis (Ambati & Fowler, 2012). Wet AMD does not 
usually involve retinal vessels, but is instead caused by abnormal growth of choroidal vessels 
that surround the eye and supply blood to the outer (photoreceptor) layer of the retina 
(Fritsche et al., 2014) (Figure 1.1).  
 
The treatment of these diseases aims to ablate neovascular lesions in order to reduce the risk 
of further vision loss. Pan-retinal photocoagulation has been the mainstay treatment against 
neovasculature for PDR and ROP for many years. While this treatment is generally effective, 
there are consequences to vision as it destroys part of the retina in an attempt to reduce its 
metabolic demand and hence, production of VEGFA (Stitt et al., 2016, Yang et al., 2010).  
Anti-VEGFA therapies have shown promise in promoting the regression of neovasculature 
that can preserve vision (Ferrara & Adamis, 2016, Gross et al., 2018, Mintz-Hittner et al., 
2011, Rosenfeld et al., 2006), however many patients show little or no response to both of 
these therapies (Ferrara & Adamis, 2016, Gross et al., 2018, Lepore et al., 2018). 
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1.4 Modelling retinal angiogenesis in development and disease 
Understanding how the growth of retinal vasculature is regulated has implications for health 
and disease as highlighted in the previous section. Many of the molecular and cellular 
mechanisms that regulate angiogenesis during development overlap with those responsible 
for vessel growth in pathological contexts (Lee et al., 2013, Raimondi et al., 2014, Selvam et 
al., 2018). Thus, understanding the regulation of both the developing retinal vasculature and 
neovascular retinal growth offers insights into potential new therapies. 
 
1.4.1 The neonatal mouse retina as a model for developmental angiogenesis 
The growing vasculature of the neonatal mouse retina is a widely used model for studying 
angiogenesis. The retina is a layered, sensory tissue responsible for detecting and decoding 
visual information that is relayed to the brain for processing (Hoon et al., 2014) (Figure 1.1). 
Photoreceptor cells in the outermost layer of the retina detect light and transmit this 
information to the brain via neurons in the inner layers of the retina. Retinal neurons are 
supported by three types of glial cells: Müller cells, astrocytes and microglia (Sorrentino et 
al., 2016). Müller cells span the full width of the retina, providing homeostatic and metabolic 
support to the neurons (Reichenbach & Bringmann, 2013). Astrocytes act as a scaffold for 
vessel growth and contribute to the blood-retinal barrier (Sorrentino et al., 2016), the 
protective retinal equivalent of the blood-brain barrier. Lastly, microglia are resident immune 
cells of the central nervous system that survey neural tissue, responding to damaging 
alterations in the microenvironment (Nimmerjahn et al., 2005, Sorrentino et al., 2016). 
 
The retinal vasculature is weaved into the retina itself, forming a network that surrounds and 
supplies the innermost neural layers (Selvam et al., 2018). Unlike in humans, the retinal 
vasculature in mice forms entirely after birth. Blood vessels enter the retina at the optic nerve 
and grow by radially expanding across the inner surface of the retina towards the periphery, 
forming the superficial vascular layer between postnatal day (P)0 and P8 (Figure 1.1). This 
process is driven by secreted growth factors, such as VEGFA, from a number of cell types 
including Müller cells, astrocytes, pigmented epithelial cells and ECs (Watkins et al., 2013). 
Around P7, perpendicular sprouts emerge from the superficial vascular layer and grow into 
the deeper layers of the retina, forming two additional layers of vasculature termed the 
intermediate and deep vascular layers. Formation of all three retinal vessel layers is completed 
by around P21(Stahl et al., 2010) (Figure 1.1).  




Figure 1.1. Retinal vascular development 
Above: Schematic showing the neural (brown), Müller glial (green) and photoreceptor 
(pink) cells with the three interweaving retinal vascular layers and choroidal vasculature 
alongside a corresponding histological cross-section through the retina. The direction of 
light to the retina is indicated by the black arrow. Image adapted from Vessey et al 2011 
(Vessey et al., 2011). Vessel beds affected in disease are highlighted on the right-hand side. 
PDR = proliferative diabetic retinopathy, ROP = retinopathy of prematurity, AMD = age-
related macular degeneration. 
Below: The mouse retina is avascular at birth (P0). During the first week of life vessels 
grow radially from the optic nerve head towards the edge of the retina. These vessels 
eventually sprout downwards to vascularise deeper layers of the retina and undergo 
remodelling to form the mature adult network. P1 image adapted from Stahl et al 2010 
(Stahl et al., 2010), adult image generated by Dr Emma Watson (Coultas laboratory). 
Images are not to scale. 
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1.4.2 Oxygen-induced retinopathy model of biphasic retinal vascular disease 
The oxygen-induced retinopathy (OIR) model was developed as an animal model of ROP 
(Smith et al., 1994). This model has been used extensively to study pathological vessel growth 
in the retina. In the first phase of this model, exposure of young pups to high oxygen for 
three to five days leads to the complete destruction of capillaries in the central retina. This 
process is referred to as ‘vaso-obliteration’ and occurs as a result of extensive EC apoptosis 
(Alon et al., 1995, Lobov et al., 2011). The second phase of the model is triggered by return 
to room air, which causes the now avascular central retina to become hypoxic due to the 
drop in oxygen tension (Chen et al., 2009). This triggers HIF1-dependent upregulation of 
VEGFA by the hypoxic retina (Bai et al., 2009, Ozaki et al., 1999). VEGFA induces the 
remaining retinal vessels at the periphery of the retina to undergo angiogenesis and 
revascularise the vaso-obliterated areas of the retina (Lange et al., 2009). However, this is a 
slow process and in addition to normal angiogenesis, the sustained high levels of VEGFA 
also lead to misdirected vessel grow from the superficial layer of the retina into the vitreous 
of the eye (Aiello et al., 1995, Bai et al., 2009, Fukushima et al., 2011) (Figure 1.2). This closely 
resembles the abnormal neovascular vessel growth that occurs in ROP, PDR and ROV 
(Smith et al., 1994) (Figure 1.2). While some diabetes mouse models replicate the early stages 
of vascular changes in diabetic retinopathy, such as vessel loss and basement membrane 
thickening, there are no diabetes mouse models that proceed to the subsequent neovascular 
phase (Forbes & Cooper, 2013). As such the OIR model is commonly used to model the 
neovascular phase of PDR. 
 
In addition to the vascular pathology, the OIR model recapitulates some of the neural retina 
complications that occur in diabetes patients, including vision defects (Dorfman et al., 2008, 
Mehdi et al., 2014, Vessey et al., 2011) and retinal inflammation that involves Müller cell 
activation – also termed “gliosis” (Mizutani et al., 1998, Vessey et al., 2011). 
 
  Mechanisms of angiogenesis in development & disease 
 11 
 
Figure 1.2. Oxygen-induced retinopathy model of biphasic retinal vascular 
disease 
P7 pups are exposed to a high oxygen environment (75%) resulting in loss of central retina 
capillaries (vaso-obliteration) within the first 48 h of high oxygen exposure. Following 
three to five days in high oxygen, pups are returned to room air where the central retina 
becomes hypoxic, driving the expression of pro-angiogenic factors that induce abnormal 
neovascularisation. Neovascularisation peaks five days after return to room air, after which 
it spontaneously resolves. Below each mouse retina image is a corresponding optical 
tomography angiography image showing blood vessel perfusion from the relevant stage 
healthy or diabetic patient. Healthy individual image adapted from Ishibazawa et al 2015 
(Ishibazawa et al., 2015) and diabetic retinopathy images adapted from Sorour et al 2018 
(Sorour et al., 2018). Green arrows indicate avascular macular, orange arrows indicate areas 
of vaso-obliteration (mouse)/vessel non-perfusion (human), blue arrow indicates 
neovascular lesions (mouse and human). Images are not to scale. 
 
  
  Mechanisms of angiogenesis in development & disease 
 12 
1.5 Angiogenic vessel growth is dependent on transcriptional regulation 
Angiogenesis is a highly coordinated, multi-step process. During angiogenesis, the 
endothelium becomes activated to form a nascent vessel sprout that extends and grows into 
avascular tissue. Once grown, vessel sprouts anastomose with each other and form a 
continuous vessel lumen to ensure blood distribution to the tissue (Betz et al., 2016). These 
processes are directed by diverse growth factor inputs that enable ECs to adapt the 
expression of genes necessary to carry out these functions. All of the steps of vessel growth 
are coordinated by two distinct EC subtypes that are formed by the activated endothelium: 
“tip” cells and “stalk” cells, that have distinct functions and gene expression patterns.  
 
1.5.1 Generation of endothelial diversity during sprouting angiogenesis 
Pro-angiogenic signals stimulate the quiescent endothelium to differentiate into two distinct 
EC types that carry out the critical cellular responses essential for new sprout formation 
(Gerhardt et al., 2003, Geudens & Gerhardt, 2011). These cell types are termed “tip” cells 
and “stalk” cells because of their location in the growing sprout. Tip cells are located at the 
front end of the growing sprout and are characterised by extensive filopodia that sense the 
external environment, promoting directed migration of the growing sprout towards 
angiogenic signals (Gerhardt et al., 2003). Stalk cells, located behind the tip cells, make up 
the body of the sprout. These ECs proliferate and supply new ECs to the growing vessel 
(Gerhardt et al., 2003). In addition to their morphological and functional differences, tip and 
stalk cells have differential gene expression patterns, indicating they are distinct EC subtypes 
(del Toro et al., 2010, Strasser et al., 2010). As discussed later, tip and stalk cells can switch 
identities, indicating that their gene expression profiles are dynamic. 
 
1.5.2 Pathways governing endothelial tip and stalk cell identity  
VEGFA gradients are required for induction of tip cells during sprouting angiogenesis 
(Gerhardt et al., 2003). This begins the chain of events that specify tip and stalk cell identity. 
VEGFA is a potent activator of angiogenic growth (Karaman et al., 2018). In mammals, the 
VEGF family of proteins comprises VEGFA, VEGFB, VEGFC, VEGFD and placental 
growth factor (Achen et al., 1998, Joukov et al., 1996, Leung et al., 1989, Maglione et al., 
1991, Olofsson et al., 1996). VEGFA is alternatively spliced into four major isoforms in 
humans, which differ in their affinities for co-receptors and extracellular glycoproteins 
(Houck et al., 1992, Woolard et al., 2009). This gives rise to soluble or matrix-bound forms 
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that help establish chemical gradients important for directed cell migration and vessel 
sprouting (Karaman et al., 2018). VEGF proteins mediate their actions through high affinity 
covalent binding to tyrosine kinase receptors (VEGFRs) (Simons et al., 2016) (Figure 1.3). 
These are VEGFR1 (also called FLT1) (Shibuya et al., 1990), VEGFR2 (FLK1) (Terman et 
al., 1991) and VEGFR3 (FLT4) (Pajusola et al., 1992). VEGF binding stabilises VEGFR 
dimerisation inducing trans-phosphorylation of the intracellular domain, which recruits 
signalling adapter proteins (Claesson-Welsh, 2016). Structural homology between VEGFRs 
allows formation of both hetero and homodimers (Huang et al., 2001). Differential signalling 
outcomes from VEGFR activation arises from phosphorylation of different tyrosine residues 
and the recruitment of distinct adapter proteins (Claesson-Welsh, 2016, Matsumoto et al., 
2005, Takahashi et al., 2001). VEGFR signalling also requires the activation of neuropilin 
family co-receptors (NRP1 and NRP2) and heparan sulphate proteoglycans. These co-
receptors are able to modulate the activity of VEGFRs (Simons et al., 2016).  
 
Although VEGFA has higher affinity for VEGFR1 than VEGFR2, the weak kinase activity 
of VEGFR1 limits its role in VEGFA signalling (Karaman et al., 2018). VEGFR1 is instead 
considered a negative regulator of VEGFA signalling as it limits the amount of free VEGFA 
available to bind VEGFR2 (Simons et al., 2016). Vegfr1–/– mice are embryonic lethal at 
embryonic day (E) 8.5-9 with excessive and disorganised vasculature (Fong et al., 1995), 
supporting the role of VEGFR1 in sequestering VEGFA. A splice variant of Vegfr1 gives 
rise to a soluble form consisting of only the extracellular domain further sequestering 
VEGFA to regulate its signalling (Kendall & Thomas, 1993). 
 
VEGFA activity helps specify tip and stalk cell identity by regulating Notch signalling 
(Blanco & Gerhardt, 2013). The endothelial Notch pathway comprises four receptors, 
NOTCH1 - NOTCH4 (Ellisen et al., 1991, Lardelli et al., 1994, Uyttendaele et al., 1996, 
Weinmaster et al., 1992), and four ligands, Jagged1 (JAG1) (Lindsell et al., 1995), JAG2 
(Shawber et al., 1996), Delta-like ligand 1 (DLL1) and DLL4 (Rao et al., 2000, Shutter et al., 
2000). As both Notch receptors and ligands are membrane bound, signalling occurs in trans 
between neighbouring cells. Notch activation suppresses tip cell identity. Tip cells have high 
levels of VEGFR2 and its activation leads to upregulation of DLL4 expression (Gerhardt et 
al., 2003, Liu et al., 2003, Lobov et al., 2007). Elevated DLL4 levels in tip cells activates 
Notch signalling in neighbouring ECs, negatively regulating tip cell fate through lateral 
inhibition (Hellstrom et al., 2007, Suchting et al., 2007) (Figure 1.3). Activation of a Notch 
  Mechanisms of angiogenesis in development & disease 
 14 
receptor by its ligand induces gamma-secretase dependent cleavage of the Notch intracellular 
domain (NICD) from the cell membrane, which then translocates to the nucleus. Once 
inside the nucleus, NICD directly interacts with the transcription factor RBPJ to promote 
transcription of Notch target genes including HES and HEY (Fischer et al., 2004, Taylor et 
al., 2002). Notch signalling in stalk cells autonomously promotes stalk cell fate by 
upregulating the decoy receptor VEGFR1 and downregulating the pro-angiogenic receptors 
VEGFR2 and NRP1, making them less receptive to VEGFA and thus less likely to take the 
tip cell position (Aspalter et al., 2015, Chappell et al., 2009, Harrington et al., 2008, Larrivee 
et al., 2012, Moya et al., 2012) (Figure 1.3). The importance of DLL4/Notch signalling in 
specifying stalk cell identity is evident by genetic Notch loss or gain of function mutations. 
ECs with a deletion of Notch1 are more likely to adopt a tip cell position, as they are unable 
to activate Notch signalling to promote stalk cell fate (Hellstrom et al., 2007). 
Pharmacological inhibition of DLL4 or loss of a single allele of Dll4 results in a 
hypersprouting retina phenotype as tip cells are unable to laterally inhibit neighbouring ECs 
to prevent expansion of tip cells (Hellstrom et al., 2007, Suchting et al., 2007). 
Hypersprouting in these retinas results in non-productive vessel growth. Conversely, 
overactivation of Notch signalling by preventing NICD degradation or deletion of the Notch 
regulator NRARP results in less vessel sprouting and growth (Izumi et al., 2012, Phng et al., 
2009). Thus, VEGFA-DLL4-Notch signalling is fine-tuned in multiple ways to facilitate the 
dynamic process of sprouting angiogenesis (Benedito et al., 2009, Harrington et al., 2008, 
Lamar et al., 2001). 
 
The transforming growth factor beta (TGF)/bone morphogenetic protein (BMP) signalling 
pathway cooperates with Notch signalling to specify stalk cell identity (Larrivee et al., 2012). 
In ECs, the activin receptor-like kinase (ALK) 1 and ALK5 receptors are activated by their 
respective ligands BMP9/10 (David et al., 2007) and TGF (Castanares et al., 2007), which 
are present in the vasculature and are able to interact with stalk cells after formation of a 
nascent lumen. Transcription is regulated downstream of ALK1/5 signalling by differentially 
phosphorylating receptor-activated (R-) SMAD proteins. ALK1 signalling activates 
SMAD1/5/8, whereas ALK5 signalling leads to SMAD2/3 activation (Goumans et al., 
2002). R-SMADs bind to the common mediator SMAD4 and translocate to the nucleus to 
promote a stalk cell gene expression program. They regulate stalk cell gene expression both 
through direct and indirect ways by cross-talk with Notch and activating HES/HEY 
(Larrivee et al., 2012, Moya et al., 2012) (Figure 1.3). While it appears that tip cells are formed 
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by default in the absence of these previously described pathways, there is evidence to suggest 
that stalk cell identity is actively suppressed in tip cells through inhibition of phosphorylated-
SMAD signalling by NRP1 (Aspalter et al., 2015) (Figure 1.3). In the absence of NRP1 ECs 
fail to repress stalk cell fate and fewer tip cells are formed. This role for NRP1 is independent 
from its role as a VEGF co-receptor (Fantin et al., 2015). In stalk cells, Notch signalling 
downregulates NRP1 in order to maintain the balance of tip cells (Aspalter et al., 2015). 
 
Angiopoeitin (ANG)/TIE signalling is an additional regulator of angiogenic vessel growth. 
This comprises the ligands ANG1 and ANG2, which activate the receptor TIE2 (Saharinen 
et al., 2017). ANG1 promotes endothelial stability and quiescence through TIE2 signalling 
(Daly et al., 2004). ANG2 is a context dependent agonist and antagonist of TIE2 signalling 
associated with vessel destabilisation (Saharinen et al., 2017). During retina angiogenesis, 
ANG2 is exclusively expressed by tip cells (del Toro et al., 2010), where it competes with 
ANG1 in binding to TIE2, destabilising the endothelium (Saharinen et al., 2008). The orphan 
receptor TIE1 also exerts a level of control over this pathway by modulating the abundance 
of TIE2 on ECs. TIE1 is highly expressed by tip cells, where it negatively regulates TIE2 
surface presentation (Savant et al., 2015). In the absence of TIE2, such as occurs in tip cells, 
ANG2 instead preferentially binds integrins to promote EC migration and sprouting growth 
by destabilising VE-cadherin adherens junctions (Felcht et al., 2012, Hakanpaa et al., 2015) 
(Figure 1.3). 
 
Tip cells bear resemblance to axonal growth cones that are responsible for axon guidance 
(Adams & Eichmann, 2010). Not only do tip cells resemble axon growth cones 
morphologically, but many of the signalling pathways that direct axon guidance also regulate 
normal sprouting angiogenesis, including SLIT/ROBO (Park et al., 2003, Rama et al., 2015), 
ephrin/Eph receptor (Wang et al., 2010b), netrin/UNC (Larrivee et al., 2007, Lu et al., 2004) 
and semaphorin/plexin/neuropilin signalling (Kim et al., 2011, Zygmunt et al., 2011). This 
highlights that there are numerous signalling pathways that feed in to exquisitely regulate 
sprouting angiogenesis. 
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Figure 1.3. Signalling pathways that specify tip and stalk cell identity 
VEGFA activates VEGFR2 signalling in tip cells and promotes their migratory behaviour 
by destabilising VE-cadherin junctions and promoting nuclear localisation of YAP/TAZ 
that further regulates VE-cadherin turnover. Hypoxia triggers the activation of MST1 to 
induce FOXO1 nuclear localisation that leads to expression of ANG2. ANG2 binds 
integrins on tip cells that also triggers VE-cadherin junction destabilisation. DLL4 is 
upregulated on tip cells by VEGFR2, which activates Notch receptors on neighbouring 
stalk cells. Notch signalling, together with TGF/BMP/ALK signalling promotes stalk cell 
identity via RBPJ and SMAD transcriptional regulation. NRP1 on tip cells inhibits 
phosphorylated-SMAD signalling to prevent stalk cell identity.  
 
1.5.3 Transcription factor regulation of tip/stalk activity and sprouting angiogenesis 
Establishment of the endothelial lineage from mesodermal progenitors during development 
is regulated by transcription factors. Mesodermal progenitor cells differentiate either directly 
into angioblasts by expression of FOXC transcription factors in conjunction with ETS 
transcription factor family member ETV2 (De Val et al., 2008), or via the haemangioblast, 
the common precursor cell to both haematopoietic and endothelial lineages, by expression 
of TAL1, GATA2 and ETV2 transcription factors (Lee et al., 2008, Lugus et al., 2007, 
Robertson et al., 2000).  
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Specification of distinct EC identity also requires the actions of transcription factors. In 
addition to the actions of Notch/RBPJ and BMP/SMAD signalling that have already been 
discussed, several other transcription factors have important roles in regulating tip/stalk 
specification and activity. Hypoxia produces reactive oxygen species in tip cells that activate 
the MST1 kinase to promote nuclear import of the transcription factor FOXO1 and the 
expression of vessel destabilising genes including Angpt2 which encodes ANG2 (Kim et al., 
2019) (Figure 1.3). In quiescent ECs, ANG1/TIE2 signalling leads to phosphorylation of 
FOXO1 that prevents nuclear localisation of FOXO1, thereby preventing its regulation of 
vessel destabilising ANG2 (Daly et al., 2004). Angpt2 is also regulated by the transcriptional-
coactivator YAP (Choi et al., 2015, Wang et al., 2017b) and ANG2 protein is reduced in 
retinal ECs lacking both YAP and the related transcription factor TAZ (Kim et al., 2017). 
VEGFR2 activation leads to dephosphorylation of YAP and TAZ, which promotes their 
translocation into the nucleus and upregulation of cytoskeleton remodelling genes to 
facilitate cell movement and sprouting angiogenesis (Wang et al., 2017b) (Figure 1.3). Loss 
of both YAP and TAZ from the endothelium reduces vessel growth and results in fewer and 
malformed vessel sprouts (Wang et al., 2017b). YAP and TAZ also regulate junction stability, 
promoting VE-cadherin turnover that permits EC migration (Neto et al., 2018) (Figure 1.3). 
Destabilisation of junctions also promotes YAP nuclear import further regulating this 
process (Choi et al., 2015, Giampietro et al., 2015).  
 
A role for the transcription factor MAFB during sprouting angiogenesis was uncovered by a 
time-course RNA-sequencing experiment on retinal ECs (Jeong et al., 2017). Endothelial 
deletion of Mafb resulted in a retinal sprouting angiogenesis defect due to fewer vessel 
sprouts. MAFB was shown to promote EC migration, suggesting a critical role within tip 
cells (Jeong et al., 2017). 
 
SOXF transcription factors SOX7, SOX17 and SOX18 regulate vascular development 
(Corada et al., 2013, Zhou et al., 2015). In ECs, SOX18 interacts with another transcription 
factor MEF2C (Hosking et al., 2001). MEF2C is upregulated in the endothelium in response 
to VEGFA (Maiti et al., 2008). While loss of MEF2C alone does not affect normal sprouting 
angiogenesis (Xu et al., 2012), combined endothelial deletion of Mef2a and Mef2c has a 
dramatic effect on vessel growth (Sacilotto et al., 2016). MEF2C binding was found to be 
enriched at tip cell genes; however, MEF2A and MEF2C protein expression was not specific 
to tip cells in retinal vessels (Sacilotto et al., 2016), suggesting that there are other factors that 
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determine when tip cell genes are turned on. MEF2C was also enriched at gene loci encoding 
other important angiogenic transcription factors: ELK3, HLX and ETS1 (Sacilotto et al., 
2016). Loss of ELK3 results in a delay in retinal vessel growth that is less severe than loss of 
MEF2A/C (Weinl et al., 2014). Ets1–/– mice are viable but loss of both Ets1 and Ets2 results 
in mid-gestation embryonic lethality with reduced angiogenesis (Wei et al., 2009), 
highlighting redundant roles for ETS1 and ETS2. Knock down of HLX in HUVECs resulted 
in a loss of genes typically expressed by tip cells (e.g. ESM1 and DLL4) and reduced 
sprouting, but was found to have a nonessential role in vivo (Prahst et al., 2014). 
 
1.5.4 Distinct behaviours of tip and stalk cells cooperate to facilitate angiogenesis 
The steps of vessel sprouting, elongation, lumen formation and anastomosis that allow new 
vessels to form and function are managed by tip and stalk cells. Tip cells are morphologically 
distinguishable from their neighbours by the presence of extensive filopodia, which are 
extended rapidly following VEGFA activation and facilitate efficient directional migration 
of tip cells (De Smet et al., 2009, Phng et al., 2013). Tip cell migratory activity is dependent 
on cytoskeletal rearrangements regulated by Rho GTPases such as RAC1 (Brantley-Sieders 
et al., 2004, van Nieuw Amerongen et al., 2003) and CDC42 (Barry et al., 2015, Fantin et al., 
2015, Lavina et al., 2018, Sakabe et al., 2017). Tip cells have a distinct gene expression profile 
that correlates with their migratory behaviour. A key group of genes upregulated in tip cells 
compared to stalk cells are genes encoding secreted molecules, including Angpt2 and Esm1 
(del Toro et al., 2010, Strasser et al., 2010). As described above, ANG2 is a vessel destabilising 
factor promoting EC migration (Felcht et al., 2012, Hakanpaa et al., 2015). Protein 
expression of ESM1 indicates that it is specifically expressed on tip cells and was shown to 
be upregulated in response to VEGFA (Rocha et al., 2014). Once secreted ESM1 binds to 
fibronectin, displacing sequestered VEGFA, thereby increasing the availability of VEGFA. 
This in turn enhances VEGFA signalling and promotes tip cell activity (Rocha et al., 2014). 
 
The extracellular matrix (ECM) is a critical regulator of tip cell behaviour by sequestering 
growth factors and providing substrates to promote sprouting. Tip cell filopodia interact 
with ECM components through integrin binding (Stenzel et al., 2011b). Integrins are 
heterodimeric complexes that are expressed on the EC surface and allow signals from the 
ECM to be relayed inside the cell (Wolfenson et al., 2013). This is predominately facilitated 
by assembling focal adhesions inside the EC, which are important for sprout formation and 
EC migration (Fraccaroli et al., 2015). The ECM composition and stiffness also determines 
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the ability of cytoskeletal changes that facilitate cell movement (Fischer et al., 2009, Franco 
et al., 2013, Myers et al., 2011). Tip cells specifically express matrix degrading enzymes that 
allow changes to ECM stiffness and increase the availability of growth factors (del Toro et 
al., 2010) (Figure 1.4). In the retina, astrocytes provide a template for vessel migration and 
growth. While astrocytes are a significant source of VEGFA, loss of astrocyte derived 
VEGFA does not impair retinal vasculature development (Scott et al., 2010, Weidemann et 
al., 2010). Failure to form an astrocyte network does disturb retinal angiogenesis (Fruttiger 
et al., 1996), as astrocytes contribute by laying down ECM components. Deposition of 
fibronectin is increased in pro-angiogenic astrocytes and loss of astrocyte derived fibronectin 
mildly impairs EC migration (Stenzel et al., 2011b, Uemura et al., 2006). Activation of 
integrin signalling in retinal astrocytes by ANG1 increases fibronectin deposition around 
sprouting vessels that facilitates retinal revascularisation in the OIR model (Lee et al., 2013). 
Fibronectin also sequesters VEGFA in the ECM and endothelial VEGFR2 signalling is 
reduced in the absence of astrocytic fibronectin. This function is shared with another 
component of the ECM, heparan-sulphate (Stenzel et al., 2011b).  
 
Although ECs already generate most of their ATP through glycolysis, tip cells increase their 
glycolytic capacity (De Bock et al., 2013a, Li et al., 2019) (Figure 1.4). The glycolysis pathway 
converts glucose into pyruvate through a series of intermediates, where each step is catalysed 
by a specific enzyme. Loss of the glycolysis rate-limiting enzyme hexokinase 2 results in 
reduced vessel growth and proliferation, consistent with glycolysis being important for vessel 
sprouts (Yu et al., 2017). Phosphofructokinase 1 (PFK1) is another rate-limiting enzyme in 
this pathway and loss of PFKFB3, which catalyses the reaction that generates an allosteric 
activator PFK1, results in reduced filopodia formation and EC migration (De Bock et al., 
2013b). Glycolysis was shown to be spatially compartmentalised within tip cells, with 
PFKFB3 and other glycolytic enzymes associated with lamellipodia and filopodia thereby 
supporting their energy requirements during migration (De Bock et al., 2013b).  
 
Sprouting involves a switch from apical-basal (epithelial) polarity to front-rear (migratory) 
polarity in tip cells (Figure 1.4). Establishing front-rear polarity occurs as tip cells re-orient 
their Golgi apparatus in front of the nucleus with respect to the leading or sprouting edge of 
the cell (Dubrac et al., 2016, Franco et al., 2015, Mayor & Etienne-Manneville, 2016). Both 
VEGFR2 and ROBO1 signals regulate this process and signalling is bridged by the adapter 
proteins NCK1&2 (Dubrac et al., 2016). Failure to polarise correlates with a defect in 
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directed migration (Dubrac et al., 2016, Lavina et al., 2018). Front-rear polarity in tip cells is 
transcriptionally regulated by FOXO1 (Kim et al., 2019). 
 
Growing sprouts in tumours can initially proceed without cell proliferation (Ausprunk & 
Folkman, 1977), indicating an important role for tip cell migration in pulling the sprout along 
(Geudens & Gerhardt, 2011). However, vessel growth cannot be sustained without 
proliferation and it is stalk cells that are particularly critical to this aspect of vessel growth. 
Stalk cells lengthen the growing sprout primarily through proliferation, contributing new 
ECs (Gerhardt et al., 2003). Additionally, vessel sprouts lengthen through elongation of the 
stalk cells themselves (Sauteur et al., 2014, Zeng et al., 2007). Stalk cells are responsible for 
forming the vessel lumen, which is critical for blood perfusion (Potente & Makinen, 2017). 
Multiple mechanisms of lumen formation have been suggested that differ between vessel 
beds and model organisms (Blum et al., 2008, Kamei et al., 2006). The critical role of 
junctional rearrangements in lumen formation have since been described, which occur by 
both blood flow independent (Wang et al., 2010a) and dependent mechanisms (Gebala et al., 
2016). In contrast to tip cells that establish front-rear polarity, stalk cells establish apical-basal 
polarity, which is key to lumen formation (Szymborska & Gerhardt, 2018). EC adherens 
junctions reinforce apical-basal polarity by acting as docking sites for moesin proteins that 
are involved in polarisation (Wang et al., 2010a). Finally, stalk cells help stabilise new vessels 
by laying down basement membrane components and recruiting supportive pericytes 
(Gerhardt et al., 2003), which maintain the blood-retinal barrier (Park et al., 2017). The 
behaviours of tip and stalk cells are summarised in Figure 1.4.  
 
1.5.5 Tip and stalk cells switch identity during angiogenesis 
While the two cell types are distinct, tip and stalk cell formation is a dynamic process, 
involving cell rearrangements and active competition for the tip cell position (Arima et al., 
2011, Jakobsson et al., 2010). Cell rearrangements are driven by differential levels of 
VEGFR1 and VEGFR2 within sprouting ECs, changing their capacity to activate Notch in 
neighbouring cells (Jakobsson et al., 2010). This contributes to cell shuffling in the sprout by 
establishing differential adhesion between tip and stalk cells (Bentley et al., 2014) (Figure 1.4). 
Tip cells typically display weak adhesion that manifests in VEGFA driven VE-cadherin 
turnover (Li et al., 2016) and increased junctional protrusions (Hayer et al., 2016), which is 
inhibited by Notch signalling (Bentley et al., 2014). In contrast, stalk cells have strong VE-
cadherin adhesion (Bentley et al., 2014). In this model, weakly adhesive tip cells are pushed 
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forward as more strongly adhesive stalk cells aim to adhere to each other. Heterogeneous 
Notch levels between stalk cells ensures that cells are continually becoming less strongly 
adhesive and thus more likely to switch and take on tip cell identity (Bentley et al., 2014). 
Sprouts may be made up of one or more tip cells (Pelton et al., 2014) and in embryoid body 
sprouting assays tip cell replacement occurs on average every four hours (Jakobsson et al., 
2010). Given the propensity of angiogenic ECs to switch between cell identities and change 
their gene expression patterns, genes required for either cell type must remain 
transcriptionally permissive. This is regulated at the level of chromatin and will be the focus 
of the next section. 
 
 
Figure 1.4. Tip and stalk cells have distinct behaviours during sprouting 
angiogenesis 
During angiogenesis, tip cells form filopodia, increase glycolysis, interact with and degrade 
the extracellular matrix (ECM) and establish front-rear polarity (Golgi apparatus represented 
in orange) that serve to promote directed migration of tip cells towards pro-angiogenic 
factors.  Tip cells have weak adherens junctions, as shown by junctional protrusions and 
internalised VE-cadherin, to facilitate migration. Stalk cells lengthen the growing sprout by 
proliferating, in addition to generating new basement membrane and establishing apical-basal 
polarity to aid with vessel lumen formation. Red colour indicates vessel lumen. Stalk cells 
have strong adherens junctions. ECs in perfused vessels display apical-basal polarity and 
orient their Golgi apparatus against the direction of blood flow. 
  
  Mechanisms of angiogenesis in development & disease 
 22 
1.6 Regulation of endothelial gene expression 
Every cell in the body, having derived from the single cell zygote, contains almost identical 
genetic information. There is considerable variation in how genetic information is expressed, 
which gives rise to distinct cell lineages. Tip and stalks cells synchronously arise from 
genetically identical quiescent ECs and coordinate sprouting angiogenesis by divergent yet 
complementary behaviours. The process of establishing distinct identities requires changes 
to their gene expression patterns (del Toro et al., 2010, Strasser et al., 2010). Control of gene 
expression is fundamentally regulated by chromatin structure (Venkatesh & Workman, 
2015). 
 
1.6.1 Chromatin organisation controls regulation of gene expression 
DNA is packaged with proteins into chromatin within the nucleus. Although transcription 
factors play an indispensable role in regulating endothelial gene expression during 
angiogenesis, the tightly compact state of chromatin is not permissive to transcription factors 
without first becoming less condensed. The smallest unit of chromatin is the nucleosome. 
Each nucleosome consists of 147 bp of DNA wrapped around a histone octamer, which is 
formed by two molecules of each of the histone proteins H2A, H2B, H3 and H4 (Kornberg, 
1974, Noll, 1974, Tessarz & Kouzarides, 2014). In general, chromatin is organised into 
euchromatin and heterochromatin, which are defined by differences in compaction and their 
influence on transcription. Euchromatin is loosely packed and considered transcriptionally 
permissive. In contrast, heterochromatin is condensed and considered transcriptionally 
repressive (Allshire & Madhani, 2018). 
 
One method of changing the compaction of chromatin is reorganising nucleosomes along 
DNA sequences. This process is dependent on ATPase chromatin remodelling complexes 
which can move, evict or restructure nucleosomes (Clapier et al., 2017). There have been 
numerous studies into the role of ATPase chromatin remodelling complexes in regulating 
vascular development. The ATPase component of the SWI/SNF-related chromatin 
remodelling complex BRG1 is required for normal yolk sac vascular remodelling, formation 
of an interconnected network during embryonic vascular development as well as expression 
of genes involved in WNT signalling and specification of venous EC identity (Davis et al., 
2013, Griffin et al., 2008, Griffin et al., 2011). However, BRG1 and its related protein BRM, 
are dispensable for postnatal retinal vascular development (Wiley et al., 2015), suggesting that 
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reorganising nucleosomes alone is not enough to allow changes in EC gene expression during 
angiogenesis. 
 
Chromatin can also be altered by modifying the histone proteins around which DNA is 
wrapped (Rothbart & Strahl, 2014). Histone-histone interactions within the nucleosome 
make up the histone core and extending from this core is an unstructured, N-terminal histone 
tail. Amino acids within both the core and tail domains of histones can be modified to alter 
gene expression. A number of means of modifying histone proteins have been described, 
including acetylation, phosphorylation, methylation and ubiquitination (Rothbart & Strahl, 
2014). For the purpose of this thesis, only histone acetylation will be considered in detail. 
 
1.6.2 Histone acetylation 
Histone acetylation involves the reversible transfer of a negatively charged acetyl group from 
acetyl-CoA to lysine residues on histone proteins. Histone acetyltransferases (HATs) are the 
enzyme responsible for this process (Brownell et al., 1996). Conversely, histone acetylation 
marks can be removed by another family of enzymes referred to as histone deacetylases 
(HDACs) (Taunton et al., 1996). These two types of enzymes constitute the ‘writers’ and 
‘erasers’ of lysine acetylation. A further group of proteins referred to as ‘readers’ are able to 
bind to histone acetylation marks and recruit further protein complexes to these regions in 
the genome. Reader proteins have specialised domains capable of recognising modified 
histone residues, for example acetylated lysine residues can be recognised by bromodomains 
(Muller et al., 2011). Histone acetylation is generally associated with transcriptionally active 
regions of the genome (Wang et al., 2008). 
 
There are multiple families of HATs, consisting of members grouped by shared structural 
and functional properties (Sheikh & Akhtar, 2019). The three most widely studied families 
are the p300 and CBP family, the GCN5 and PCAF family, and the MYST family. P300 was 
shown to acetylate MEF2 target gene enhancers required for normal MEF2 transcription 
factor binding and hence gene expression, which was prevented in the presence of HDACs 
(Sacilotto et al., 2016). Loss of the histone deacetylase activity of HDAC10 changes the ability 
of ECs to sprout in vitro (Duan et al., 2017), highlighting the role of dynamically regulating 
histone acetylation marks to regulate gene expression patterns associated with changes to EC 
behaviour. 
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1.6.3 MYST family of histone acetyltransferases 
The MYST family, named after founding members MOZ, Ybf2/Sas3, Sas2, TIP60, 
constitute the largest family of HATs found in all eukaryotic organisms. Members are 
characterised by the highly conserved MYST domain that is responsible for HAT activity 
(Voss & Thomas, 2018). There are five MYST family members in mammals. These are MOZ 
(also known as MYST3/KAT6A), QKF (MYST4/KAT6B/MORF), MOF 
(MYST1/KAT8), TIP60 (KAT5) and HBO1 (MYST2/KAT7). The MYST family can be 
further subdivided into three groups based on domain homology: MOZ and QKF, MOF 
and TIP60, and HBO1 alone (Figure 1.5). There is considerable difference in the histone 
acetylation targets and genes and therefore cellular processes regulated by the different 





Figure 1.5. MYST family of histone acetyltransferases 
All five members in the MYST family of histone acetyltransferases contain the MYST 
catalytic domain. The MYST family are further subdivided into three groups based on 
domain homology: MOZ and QKF, MOF and TIP60, and HBO1 alone. NEMM = N-
terminal Enok, MOZ and MORF homology domain, PHD = plant homeodomain, Ser = 
serine-rich domain, Met-rich = methionine-rich domain, Ch = chromodomain, Zn = zinc 
finger domain.  
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1.6.4 HBO1 
Histone acetyltransferase binding to origin recognition complex 1, or HBO1 (also known as 
lysine acetyltransferase (KAT)7 or MYST2), was first identified in a screen to identify novel 
interactors with the origin recognition complex (ORC), forming part of the pre-replication 
complex (Iizuka & Stillman, 1999). The assembly of the pre-replication complex is essential 
for replication licensing, which ensures DNA is replicated only once per cell cycle, as 
necessary for normal cell proliferation (Bleichert et al., 2017, Fragkos et al., 2015). HBO1 
was later found interacting directly with other pre-replication complex members (Burke et 
al., 2001, Miotto & Struhl, 2008, Stedman et al., 2004). HBO1 was shown to be important in 
regulating proliferation through its role in replication licensing (Johmura et al., 2008, Wu & 
Liu, 2008). Supporting a role for HBO1 in regulating cell proliferation, HBO1 is highly 
expressed and has been implicated in a range of primary cancers, including testicular, ovarian 
and breast cancers (Duong et al., 2013, Iizuka et al., 2013, Iizuka et al., 2009, Song et al., 
2013). However, as noted below, more recent studies have not supported a role for HBO1 
in the direct regulation of cell proliferation.  
 
HBO1 exerts its catalytic function by forming other multi-subunit complexes, that includes 
an inhibitor of growth (ING) protein (ING 4 or ING5), EAF6 and a scaffold protein of 
either the JADE or BRPF family (Doyon et al., 2006, Lalonde et al., 2013, Mishima et al., 
2011). JADE and BRPF family scaffold proteins have been shown to dictate the histone 
acetylation target specificity of HBO1 (Lalonde et al., 2013). JADE1 was shown to direct the 
activity of HBO1 towards histone H4 acetylation (H4ac) (Foy et al., 2008, Iizuka et al., 2009), 
necessary for replication licensing (Burke et al., 2001, Miotto & Struhl, 2010, Wong et al., 
2010). Alternatively, BRPF proteins direct HBO1 towards histone H3 acetylation (H3ac) 
(Feng et al., 2015, Lalonde et al., 2013, Mishima et al., 2011, Yan et al., 2016). The BRPF 
family member BRD1 (also known as BRPF2) was initially thought to be exclusive to the 
MOZ/QKF complexes (Doyon et al., 2006, Ullah et al., 2008), but has since been shown to 
specifically direct HBO1 towards histone H3 lysine 14 acetylation (H3K14ac) (Lalonde et 
al., 2013, Mishima et al., 2011, Tao et al., 2017). ING5 also shows promiscuity amongst the 
MYST family HAT complexes as it forms part of both the HBO1 and MOZ/QKF 
complexes, whereas ING4 is exclusively part of the HBO1 complex (Doyon et al., 2006). 
ING4 binds to H3K4me3 via its plant homeodomain finger, which docks HBO1 on histone 
H3 for acetylation of lysines on this histone (Hung et al., 2009, Saksouk et al., 2009).  
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Many of the studies interrogating the role and acetylation targets of HBO1 have used over-
expression and/or cell-free systems, which may not recapitulate the normal behaviour of 
HBO1 in vivo. Indeed, the role for HBO1 in replication licensing, proliferation and H4ac 
remain contentious as in vivo mouse data have not supported these hypotheses. Generation 
of Hbo1–/– mice revealed that HBO1 was exclusively required for H3K14ac and not required 
for acetylation at other histone residues including on histone H4 (Kueh et al., 2011). This 
was confirmed by other studies (Feng et al., 2015, Zou et al., 2013). Hbo1–/– embryos are 
developmentally delayed and undergo developmental arrest at E8.5, which is ultimately 
embryonic lethal at E10.5. Hbo1–/– embryos display a range of defects including abnormal 
yolk sac vasculature and dilated dorsal aortae and pharyngeal arch arteries. The ability of 
Hbo1–/– embryos to reach a post-gastrulation stage indicates that the extensive proliferation 
required in the early embryo was able to proceed normally in the absence of HBO1. Instead, 
HBO1 was found to be important for the expression of lineage specific genes required for 
post-gastrulation differentiation, in particular those involved in patterning of the heart 
(Gata4, Tbx1), vasculature (Tie1, Tie2, Flk1) and neural tube (Otx2, Sox2) were downregulated 
in Hbo1–/– embryos (Kueh et al., 2011). The role for HBO1 in regulating cell specific gene 
expression has been supported by mice deficient in HBO1 complex members. The HBO1-
BRD1 complex was shown to bind key erythroid genes required for normal erythropoiesis 
(Mishima et al., 2011). Brpf1–/– mice are embryonic lethal at E9.5 with a multitude of 
developmental defects (You et al., 2014, You et al., 2015), including failed vasculogenesis 
within the yolk sac and embryo proper as well as vascular defects in the placenta (You et al., 
2015).  
 
Recently, HBO1 was shown to promote zebrafish EC migration and branching (Yan et al., 
2018). Zebrafish carry two orthologues of Hbo1, kat7a and kat7b with 13% and 76% 
sequence homology to Hbo1 respectively. Morpholino knock-down of kat7b expression in 
zebrafish resulted in reduced intersegmental vessel sprouting and defects in forming the sub-
intestinal vein, relating to downregulated VEGFR2 expression (Yan et al., 2018). This result 
suggests that HBO1 regulates vessel sprouting during angiogenesis, in part by regulating EC 
perception of VEGFA. Together the observation that HBO1 regulates the expression of 
genes required for cell differentiation and the vascular phenotype observed in kat7b 
morphants and Hbo1–/– embryos posit a role for HBO1 in regulating gene expression patterns 
that accompany EC differentiation during sprouting angiogenesis.  
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1.7 Endothelial cell death in vessel regression and remodelling 
Under normal circumstances, blood vessel regression is essential for making healthy, 
functional vessel networks. It is necessary to selectively remove excess vessel segments 
during network refinement and maturation in order to establish an efficient hierarchical 
network. It is also important for preventing disease by removing redundant vessel networks 
in their entirety, an example being the hyaloid vessels of the developing eye. However, 
excessive or damage-induced vessel regression can cause ischaemic disease, such as diabetic 
retinopathy. Cell death is a mechanism for removing redundant cells and tissues from the 
body. The involvement of EC death in vessel regression has been reported in a range of 
regressing vessels (Korn & Augustin, 2015) and increased death of ECs is correlated with 
vessel loss in diabetic retinopathy (Mizutani et al., 1996). Understanding how cell death in 
ECs is controlled and its contribution to vessel regression is therefore important to 
understanding vessel loss in disease, particularly retinal vascular disease. 
 
1.7.1 Cell death pathways 
Cells respond to insurmountable cellular stress through activation of cell death pathways. 
There are multiple cell death pathways that have inherently different properties. Apoptosis 
is a programmed form of cell death that is immunologically inert. It removes superfluous or 
damaged cells to facilitate normal development and to maintain homeostasis in adults (Arya 
& White, 2015, Czabotar et al., 2014). Apoptosis is regulated by two distinct but converging 
pathways: the BCL2-regulated and death-receptor pathways of apoptosis. These pathways 
converge on the activation of cysteine-aspartic proteases, or caspases, that orchestrate the 
destruction of the cell by fragmenting hundreds of proteins and activating DNA degrading 
enzymes. There are two types of caspases involved in apoptosis: “initiator” caspases that do 
not themselves destroy cellular contents but activate “executioner” caspases, such as caspase 
3, that do (McIlwain et al., 2013). In contrast to apoptosis, necrosis and necroptosis are both 
inflammatory forms of cell death (Pasparakis & Vandenabeele, 2015).  
 
1.7.2 BCL2-regulated pathway of apoptosis 
The BCL2-regulated pathway of apoptosis is also referred to as the ‘intrinsic’ or the 
‘mitochondrial’ pathway because of the involvement of mitochondria. It removes redundant 
cells during development, shaping normal tissue development, and is also activated in 
response to cellular stress and damage. BCL2 family proteins are defined by the presence of 
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one or more BCL2 homology (BH) domains, of which there are four (BH1 - BH4). The 
balance between competing factions of pro-survival and pro-death members of the BCL2 
family determines whether cells live or die (Figure 1.6). BAK and BAX are a sub-family of 
BCL2 proteins that act as the pro-apoptotic effector proteins in this pathway. Their 
activation commits the cell to undergo apoptotic death. The activation of BAK and BAX 
relies on another pro-apoptotic sub-family, the BH3-only proteins (BIM, PUMA, NOXA, 
BID, BAD, BIK, HRK and BMF). The BH3-only proteins sense and respond to apoptotic 
stimuli (Adams & Cory, 2018). When unleashed, they directly bind and activate BAK and 
BAX (Ren et al., 2010). BH3-only proteins also trigger BAK and BAX activation by binding 
to the pro-survival subfamily of BCL2 proteins (Chen et al., 2005, Willis et al., 2007). This 
includes BCL2, MCL1, BCLXL, BCLW and A1 (Adams & Cory, 2018). Under healthy 
conditions, pro-survival BCL2 proteins directly restrain BAK and BAX, preventing their 
activation (Czabotar et al., 2011, Fletcher et al., 2008). BH3-only proteins prevent this 
interaction. Once activated, BAK and BAX form oligomers on the outer mitochondrial 
membrane, perforating it and allowing release of apoptogenic factors such as cytochrome c 
and SMAC/DIABLO (Kalkavan & Green, 2018, Munoz-Pinedo et al., 2006). Cytosolic 
cytochrome c binds to APAF1 triggering a conformational change that allows APAF1 
oligomerisation into a signalling platform called the apoptosome (Li et al., 1997). The 
apoptosome enables the initiator caspase of this pathway, caspase 9, to dimerise and thus 
become activated (Boatright et al., 2003). Cells produce endogenous caspase inhibitors to 
prevent aberrant apoptosis, such as IAP proteins, which prevent the actions of executioner 
caspases 3 and 7 (Deveraux et al., 1998, Roy et al., 1997). Release of SMAC/DIABLO from 
the mitochondria during apoptosis inactivates IAPs (Du et al., 2000). Mice in which the 
BCL2-regulated pathway is inactive show failed interdigital cell removal, an imperforate 
vagina and accumulation of cells within the haematopoietic and central nervous systems (Ke 
et al., 2018, Lindsten et al., 2000). 
 
1.7.3 Death receptor pathways of cell death 
The death receptor pathway of apoptosis can be activated when a death ligand binds to a 
death receptor (Figure 1.6). Death receptors are members of the TNF superfamily containing 
a cytoplasmic death domain. These include FAS, TNFR1, APO-3, TRAIL-R1, TRAIL-R2 
and TNFRSF21, which bind their respective ligands FASL, TNF, APO3L, TRAIL and APP 
(Wilson et al., 2009). Recruitment of FADD together with pro-caspase 8 to the activated 
death receptor leads to formation of a death-inducing signalling complex (DISC) (Boldin et 
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al., 1996, Chinnaiyan et al., 1995, Kischkel et al., 1995, Muzio et al., 1996). This complex is 
modulated by the inhibitor cFLIP (Irmler et al., 1997). DISC formation activates the initiator 
caspase 8. The death receptor and BCL2-regulated pathways are therefore separate apoptotic 
pathways that converge on caspase activation. While this is true in most cells, the BCL2-
regulated pathway is needed to amplify the death receptor response in some cell types. In 
these cells, caspase 8 cleaves the BH3-only protein BID to form truncated BID, which 
activates BAK and BAX and mitochondria-dependent apoptosis (Li et al., 1998, Luo et al., 
1998). This is known as ‘type II’ cell death and occurs in cells such as hepatocytes and 
pancreatic  cells (Kaufmann et al., 2012, Yin et al., 1999).  
 
1.7.4 Necroptosis 
Necroptosis is another programmed cell death pathway that is downstream of death receptor 
activation (Figure 1.6). It differs from apoptosis in that it is inherently inflammatory in nature 
and bears morphological features in common with necrosis (Pasparakis & Vandenabeele, 
2015). It is likely to have evolved as a host defence against pathogens but has been implicated 
in a range of diseases, including inflammatory diseases (Gunther et al., 2011, Welz et al., 
2011). Necroptosis is activated downstream of TNF receptor activation when certain 
conditions are met, such as when caspase 8 is inhibited, diverting the signalling response 
from apoptosis to necroptosis (Holler et al., 2000). During necroptotic cell death, TNFR1 
activation and signalling leads to the formation of the necrosome, which includes RIPK1 
and RIPK3 that phosphorylate each other (Cho et al., 2009, He et al., 2009), and then recruit 
and phosphorylate MLKL to initiate necroptosis (Sun et al., 2012). Loss of Casp8 in ECs 
causes embryonic lethality with cardiovascular defects (Kang et al., 2004, Varfolomeev et al., 
1998). This is due to activation of necroptosis as it can be rescued by the additional deletion 
of the necroptosis pathway genes Ripk3 or Mlkl, allowing the survival of double knockouts 
to adulthood (Alvarez-Diaz et al., 2016, Kaiser et al., 2011). 
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Figure 1.6. Cell death pathways 
There are two distinct but converging pathways of apoptotic cell death: the BCL2-
regulated and death receptor pathway. The BCL2-regulated pathway is controlled by the 
interaction between the three BCL2 subfamilies. Activated BAK and BAX can 
permeabilise the mitochondria leading to the release of apoptogenic factors that activate 
caspases to cause apoptosis. The death receptor pathway is activated when a death 
receptor ligand binds to a death receptor and activates caspases to cause apoptosis. Death 
receptors may also trigger an alternative cell death of necroptosis, which is caused by the 
activation of RIPK and MLKL.  
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1.7.5 Regulation of endothelial cell survival 
ECs rarely undergo apoptosis in quiescent vessel beds. Their survival is maintained by a 
number of factors including growth factors, blood flow shear stress and cell contacts with 
the ECM and neighbouring cells (Watson et al., 2017).  
 
The growth factor VEGFA is not only a potent stimulator of vessel sprouting but is also an 
important survival factor for ECs. VEGFA promotes EC survival through PI3K/AKT 
signal transduction pathways (Fujio & Walsh, 1999, Gerber et al., 1998b). In vivo, inhibition 
of VEGFA causes EC apoptosis and vessel regression in some tissues, such as the trachea 
and small intestine (Baffert et al., 2004, Kamba et al., 2006), but not others like the brain and 
retina (Kamba et al., 2006, Lobov et al., 2011). While apparently not essential for their 
survival, exogenous addition of VEGFA is nonetheless able to protect retinal ECs from 
apoptosis in the OIR model (Alon et al., 1995). Autocrine VEGFA produced by ECs is 
necessary for them to maintain basal metabolism (Domigan et al., 2015). EC-specific deletion 
of Vegfa results in widespread EC death in adult vascular beds, but it is unclear if this is by 
apoptosis or autophagic cell death (Domigan et al., 2015, Lee et al., 2007). ANG1 is another 
growth factor that promotes EC survival (Kim et al., 2000, Kwak et al., 1999). Like VEGFA, 
TIE2 activation by ANG1 promotes EC survival through PI3K/AKT signalling (Kim et al., 
2000). 
 
Shear stress is another important survival factor for ECs (Bartling et al., 2000). Disruptions 
to blood flow can lead to extensive apoptosis (Lobov et al., 2011). A range of EC-surface 
receptors can sense shear stress, including integrins, receptor tyrosine kinases, G-protein 
coupled receptors and intercellular junction proteins (Zhou et al., 2014). While the direct link 
between mechano-sensing and EC survival has not been thoroughly explored, there is some 
evidence to suggest that shear stress can regulate EC survival through AKT signalling 
(Dimmeler et al., 1998). Ligand independent activation of VEGFR2 occurs in response to 
shear stress, resulting in activation of PI3K/AKT signalling and eNOS activation by forming 
a complex with VE-cadherin and beta-catenin (Jin et al., 2003, Shay-Salit et al., 2002). This 
complex has been shown to promote EC survival by activating BCL2 upon ligand activation 
of VEGFR2 (Carmeliet et al., 1999). Many EC mechanosensors are able to regulate levels of 
nitric oxide (NO), a potent vasodilator, by activating endothelium NO synthase (Zhou et al., 
2014). NO has been implicated in EC survival through a range of mechanisms that ultimately 
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lead to increased BCL2 (Rossig et al., 2000) and reduced caspase activation (Haendeler et al., 
1997, Hermann et al., 1997). 
 
Contact with other ECs through PECAM1 (Gao et al., 2003) and VE-cadherin (Carmeliet et 
al., 1999) provides survival cues to ECs. In the absence of VE-cadherin, EC apoptosis is 
increased due to a failure to form a complex with and transmit pro-survival signals with 
VEGFR through PI3K/AKT (Carmeliet et al., 1999). Perivascular cells also support EC 
survival. During angiogenesis, retinal EC apoptosis increases in the absence of pericytes 
(Park et al., 2017), which may relate to reduced vessel stability. Failure to form contacts with 
ECM substrates also results in rapid EC apoptosis (Meredith et al., 1993). Endothelial-
specific loss of focal adhesion kinase, required for transmitting signals stimulated by ECM-
integrin binding, leads to increased apoptosis of ECs during angiogenesis (Braren et al., 
2006). 
 
1.7.6 Regulation of apoptosis in endothelial cells 
ECs are highly dependent on the BCL2-regulated pathway for survival and death. BAK and 
BAX are essential for EC apoptosis (Hahn et al., 2005, Watson et al., 2016a). Induction of 
apoptosis is mediated largely by the pro-apoptotic BH3-only protein BIM (Koenig et al., 
2014, Wang et al., 2017a). Bim–/– primary human ECs show reduced apoptosis following 
serum-starvation. In mice, Bim–/– retinas show an almost complete absence of EC apoptosis 
at both P5 and P14 (Koenig et al., 2014, Wang et al., 2011). While phenotypically normal, 
reduced EC apoptosis in Bim–/– retinas leads to increased vessels within the retina and 
accumulation of ECs (Wang et al., 2011). This is in contrast to deletion of both Bak and Bax 
from the endothelium where increased density of ECs within arterial and venous vessels and 
capillaries did not correspond to a change in overall vessel area in the adult retina (Watson 
et al., 2016a). BIM is also responsible for apoptosis of tumour ECs following anti-VEGFA 
treatment in mice (Naik et al., 2011).  
 
BCL2 pro-survival proteins help to keep ECs alive. VEGFA has been shown to regulate its 
EC survival effects through upregulation of BCL2 in vitro (Gerber et al., 1998a, Nor et al., 
1999). Overexpression of BCL2 enhances EC survival following serum deprivation (Karsan 
et al., 1997). Supporting this, Bcl2–/– mice showed increased apoptosis, which corresponded 
to reduced retinal angiogenesis and neovascular vessel growth during OIR (Wang et al., 
2005). However, this effect was not reproduced in endothelial-specific Bcl2 mutants (Zaitoun 
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et al., 2015), which may instead be secondary to the polycystic kidney disease and severe 
growth retardation that cause these mice to die within the first few weeks of life (Nakayama 
et al., 1994, Veis et al., 1993). Alternatively, BCL2 may promote the survival of a non-EC 
cell type that protects the vasculature. EC-specific loss of Bcl2 did, however, attenuate laser-
photocoagulation induced choroidal neovascularisation (Zaitoun et al., 2015). In contrast to 
BCL2, another pro-survival protein MCL1 is critical for the survival of ECs during sprouting 
angiogenesis. EC-specific deletion of Mcl1 reduced the growth and complexity of retinal 
vessels at P5 (Watson et al., 2016b). EC apoptosis was markedly increased, which was 
particularly prominent within regions that are undergoing high rates of vessel production, 
including around veins and within the sprouting front (Watson et al., 2016b). 
 
The death receptor pathway of apoptosis as well as necroptosis are dispensable for EC death 
and vessel remodelling (Davies et al., 2003, Watson et al., 2016a). Instead, death receptor 
apoptosis contributes to contexts of pathological vessel growth. While studies showed that 
in Fasl loss of function mice vaso-obliteration proceeded normally (Barreiro et al., 2003, 
Davies et al., 2003), they showed increased neovascular lesions and fewer TUNEL+ cells 
within the neovasculature were observed, suggesting that activation of EC death receptors is 
important in the clearance or prevention of neovascular lesions (Barreiro et al., 2003, Davies 
et al., 2003). 
 
1.7.7 Apoptosis-independent vessel regression during angiogenesis  
While angiogenesis is generally regarded as a process of vessel growth, the production of 
mature, efficient blood vessel networks by angiogenesis is just as dependent on vessel 
removal as it is on new vessel formation. Sprouting angiogenesis creates an initially dense 
and immature vessel network incapable of effective blood delivery. The removal of selected 
vessel segments from this immature network through vessel ‘pruning’ shapes it into a mature, 
hierarchical network that allows efficient blood flow. As in other remodelling tissues, 
endothelial apoptosis is associated with vessel regression during angiogenesis (Watson et al., 
2016a, Zhang et al., 2018). Interestingly, while deletion of both Bak and Bax from the 
endothelium completely prevents EC apoptosis in the developing retina (Watson et al., 
2016a), this only transiently delays vessel pruning around arteries where EC apoptosis is 
normally highest, but has no impact on the regression of other capillaries (Watson et al., 
2016a). This is consistent with the observation that only 5% of regressing vessels in the retina 
actually undergo apoptosis (Franco et al., 2015). Instead, vessel pruning during angiogenesis 
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occurs through EC migration in response to haemodynamic forces (Watson et al., 2017). 
This was first shown using time-lapse imaging of remodelling blood vessels in the zebrafish 
brain, where ECs migrated out of low-flow vessels and into adjacent high-flow vessels, 
resulting in the regression of the low-flow vessels (Chen et al., 2012). EC migration has been 
shown to drive vessel pruning in other vessels beds in zebrafish (Kochhan et al., 2013, Lenard 
et al., 2015) and in the mouse retina (Franco et al., 2015). Together, the existing model posits 
that EC-migration drives vessel pruning, while apoptosis clears away redundant ECs when 
they are unable to relocate to the protective environment of neighbouring vessels (Franco et 
al., 2015, Watson et al., 2017). 
 
1.7.8 Apoptosis-dependent vessel regression 
While EC apoptosis is infrequent and dispensable for the pruning of individual vessels during 
angiogenesis, it becomes highly active when large numbers of vessels regress together or 
when whole networks involute. EC apoptosis is prominent during regression of the hyaloid 
and pupillary vessels. These transient networks supply the developing eye before undergoing 
complete involution when the retinal vascular network forms (Ito & Yoshioka, 1999). EC 
apoptosis is also prominent during vessel regression in the involuting mammary gland 
(Walker et al., 1989), luteolysis in the ovary (Modlich et al., 1996) and certain vessel beds 
deprived of VEGFA (Kamba et al., 2006). In the absence of BAK and BAX, EC apoptosis 
is blocked and the hyaloid network fails to regress, showing that apoptosis can indeed cause 
vessel regression (Hahn et al., 2005, Watson et al., 2016a). Mice lacking the pro-apoptotic 
BH3-only protein BIM also have persistent hyaloid vessels (Koenig et al., 2014, Wang et al., 
2011). A role for EC apoptosis in initiating vessel regression by impeding blood flow was 
demonstrated by early studies in the pupillary membrane. These showed that individual 
apoptotic ECs protruded into the vessel lumen, causing blood flow disruption leading to 
synchronous apoptosis by the remaining ECs and subsequent vessel degeneration (Meeson 
et al., 1996). However, adult Bak–/–Bax–/– mice do not retain a pupillary membrane network, 
indicating that despite the presence of dying cells, its regression is not actually dependent on 
apoptosis (Hahn et al., 2005). Instead, it is likely caused by vessel stretching that occurs with 
rapid growth of the eye (Poche et al., 2015). Similarly, hyaloid vessel network regression is 
only partially dependent on EC apoptosis and many vessels in the hyaloid network still 
regress even in the absence of apoptosis. These were generally short and showed evidence 
of cell migration (Watson et al., 2016a). ECs in shorter vessels tend to survive vessel 
regression better than those in longer vessels, which are more prone to apoptosis (Watson 
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et al., 2017, Zhang et al., 2018) (Figure 1.7). This is thought to reflect the chance of an EC 
migrating into a perfused vessel (Franco et al., 2015). Thus, while there is a close relationship 
between blood flow, vessel regression and EC apoptosis, determining which causes the other 
can be difficult to distinguish, as exemplified by the conflicting results in the pupillary 
membrane (Hahn et al., 2005, Meeson et al., 1996). These findings also show that the 
presence of EC apoptosis does not mean that it is always required for vessel regression, or 




Figure 1.7. Endothelial apoptosis dependent and independent vessel regression 
ECs from low flow vessels (green and blue nuclei) migrate into vessels of higher flow 
during vessel pruning. ECs within short vessels have a better chance of successful 
migration and a sleeve of basement membrane (collagen IV) is left behind. Long vessels 
contain more ECs and ECs that fail to successfully migrate undergo apoptosis. Red arrow 
indicates direction of blood flow and orange Golgi apparatus highlight that ECs within 
vessels polarise against the direction of blood flow.  
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1.7.9 Apoptosis-dependent vessel regression in disease 
Given that an initial loss of vasculature precedes neovascularisation and retinal damage in 
biphasic retinal vascular diseases like ROP and PDR, it is important to understand how vessel 
loss occurs in these diseases. EC apoptosis is known to occur in diabetic retinopathy, prior 
to progression to PDR suggesting it may be an important factor in vessel loss in this disease 
(Mizutani et al., 1996). EC apoptosis occurs due to loss of perivascular supporting cells in 
addition to hyperglycaemia induced EC death (Ido et al., 2002, Quagliaro et al., 2003, Yang 
et al., 2008). EC apoptosis is also associated with vaso-obliteration in the OIR model of 
biphasic retinal vascular disease (Alon et al., 1995, Lobov et al., 2011). This has been 
suggested to occur secondary to loss of blood flow (Lobov et al., 2011). Indeed, retinas are 
highly sensitive to oxygen levels and constrict their vessels when exposed to high oxygen 
levels (Lobov et al., 2011, Werkmeister et al., 2012). While Bim–/– mice are protected from 
vaso-obliteration and subsequent neovascularisation in the OIR model (Wang et al., 2011), 
this was not recapitulated when Bim was deleted specifically from the endothelium making 
the role of EC apoptosis in vaso-obliteration unclear (Wang et al., 2017a). Furthermore, 
given that the loss of blood flow apparently precedes EC apoptosis in the OIR model, the 
exact role that apoptosis plays in vessel regression in the OIR model and by extension, it’s 
possible roles in biphasic retinal vascular disease is also unclear.  
 
1.8 Aims and hypotheses 
Angiogenesis is essential to meet the metabolic demands of growing tissues. While 
angiogenesis is generally absent from healthy adults, it can become reactivated in a range of 
human disease contexts. Pathological activation of angiogenesis can be triggered in response 
to ischaemia caused by excessive vessel loss, e.g. in biphasic retinal vascular diseases. 
Understanding the mechanisms by which blood vessels grow and regress may therefore 
reveal new therapeutic options for preventing vascular disease. This thesis will examine two 
distinct hypotheses relevant to retinal vascular development and disease. First: how gene 
expression changes necessary for angiogenic vessel growth are regulated, and second: how 
EC apoptosis contributes to vessel regression. 
 
Regulation of endothelial gene expression is needed for angiogenic vessel growth. In the first 
part of my thesis (Chapters 3 and 4), I will explore the hypothesis that a chromatin regulator 
that promotes open, accessible chromatin is necessary for ECs to dynamically respond to 
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pro-angiogenic signals and switch on gene expression patterns necessary for the sprouting 
angiogenesis response.  
Aims: 
1. To understand the EC-autonomous role for HBO1 during developmental sprouting 
angiogenesis and pathological neovascular growth using the OIR model 
2. To determine whether HBO1 is necessary for endothelial gene expression changes 
accompanying sprouting angiogenesis 
 
EC apoptosis is associated with vessel regression in various contexts and is present during 
the regression of long vessels or when whole networks undergo involution. In the second 
part of my thesis (Chapter 5), I will explore the hypothesis that apoptosis is required for 
clearing ECs during vaso-obliteration in the OIR model and that preventing apoptosis from 
occurring during the vaso-obliteration phase may provide benefits such as preventing a 
pathological, neovascular response. 
Aims: 
3. To determine the role of EC apoptosis in vessel regression that causes tissue 
ischaemia  
4. To understand if and how preventing EC apoptosis in a model of biphasic retinal 
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2 Materials & Methods 
Chapter 2: Materials and Methods 
2.1 Mice 
2.1.1 Housing and ethics 
Mice were bred and housed at The Walter & Eliza Hall Institute mouse facility (Parkville 
campus). Mice were housed in Airlaw cages and exposed to a 12 h light/dark cycle and 
provided with g-irradiated feed (Barastoc, Ridley AgriProducts) and sterilised water ad libitum. 
All procedures were conducted in accordance with the animal ethics regulations of the 
National Health and Medical Research Council and with approval from the Walter and Eliza 
Hall Animal Ethics Committee.  
 
2.1.2 Mouse strains and genotyping 
Conditional Hbo1 mice (Kueh et al., 2011), Cdh5(PAC)-creERT2 mice (Wang et al., 2010b), 
mTmG mice (Muzumdar et al., 2007), conditional Bax mice (Knudson et al., 1995), Bak null 
mice (Lindsten et al., 2000), Mlkl null mice (Murphy et al., 2013), Casp8 null mice (Salmena 
et al., 2003) and Tie2-cre mice (Kisanuki et al., 2001) have all been described previously. 
Animals were maintained on an inbred C57BL/6 background. The day of birth was termed 
P0. Mice of both sexes were used at all ages.  
 
All litters from Bak–/–Baxflox mating and all Hbo1 litters used for lung RNA-sequencing 
samples were fostered to BALB/c dams. BALB/c foster dams were also used in OIR 
procedure (Section 2.1.4).  
 
Tail samples for genotyping were digested in DirectPCR Lysis Reagent (mouse tail) (Viagen, 
102-T) with 200 µg/ml proteinase K (Roche) at 55˚C for at least 1 h in Thermomixer 
(Eppendorf) at 1400 rpm. Proteinase K was heat inactivated at 95˚C for 5 min at 1400 rpm. 
Oligonucleotides used for genotyping are listed in Table 2.2. Genotyping was performed 
using MyTaq HS Red Mix (Bioline). 
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Table 2.1. Summary of mouse genotypes and controls 
Mutant mouse: Control mice used: 
Hbo1iEC/iEC Hbo1flox/flox (no cre) 
Hbo1flox/+ (no cre) 
Hbo1flox/+ Cdh5(PAC)-creERT2+ 
Hbo1iEC/iEC;mTmG+ Hbo1flox/+ Cdh5(PAC)-creERT2+ mTmG+ 
Bak–/–BaxEC/EC Bak–/–Baxflox/flox (no cre) 
Bak–/–Baxflox/+ (no cre) 
Bak–/–Baxflox/+ Tie2-cre+ 
Bak–/–BaxiEC/iEC Bak–/–Baxflox/flox (no cre) 
Bak–/–Baxflox/+ (no cre) 
Bak–/–Baxflox/+ Cdh5(PAC)-creERT2+ 
 
2.1.3 Tamoxifen treatment 
Mice carrying the Cdh5(PAC)-creERT2 transgene were treated with tamoxifen free base (MP 
Biomedicals) in order to induce cre recombinase mediated loxP recombination. Most control 
mice were also treated with tamoxifen in order to exclude any tamoxifen off-target effects. 
Postnatal pups analysed at P6 were administered 50 µg tamoxifen dissolved in corn oil by 
intra-gastric injection using 0.3 mL syringe with attached 29G needle (BD #326103) at P1 
and P2. Pups that were exposed to high oxygen environment from P7 until P12, were 
administered with 50 mg/kg dose of tamoxifen dissolved in corn oil upon return to room 
air by oral gavage at P12 and P13. 
 
2.1.4 Oxygen induced retinopathy (OIR) model 
Nursing dam and litter were housed in a Perspex chamber (BioSpherix) and exposed 
continuously to 73±1% oxygen levels maintained by a ProOx110 oxygen controller 
(BioSpherix). Exposure to high oxygen was from P7 for up to 5 d before returning to normal 
room air (~20% oxygen). For all OIR experiments in Chapter 3 mice were exposed to high 
oxygen for 5 d. For OIR experiments in Chapter 5 mice were exposed to high oxygen for 24 
h to 3 d as indicated in each figure. Pups were fostered to BALB/c females following 
exposure to 3 days of high oxygen to prevent oxygen toxicity in dams. Neovascularisation 
was assessed 5 d following return to room air.  
 
  Mechanisms of angiogenesis in development & disease 
 43 
2.2 Imaging techniques 
2.2.1 Immunofluorescence labelling 
Eyes were enucleated and fixed in 4% paraformaldehyde for 2 h at 4˚C. Following 3x 10 min 
washes in DPBS, eyes were dissected to isolate retinas. Retinas were blocked in blocking 
solution (2% normal donkey serum 1% Triton X-100 in DPBS) for at least 1 h at room 
temperature. Retinas were incubated in primary antibodies (see Table 2.3) diluted in blocking 
solution overnight at 4˚C. Retinas were washed in 0.01% Triton X-100 in DPBS for at least 
5x 1 h washes at room temperature. Retinas were incubated in secondary antibodies (see 
Table 2.4) diluted in blocking solution overnight at 4˚C (mice at any age). Retinas were 
washed in 0.01% Triton X-100 in DPBS for at least 5x 1 h washes at room temperature and 
then mounted in Prolong Gold or Diamond onto glass slides. If Hoechst staining was 
required, retinas were incubated in 2 µg/ml Hoechst-33342 for 2 h at room temperature 
prior to mounting and then imaged on the same day. 
 
2.2.2 EdU proliferation assay 
5-ethynyl-2’-deoxyuridine (EdU) was dissolved in DMSO to a concentration of 10 mg/ml. 
P6 pups were administered 100 µg EdU diluted in DPBS by intra-peritoneal injection using 
0.3 mL syringe with attached 29G needle (BD #326103). Cells were labelled with EdU for 2 
h before euthanising mouse. Eyes were dissected and stained as per procedure above. Click-
iT EdU Alexa Fluor 647 (Invitrogen #C10340) was performed as per manufacturer’s 
instructions prior to mounting retina onto glass slide.  
 
2.2.3 Hypoxyprobe 
Mice were administered pimonidazole (HP3-100 kit, Hypoxyprobe) at 60 mg/kg by intra-
peritoneal injection using 0.3 mL syringe with attached 29G needle (BD #326103) 30 min 
to 2 h prior to euthanisation. 100 mg/ml pimonidazole stock solution was prepared to 
required dose in PBS to a final volume of 50 µl. Eyes were dissected and retina stained as 
above including rabbit anti-pimonidazole. 
 
2.2.4 Image acquisition 
All retina images were acquired using Leica TCS SP8 confocal microscope. Overview images 
were acquired using either 10x/0.4 NA objective or 20x/0.75 NA objective. Detailed images 
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were acquired using 40x/1.30 NA objective. All images were obtained as Z-stacks through 
the entire region of interest. Maximum intensity projection images were used for presentation 
and despeckled for clarity where necessary.  
 
2.2.5 Live-retina imaging 
Mice with the mTmG reporter were used for live-imaging experiments. Pups were 
administered tamoxifen at P1 and P2 as described above and retinas were live-imaged at P6. 
2% low-melting agarose gel was dissolved in DMEM by shaking at 60˚C and then diluted 
1:1 with 20% foetal calf serum (FCS) in DMEM to give a final concentration of 1% agarose 
and 10% FCS. 350 µl was added to glass-bottom dish (Eppendorf), allowed to set and then 
warmed in 37˚C incubator until retinas were ready for mounting. Eyes were enucleated and 
dissected in cold DMEM. A retina was transferred immediately after dissection using cut-off 
P1000 tip and flat-mounted on an agarose covered dish with vessel surface down. A small 
piece of filter mesh was soaked in leftover molten agarose and laid flat on top of retina. The 
retina dish was laid in custom 3D printed holder and transferred to Leica TCS SP8 confocal 
microscope. Microscope was maintained at 37˚C with 5% CO2. Various positions of interest 
were marked and images at each position using 10x/0.4 NA objective were acquired every 
30 min for 4 h, with 1 µm Z-slice resolution.  
 
2.3 Image analysis 
All analysis of confocal images was performed in FIJI unless otherwise specified. 
 
2.3.1 Endothelial H3K14ac expression 
Using individual Z-slices, EC nuclei were identified by Hoechst-33342 staining within 
PECAM1 signal. Entire EC nuclei were traced manually using freehand selection tool on Z-
slice with brightest Hoechst signal (as determined by eye). EC nuclei were added as a region 
of interest (ROI). At least 50 EC nuclei ROIs were counted per image and mean grey value 
of H3K14ac channel for each ROI was measured. H3K14ac levels in ECs were normalised 
to mean H3K14ac expression in 50 non-EC nuclei (determined as being PECAM1-).  
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2.3.2 Vessel area 
Total vessel area was calculated using maximum projection images of entire retina vascular 
network based on PECAM1 signal. Analysis was performed using threshold function on 
despeckled images with central region of retina (optic nerve head) removed from image 
manually. 
 
2.3.3 Radial outgrowth 
Radial outgrowth was quantified as mean distance from optic nerve head at centre of retina 
to edge of vasculature for the four segments of the P6 retina using straight freehand line tool. 
 
2.3.4 Branch points / segment density 
Branch points and segment density were counted within two ROIs per retina from maximum 
projection collagen IV images. Regions contained some arterial and venous plexus as well as 
some of the sprouting front plexus. These images were despeckled, a 2 pixel median filter 
applied and made binary by thresholding area. The images were then skeletonised and the 
skeleton was analysed. Results output included details of number of junctions (branch points) 
as well as number of segments. These results were normalised to the area of the cropped 
region analysed.   
 
2.3.5 Endothelial proliferation 
Proliferation was determined by labelling cells with EdU (see Section 2.2.2). Proliferating 
ECs were quantified from maximum projection retina overview images with optic nerve head 
area removed. Analysis was automated and generated binary masks of PECAM1, FLI1 and 
EdU signals using automatic thresholding and various morphological filters. The output 
generated total EC number across retina (defined as PECAM1+ FLI1+) as well as total 
proliferating cells across the retina. The number of proliferating ECs was thus calculated as 
PECAM1+ FLI1+ EdU+.  
 
2.3.6 Endothelial cell density and vessel width 
To calculate the number of ECs within the remodelling plexus, maximum projection images 
of FLI1 and PECAM1 staining that excluded the sprouting zone (see Figure 3.1 for definition 
of the zones) were analysed using the automated EdU tool described above. This generated 
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the number of ECs, which was normalised to vessel area. To measure EC density and vessel 
width at the edge of the sprouting front, a ROI was cropped from around the end of a vein 
and an artery. The number of ECs in each ROI were manually counted based on FLI1 signal 
and normalised to vessel area for EC density analysis or to total vessel length for vessel width 
analysis. The area of vasculature was measured in each region as per Section 2.3.2. The length 
of vasculature was measured as per Section 2.3.4, with the total vessel length calculated by 
summing all segments together.   
 
2.3.7 Endothelial apoptosis 
Apoptotic ECs were defined as PECAM1+ cleaved-caspase 3+ within collagen IV signal as 
determined from individual Z-slices. Apoptotic ECs were quantified from individual Z-slices 
for retina vascular overview images with optic nerve head area removed. Apoptotic ECs 
normalised to vascular area. 
 
2.3.8 Vessel regression 
Vessel regression was determined as a ratio of PECAM1+ vessel segment length to collagen 
IV+ vessel segment length. Vessel regression was quantified within the central retina 
between arteries and veins in a semi-automated fashion. Binary masks of both PECAM1 and 
collagen IV channel were made by various morphological filters and thresholding signal 
manually. Collagen IV+ PECAM1- vessel segment mask (ie. regressing vessels) was generated 
by subtracting PECAM1 mask from collagen IV mask. Collagen IV+ PECAM1- mask and 
collagen IV mask were then skeletonised and length of vessels within each mask was 
measured. Collagen IV+ PECAM1– : collagen IV ratio was generated automatically based on 
vessel length. Data was represented as PECAM1 : collagen IV ratio, calculated as 1 minus 
automated ratio. 
 
2.3.9 Tip cells 
Tip cells were defined as ESM1+PECAM1+ cells at the edge of the P6 retina sprouting 
front. ESM1+ cells were counted manually along the sprouting front in one half of the retina. 
ESM1+ cells were represented as total number per mm of sprouting front, measured as 
straight line across edge of vasculature. 
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2.3.10 Filopodia clusters 
Filopodia clusters were defined as distinct extensions of PECAM1 signal from the edge of 
the sprouting front. Individual clusters were counted manually in tip cells along the sprouting 
front in one half of the retina. Filopodia clusters were represented as total number per mm 
of sprouting front. 
 
2.3.11 Golgi apparatus orientation 
Golgi apparatus was visualised using GM130 and the orientation was analysed in ESM1+ 
ECs along the sprouting front in one half of the retina. GM130 overlapped with ESM1 signal 
and together with individual Z-slices the Golgi apparatus that belonged to each EC was able 
to be determined. The following criteria were used to assign Golgi apparatus orientation: (1) 
Golgi apparatus were defined as front polarised if any part of the Golgi apparatus was 
between the sprouting edge and nucleus, (2) Golgi apparatus were defined as rear polarised 
if any part of the Golgi apparatus was at the opposite side of nucleus to sprouting edge and 
(3) Golgi apparatus were defined as side polarised if Golgi was neither front nor rear 
polarised or if Golgi apparatus was both front and rear polarised. Golgi apparatus orientation 
was represented as percentage in each position. 
 
2.3.12 Live-imaging analysis 
Sprout direction and overall growth was measured with reference to the leading edge of 
retina vessel growth for each video. The leading edge was defined by a straight line 
perpendicular to the direction of growth. To measure sprout length a line was drawn from a 
fixed point at the base of a sprout to the tip of the sprout at each time point up to t = 3.5 h 
and length of the line was measured. For each sprout the initial sprout length was subtracted 
from the length at each timepoint and these values showed sprout growth trajectory. Data 
were represented as the net growth in 3.5 h of imaging. Negative values for sprout length 
indicate a sprout that has retracted over time. These lines were also associated with a 
directionality, as was the leading edge line. The angle of the leading edge was subtracted from 
the angle at each time point and these values represented the directionality of the sprout over 
time. Angles between -45˚ to 45˚ or 135˚ to 225˚ were parallel to leading edge and considered 
sideways growth. Angles between 45˚ to 135˚ were perpendicular to leading edge and 
considered forwards growth. Angles between -90˚ to -45˚ were perpendicular to leading edge 
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and considered backwards growth. Sprouts were considered growing in a particular direction 
if the majority of time points were in that direction.  
 
2.3.13 Neovascularisation and vaso-obliteration 
Neovascular and vaso-obliterated area were analysed using maximum projection images of 
whole retinal vasculature stained with collagen IV and PECAM1, respectively. Neovascular 
area or vaso-obliterated area were separately traced using quick selection tool in Adobe 
Photoshop CC 2015 software. The traced image was made binary and the area was analysed 
in FIJI. These measurements were normalised to total retina area.  
 
2.3.14 Junction activity 
Small regions were cropped around tip cells (defined as ESM1+ ECs along the sprouting 
front) and manually sorted in a blinded manner into three categories based on the junctional 
marker VE-cadherin (Bentley et al., 2014): active, mixed or inhibited. Active junctions 
showed jagged or zig-zag VE-cadherin signal and internalised VE-cadherin, which was 
evident by punctate VE-cadherin expression. Inhibited junctions had no internalised VE-
cadherin and showed straight line VE-cadherin signal between ECs. Mixed junctions had 
one feature of both active and inhibited junctions.  
 
2.4 Fluorescent Activated Cell Sorting (FACS) 
P6 lungs were removed and cut into four pieces. Each piece was transferred to eppy and 
mashed with scissors. 1 ml of dissociation buffer (Table 2.5) was added to each tube and 
incubated at 37˚C, 800 rpm in orbital shaker for 40 min. Samples were trituated ~20 times 
after 20 and 40 min. Samples were filtered through 70 µm filter mesh cap (Falcon) into 50 
ml tube, pooling separate tubes for each sample. Filters were washed with FACS buffer (2% 
FCS in KDS-BSS). Samples were spun at 1500 rpm, 5 min and supernatant removed. For 
red blood cell depletion, 10 ml FACS buffer was added to each tube and cell number in each 
sample were automatically counted using Countess cell counter (Invitrogen). Samples were 
pelleted, resuspended in 400 µl FACS buffer containing rat anti-TER119 antibody and 
transferred to eppy. Samples incubated with TER119 antibody for 20 min, on roller at 4˚C. 
1 ml FACS buffer added to each sample and pelleted at 2.5 rpm, 5 min in bench top 
centrifuge. Cell pellets were resuspended in 1 ml FACS buffer and appropriate volume of 
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anti-rat IgG Dynabeads (Invitrogen #11035) was added to each tube for ratio of 1 bead : 1 
cell (based on cell counts). Samples incubated with beads for 20 min, on roller at 4˚C, 
allowing beads to bind to rat-anti TER119 antibody bound to the surface of red blood cells. 
Red blood cells were depleted by applying sample to magnet and transferring supernatant to 
new tube. Samples were pelleted and resuspended in antibody cocktail mix (see Table 2.6) 
and incubated on ice for at least 30 min, flicking tube occasionally. Samples were washed in 
FACS buffer and resuspended in 1 ml FACS buffer containing 0.1 µg/ml DAPI. ECs were 
sorted using ARIA IIu sorter (BD Bioscience) twice. ECs were defined as 
PECAM1hiICAM2+CD45.2-. Dead cells were excluded based on DAPI uptake. The first sort 
was based on ‘yield’ parameter and collected into FACS tubes, which were spun down and 
resorted based on ‘4-way purity’ parameter into eppies. Small volume of EC sample was 
reanalysed to check for purity. ECs were pelleted and stored at -80˚C. 
 
2.5 RNA-sequencing of lung endothelial cells 
Three pairs of Hbo1iEC/iEC and littermate controls were used to determine differential gene 
expression. RNA from lung ECs sorted as per Section 2.4 was extracted using RNeasy Micro 
Kit (Qiagen) as per manufacturers protocol. RNA quality and quantity were measured using 
TapeStation 2200 (Agilent technologies). 120 ng per sample were used for RNA-sequencing 
library preparation using the TruSeq RNA Sample Prep Kit (Illumina) and eight uniquely 
indexed adaptors. Indexed libraries were sequenced on a NextSeq 500 instrument using the 
v2 150 cycle High Output kit (Illumina) to generate 80 bp paired end reads and yielding ~20 
million reads per sample. Base calling and quality scoring were determined using by Real 
Time Analysis (v2.4.6) software and FASTQ file generation and demultiplexing used 
bcl2fastq conversion software (v2.15.0.4). Bioinformatic analyses were conducted by Dr 
Waruni Abeysekera of the WEHI Bioinformatics Support Unit and Professor Gordon Smyth 
of the WEHI Bioinformatics Division. Reads were aligned to the mouse genome (mm10) 
using the Rsubread package (Liao et al., 2013) and assigned to genes using featureCounts 
(Liao et al., 2014), which was annotated using the gene information file 
Mus_musculus.gene_info.gz from June 2017.  Unmapped reads, ribosomal genes and genes 
with less than 0.3 counts per million in at least three samples were removed from analysis. 
One mutant sample (and its littermate control) were weighted down in the analysis as it did 
not show robust deletion of Hbo1 (based on RPKM). The data were adjusted for litter effect. 
Differential expression analysis was performed using limma software package (Ritchie et al., 
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2015). To correct for multiple testing, p-values were adjusted using Benjamini and Hochberg 
method and considered significant if the false discovery rate (FDR) was less than 0.05. 
Differential expression of pathway genes was analysed by ROAST gene set testing (Wu et 
al., 2010).  
 
2.6 Statistics 
All statistical analysis was performed using Graphpad PRISM 7. Tests used and sample sizes 
indicated in relevant figure legends.  
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Table 2.2. Genotyping oligonucleotides 
Gene Primer 
Name 
Primer Sequence Size of PCR 
products 
Hbo1 – conditional 







190 bp (wt) 




(Wang et al., 2010b) 
& Tie2-cre 















330 bp (wt) 
250 bp 
(mTmG) 
Bax – conditional 








242 bp (wt) 
350 bp (fl) 
300 bp (del) 
Bak – null 







580 bp (wt) 
1000 bp (-) 
Mlkl – null 







499 bp (wt) 
159 bp (-) 
Caspase 8 – null 
(Salmena et al., 2003) 
Casp 8 F 
Casp 8 R 
CCAGGAAAAGATTTGTGTCTAGC 
GGCCTTCCTGAGTACTGTCACCTGT 
697 bp (wt) 
800 bp (fl) 
200 bp (del) 
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Table 2.3. Primary and conjugated imaging antibodies 









1:50 5A1E Rabbit Cell Signaling 
Technology #9664 
Collagen IV 4 µg/ml Poly Goat Millipore #AB769 
DLL4 5 µg/ml Poly Goat R&D Systems 
#AF1389 
EGFP 5 µg/ml Poly Rabbit Invitrogen #A11122 
EGFP 5 µg/ml Poly Goat Abcam #ab5450 
ESM1 2 µg/ml Poly Goat R&D Systems 
#AF1999 
Fibronectin 5 µg/ml Poly Rabbit Abcam 
#AB2033 
FLI1 1 µg/ml Poly Rabbit Abcam #ab15289 
GFAP 1:500 DAKO Rabbit Z0334 
GM130 - Alexa-
Fluor 647 
1 µg/ml EP892Y Rabbit Abcam #ab195303 
H3K14ac 1:500 Poly Rabbit Millipore 
#07-353 
ICAM2/CD102 2.5 µg/ml 3C4(mlC2/4) Rabbit BD Pharmingen 
#553336 
PECAM1 5 µg/ml MEC13.3 Rat BD Pharmingen 
#553370 
PECAM1 1 µg/ml Poly Goat R&D Systems 
#AF3628 
Phospho-histone 
H3 (Ser10) – 
Alexa-Fluor 488 
2 µg/ml Poly Rabbit Millipore #06-570-
AF488 





5 µg/ml Poly Rabbit Abcam 
#AB4833 
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Pimonidazole 5 µg/ml Poly Rabbit Hypoxyprobe 
#Pab2627AP 




Table 2.4. Secondary imaging antibodies 
Antibody Dilution Host species Source 
Anti-goat-AF647 1:400 Donkey Jackson 
#705-605-147 
Anti-goat-Cy3 1:400 Donkey Jackson 
#705-165-147 
Anti-goat-DL405 1:400 Donkey Jackson 
#705-475-147 
Anti-rabbit-AF647 1:400 Donkey Jackson 
#711-605-152 
Anti-rabbit-Cy3 1:400 Donkey Jackson 
# 711-165-152 
Anti-rat-AF647 1:400 Donkey Jackson 
#712-605-150 
Anti-rat-DL488 1:400 Donkey Jackson 
#712-605-150 
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Table 2.5. Buffers 
Buffer Ingredients 
KDS-BSS (Ken Douglas 
Shortman Balanced Salt 
solution) 
pH 7.05-7.25 
Made by the WEHI media 
department 
150 mM NaCl 
3.7 mM KCl 
2.5 mM CaCl2.2H2O 
1.2 mM MgSO4.7H2O 
0.8 mM K2HPO4 
1.2 mM KH2PO4 
14.8 mM HEPES 
Made up in Type I H2O 
FACS dissociation buffer 0.25 U/ml Liberase TM (Roche, #05401119001) 
10 µg/ml DNase 1 (Worthington, #LS002139) 
Made up in DPBS (Gibco) 
 
 
Table 2.6. Flow cytometry antibodies 
Antibody Dilution Clone Source 
CD45.2 - PerCPCy5.5 1:200 104 BD Pharmingen #552950 
ICAM2 - FITC 1:500 3C4 BD Pharmingen #557444 
PECAM1 - APC 1:400 390 eBioscience #17-0311 





  Mechanisms of angiogenesis in development & disease 
 55 
  
















Chapter 3:  









  Mechanisms of angiogenesis in development & disease 
 59 
3 Chapter 3: The role of HBO1 in sprouting and pathological angiogenesis 
Chapter 3: The role of HBO1 in sprouting and pathological 
angiogenesis 
3.1 Introduction 
Sprouting angiogenesis is dependent on the differentiation of morphologically, functionally 
and molecularly distinct endothelial tip and stalk cells in response to pro-angiogenic signals. 
Despite arising from the same quiescent vasculature, tip and stalk cells have distinct gene 
expression profiles (del Toro et al., 2010, Strasser et al., 2010) and can rapidly switch between 
these identities (Jakobsson et al., 2010). Chromatin at gene loci important for these cell fate 
decisions must remain in an open, permissive state to allow genes to be quickly switched on 
or off. Post-translational histone modification is one mechanism of regulating transcription 
factor binding (Rothbart & Strahl, 2014). HATs are responsible for acetylating histone lysine 
residues, which is generally associated with open, transcriptionally active chromatin 
(Karmodiya et al., 2012). The HAT HBO1 has been posited to have a role in regulating gene 
expression patterns necessary for cell differentiation during development. HBO1 regulates 
global H3K14ac in all cell types and across multiple regions of the genome with enrichment 
at transcriptionally active gene loci (Karmodiya et al., 2012, Kueh et al., 2011). I therefore 
hypothesised that HBO1 may be important for cell fate decisions and associated changes in 
gene expression in ECs. In this chapter, I have characterised the EC-autonomous role of 
HBO1 in both developmental and pathological angiogenesis by deleting the Hbo1 gene 
specifically in ECs. I have used the neonatal mouse retina to study sprouting angiogenesis in 
a developmental context and have used the oxygen-induced retinopathy model of 
pathological angiogenesis to understand the role of HBO1 during abnormal vessel growth.   
3.2 Results 
3.2.1 Endothelial H3K14ac levels are elevated in sprouting vessels 
HBO1 is ubiquitously expressed across tissues, however its activity may differ across cell 
types. To understand where HBO1 is most active within the EC network, a readout for 
HBO1 activity was required. As H3K14 is the only acetylation target of HBO1 and no other 
HAT compensates for loss of HBO1 (Kueh et al., 2011), this mark represents a specific 
readout for HBO1 activity. The distribution of H3K14ac across retinal endothelium was 
assessed in ECs within both the remodelling and sprouting zones of a wild type postnatal 
(P)6 mouse retina. This timepoint was chosen as extensive angiogenesis is occurring at this 
  Mechanisms of angiogenesis in development & disease 
 60 
time. The sprouting zone is the area associated with active vessel growth and tip cell activity, 
whereas the remodelling zone undergoes vessel rearrangements to form a hierarchical and 
efficient conduit for blood flow (Figure 3.1a). While H3K14ac expression in individual ECs 
was highly variable in both the sprouting (SD = 6.1) and remodelling (SD = 8.1) regions 
(Figure 3.1b), collectively ECs in the sprouting zone of control mice had a 1.38-fold increase 
in H3K14ac relative to remodelling zone ECs (Figure 3.1c). This suggests the HAT activity 





Figure 3.1. H3K14ac expression is higher in endothelial cells involved in vessel 
growth 
(a) Vasculature from a P6 wild type retina where the pink line demarcates zones of vessel 
sprouting/growth and vessel remodelling. Coloured boxes indicate regions where EC 
H3K14ac was measured. Examples of EC H3K14ac expression in sprouting zone (blue 
outline) and remodelling zone (orange outline) are shown at right (b) Graph shows raw 
H3K14ac expression within ECs of a single representative control mouse in the 
remodelling zone (circle) and sprouting zone (triangle). Data are mean ± SD. Each data 
point represents one individual EC. (c) H3K14ac ratio between ECs in sprouting zone 
compared to remodelling zone for P6 wild type mice. Data are mean ± SEM. Each data 
point represents one individual animal.  
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3.2.2 Cdh5(PAC)-creERT2 efficiently deletes Hbo1 within the endothelium 
To study the EC-autonomous role for HBO1 during sprouting angiogenesis, mice carrying 
Hbo1 conditional alleles (Kueh et al., 2011) were crossed to those expressing the tamoxifen 
inducible, endothelial specific Cdh5(PAC)-creERT2 transgene (Wang et al., 2010b). These 
mice are hereafter referred to as Hbo1iEC/iEC mice. The genotypes of control mice included 
Hbo1fl/+;Cdh5(PAC)-creERT2+ (heterozygote following tamoxifen administration), Hbo1fl/+ and 
Hbo1fl/fl. Pups were administered tamoxifen at P1 and P2 to activate cre recombinase and 
induce EC-specific deletion of Hbo1. As there are no antibodies against HBO1 that work 
reliably by wholemount immunohistochemistry, H3K14ac was used as a surrogate readout 
for loss of HBO1 activity within the endothelium. Levels of H3K14ac were assessed in ECs 
within the vein and surrounding plexus in the P6 retina by quantitative imaging (Figure 
3.2a,b). Hbo1iEC/iEC mice showed less variability in the level of H3K14ac in individual ECs in 
both the sprouting (SD = 4.6) and remodelling (SD = 4.1) zone (Figure 3.2c). To compare 
H3K14ac between mice, endothelial H3K14ac was normalised to surrounding non-ECs to 
account for differences in staining across retinas. Hbo1iEC/iEC mice showed a significant 
reduction in EC H3K14ac compared to control mice (Figure 3.2d- note that the bimodal 
distribution of H3K14ac in controls did not segregate by genotype, with heterozygous mice 
included in both higher and lower H3K14ac populations). Expression of H3K14ac in three 
Hbo1iEC/iEC mice at levels similar to controls (purple outline, Figure 3.2d) reflected inter-litter 
variability, as their littermate controls (purple circles, Figure 3.2d) also had higher levels of 
H3K14ac compared to other control mice. Additionally, these mice showed reduced 
individual EC variability in H3K14ac (not shown) consistent with deleted Hbo1. Notably, 
differential H3K14ac levels between the sprouting and remodelling zones were no longer 
observed following deletion of Hbo1, with the exception of one mouse that may reflect 
incomplete Hbo1 deletion (Figure 3.2e). This suggests the residual H3K14ac signal in the 
Hbo1iEC/iEC mice represents background signal and that HBO1 was effectively inactivated in 
three of four animals. 


























Figure 3.2. Endothelial H3K14ac is reduced in the absence of HBO1 
(a) Images of the venous plexus region stained for PECAM1 (cyan), Hoechst-33342 
(yellow) and H3K14ac (magenta) in P6 control and Hbo1iEC/iEC retinas. Scale bar = 20 µm. 
Arrowheads indicate EC nuclei. Red arrow indicates EC from Hbo1iEC/iEC mouse that has 
high H3K14ac expression, which has likely escaped cre deletion of Hbo1. (b) Orange box 
indicates vein and plexus region where EC H3K14ac levels were measured in d. (c) Raw 
H3K14ac expression within ECs of a single representative Hbo1iEC/iEC mouse in the 
remodelling zone (circle) and sprouting zone (triangle). Data are mean ± SD. Each data 
point represents one individual EC.  (d) Quantification of H3K14ac levels in P6 control 
(n = 9) and Hbo1iEC/iEC (n = 9) retinas. H3K14ac levels within the endothelium have been 
normalised to surrounding non-ECs to account for differences in H3K14ac staining. Solid 
purple symbols indicate control mice from the same litter as the three Hbo1iEC/iEC mice that 
show higher H3K14ac expression (purple outline). Data are mean ± SEM. Each circle 
represents one individual animal. (e) Ratio of H3K14ac levels in sprouting zone ECs to 
remodelling zone ECs in P6 control (n = 3) and Hbo1iEC/iEC (n = 3) retinas. Student’s two-
tailed t-test, *p<0.05, ****p<0.0001. Data are mean ± SEM. Each circle represents one 
individual animal. 
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3.2.4 Vessel growth is reduced in the absence of HBO1 
To investigate the effect of HBO1 loss on sprouting angiogenesis, Hbo1iEC/iEC and littermate 
control pups were administered tamoxifen at P1 and P2 and the retinal vasculature analysed 
at P6. Staining with the endothelial marker PECAM1 revealed reduced vascularisation in the 
Hbo1iEC/iEC retinas (Figure 3.3a). Total vessel area and radial vessel outgrowth, a measure of 
centripetal vascular growth, were significantly reduced in Hbo1iEC/iEC mice compared to 
controls (Figure 3.3b,c). To measure the density of vessel networks, images of retinal vessels 
were segmented and skeletonised (Figure 3.3d). Signal from collagen IV staining, a 
component of the vascular basement membrane, was used for this analysis as it allowed 
cleaner segmentation of vessel networks than PECAM1. From these images, Hbo1iEC/iEC 
retinas were found to have a reduced number of vessel branch points and vessel segments 
per area of retina implying a less dense vessel network (Figure 3.3e,f).  
 
A range of cellular events may cause a reduction in vessel density including reduced 
proliferation, increased cell death or increased vessel regression. To assess proliferation, mice 
were injected with the thymidine nucleoside analogue 5-ethynyl-2’-deoxyuridine (EdU), 
which is incorporated into newly synthesised DNA during S phase of the cell cycle. Cells 
were labelled with EdU for 2 h, allowing any replicating cells within this time to be labelled. 
Proliferating ECs were determined by immunofluorescence based on co-expression of EdU, 
PECAM1 and FLI1, which is an EC specific nuclear maker (Folpe et al., 2001)(Figure 3.4a,b). 
Despite increased variability in proliferation rates in Hbo1iEC/iEC retinas, they were on average 
not significantly different from control mice (Figure 3.4c). Further supporting this, the 
number of ECs relative to vessel area was unchanged between control and Hbo1iEC/iEC mice 
(Figure 3.4d). 




Figure 3.3. HBO1 is important for sprouting angiogenesis 
(a) PECAM1 overview of P6 control and Hbo1iEC/iEC retinas. Scale bar = 500 µm. 
Quantification of (b) total retinal vessel area and (c) radial outgrowth for control (n = 12) 
and Hbo1iEC/iEC (n = 11). (d) Collagen IV staining of control and Hbo1iEC/iEC plexus and 
examples from corresponding branch point and segment analysis output. Branch points 
represented by orange dots; segments represented by white lines. Quantification of (e) 
branch points and (f) vessel segments for control (n = 8) and Hbo1iEC/iEC (n = 8). Student’s 
two-tailed t-test, **p<0.01, ***p<0.001. All data are mean ± SEM. Each circle represents 
one individual animal. 
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Figure 3.4. ECs deficient in HBO1 do not have a proliferation defect 
(a) Proliferating ECs in P6 control and Hbo1iEC/iEC retinas within the capillary plexus 
between artery and vein in sprouting zone (this region is represented by orange box in 
retina image on left-hand side) stained for PECAM1 (cyan), endothelial nuclear marker 
FLI1 (magenta) and EdU (yellow). Scale bar = 30 µm. (b) Examples of proliferation 
analysis output for images in (a). ECs automatically detected as EdU+ are outlined by 
yellow line. (c) Quantification of proportion of proliferating ECs in control (n = 6) and 
Hbo1iEC/iEC (n = 7) retinas. (d). Quantification of number of ECs within remodelling plexus 
per vessel area for control (n = 6) and Hbo1iEC/iEC (n = 7) mice. Student’s two-tailed t-test, 
ns p≥0.05. All data are mean ± SEM. Each circle represents one individual animal. 
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Increased apoptosis can result in a less dense vascular network (Watson et al., 2016b). To 
understand whether an increase in apoptosis was responsible for the Hbo1 phenotype, P6 
retinas were stained with an antibody against cleaved (active) caspase 3, which marks cells in 
which apoptosis has been activated. Apoptotic ECs were identified as active caspase 3+ 
PECAM1+ and enclosed within a collagen IV basement membrane (Figure 3.5a). There was 
no significant difference in the number of apoptotic ECs between control and Hbo1iEC/iEC 
mice, indicating that increased apoptosis does not account for the reduction in 
vascularisation (Figure 3.5b,c). 
 
Finally, vessel regression in P6 retinas was assessed to determine whether this could account 
for the reduction in vascularisation. A low level of vessel regression occurs normally during 
retinal angiogenesis, as part of the remodelling process (Korn & Augustin, 2015) and 
excessive regression can lead to a sparse vascular network (Phng et al., 2009). As vessels 
regress, they leave behind a ‘sleeve’ of collagen IV basement membrane devoid of 
PECAM1+ ECs (Figure 3.5d). Vessel regression can therefore be determined from the ratio 
between PECAM1 and collagen IV (Phng et al., 2009). Control and Hbo1iEC/iEC vessels 
showed similar ratios of PECAM1 to collagen IV (Figure 3.5e), indicating that excessive 
vessel regression was not contributing to the Hbo1 phenotype.  
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Figure 3.5. EC apoptosis and vessel regression are normal in Hbo1iEC/iEC retinas 
(a) Apoptotic ECs are active caspase 3+ (magenta), PECAM1+ (yellow) and enclosed within 
collagen IV (cyan). Scale bar = 20 µm. (b) Plexus region in P6 control and Hbo1iEC/iEC retinas 
stained for collagen IV with orange dots indicating where apoptotic ECs were detected. Scale 
bar = 150 µm. (c) Quantification of apoptotic ECs per vessel area in control (n = 6) and 
Hbo1iEC/iEC (n = 4) retinas. (d) Regressing vessels are PECAM1– collagen IV+, examples are 
indicated by white arrowheads. (e) Quantification of vessel regression across retina for 
control (n = 9) and Hbo1iEC/iEC (n = 7) retinas. Student’s two-tailed t-test, ns p≥0.05. All data 
are mean ± SEM. Each circle represents one individual animal. 
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3.2.5 Tip cells are specified but fail to sprout normally in the absence of HBO1 
A further explanation for reduced vessel growth may be due to less tip cell activity. While 
control mice had many vessel sprouts extending out from the leading edge of the vessel 
front, Hbo1iEC/iEC retinas had fewer making the sprout front blunted in appearance (Figure 
3.6a). This suggested that there may be some abnormality in the ability of Hbo1iEC/iEC mice to 
form tip cells as these cells are responsible for initiating and directing the migration of new 
sprouts. By counting filopodia clusters extending from tip cells (Figure 3.6b), there was a 
significant decrease in Hbo1iEC/iEC retinas compared to controls (Figure 3.6c). To determine 
whether there was a failure to specify tip cells in the absence of HBO1, retinas were stained 
with the tip cell-specific marker ESM1 (Figure 3.6a). Interestingly, there was no difference 
in the number of ESM1+ ECs along the sprouting front between control and Hbo1iEC/iEC  
mice (Figure 3.6d). Consistent with this, staining for another tip cell marker, DLL4, showed 
ECs at the sprouting front of Hbo1iEC/iEC retinas expressing DLL4, consistent with successful 
tip cell specification (Figure 3.6e). These results suggest that the altered sprouting in 
Hbo1iEC/iEC mice is not due to a failure to specify tip cells, but due to changes to their 



























Figure 3.6. HBO1 is important for tip cell sprouting, but not tip cell identity 
(a) Vessels in the sprouting zone in P6 control and Hbo1iEC/iEC retinas stained for 
PECAM1 (greyscale) and tip-cell marker ESM1 (magenta). Scale bar = 80 µm. (b) Arrows 
point to examples of tip cell filopodia clusters quantified in (c). (c) Quantification of 
filopodia clusters per length of sprouting front for control (n = 10) and Hbo1iEC/iEC retinas 
(n = 11). (d) Quantification of the number of ESM1+ ECs per length of sprouting front 
for control (n = 10) and Hbo1iEC/iEC retinas (n = 11). (e) Representative example of DLL4 
expression (greyscale) in tip cells of control and Hbo1iEC/iEC retinas. Retinas also stained 
with VE-cadherin (green) and FLI1 (magenta). Scale bar = 30 µm. Student’s two-tailed 
t-test, ns p≥0.05, ****p<0.0001. All data are mean ± SEM. Each circle represents one 
individual animal. 
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3.2.7 Tip cells deficient in HBO1 do not exhibit biased front-rear polarity 
The lack of vessel sprouts despite normal numbers of tip cells could possibly be explained 
by a migratory defect in Hbo1iEC/iEC tip cells. A key process required for tip cell migration is 
the establishment of front-rear polarity (Dubrac et al., 2016), which establishes a leading edge 
for the cell. Polarity can be determined by the positioning of the Golgi apparatus relative to 
the nucleus. In migrating cells, the Golgi apparatus is positioned in front of the nucleus, 
toward to the leading edge. It has previously been shown that the majority of tip cells position 
the Golgi apparatus at the front of the cell, toward the direction of sprout elongation (Dubrac 
et al., 2016). To assess front-rear polarity and migratory direction of tip cells, retinas were 
stained with the Golgi apparatus marker GM130, the nuclear marker FLI1 and the tip cell 
marker ESM1. Positioning of the Golgi apparatus was assigned as front, middle or rear of 
the cell relative to the direction of sprout elongation as shown in Figure 3.7a. In control mice, 
most tip cells were preferentially polarised in the direction of sprout elongation (Figure 
3.7b,c). In contrast, Hbo1iEC/iEC tip cells showed no polarity bias and Golgi apparatus were 
randomly aligned relative to the direction of sprout elongation (Figure 3.7c). This suggests 
that these ECs were unable to undergo directed migration, which may account for the failed 
sprout elongation. Consistent with failed sprout elongation, the sprouting front of Hbo1iEC/iEC 
retinas showed areas of increased EC density (Figure 3.7b,d). This corresponded to an 
increase in vessel width in Hbo1iEC/iEC sprouting front vessels as compared to controls (Figure 
3.7e). Together, these data suggest that ECs accumulate within the sprouting front as tip cells 
are unable to exhibit directed migration. 
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Figure 3.7. Tip cells fail to establish biased front-rear polarity in the absence of 
HBO1 
(a) To establish front-rear polarity tip cells orientate their Golgi apparatus in front of the 
nucleus with respect to the sprouting/leading edge of the cell (shown by orange shape). 
Tip cells may alternatively orientate their Golgi apparatus to the middle of the nucleus 
(blue) or behind the nucleus (green) with respect to sprouting edge. (b) P6 control and 
Hbo1iEC/iEC retinas stained for Golgi apparatus marker GM130 (cyan), FLI1 (blue) and 
PECAM1 (red). Scale bar = 20 µm. For clarity, GM130 signal has been masked to 
PECAM1 signal. Arrowheads indicate front polarised tip cells, double headed arrow 
indicates middle polarised tip cells and arrows indicate rear polarised ECs. (c) Proportion 
of ESM1+ tip cells polarised in each direction for control (n = 5) and Hbo1iEC/iEC (n = 6) 
mice. Two-way ANOVA, ns p ≥0.05, ****p<0.0001. (d) Quantification of EC density 
within vessels at the edge of sprouting front as determined by the number of ECs per 
length of vessel for control (n = 6) and Hbo1iEC/iEC (n = 6) retinas. (e) Quantification of 
the width of vessels at the edge of sprouting front as determined by vessel area per length 
of vessel for control (n = 6) and Hbo1iEC/iEC (n = 6) retinas Student’s two-tailed t-test, 
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3.2.8 Assessing the tip cell migratory defect using live-imaging 
To investigate whether there was a migratory defect in Hbo1-deficient tip cells in the retina, 
I developed a novel protocol for live-imaging retinal angiogenesis ex vivo. To track EC 
behaviour over time, Hbo1iEC/iEC mice were crossed with the mTmG reporter allele. This allele 
ubiquitously expresses membrane-localised dTomato in all cells and membrane-localised 
EGFP upon cre-recombination (Muzumdar et al., 2007). Mice carrying both these alleles are 
referred to as Hbo1iEC/iEC;mTmG+ mice. In this experiment, controlmTmG+ and Hbo1iEC/iEC;mTmG+ 
mice were treated with 50 µg tamoxifen on P1 and P2 then the retinas dissected and live-
imaged at P6. On dissection, retinas were immediately flat mounted with the vessel surface 
(inner limiting membrane) facing down onto a bed of 1% agarose in 10% FCS in DMEM. 
Retinas were imaged every 30 min for 3.5 h (Figure 3.8a). Between four and six fields of view 
per retina were imaged and between 25 and 67 (median = 61) sprouts per retina were 
analysed. Sprout behaviour was dynamic in both control and Hbo1iEC/iEC retinas (Figure 3.8b).  
Four general classes of sprout behaviour were observed during the imaging period (Figure 
3.8c): 1) sprouts that lengthened, 2) sprouts that initially lengthened but then retracted, 3) 
sprouts that did not change in length and 4) sprouts that only retracted. Figure 3.8d 
summarises the net change in sprout length for all sprouts measured in each mouse. Positive 
values indicate the amount by which the sprout increased in length (in µm), whereas negative 
values indicate the amount by which the sprout retracted. Both control and Hbo1iEC/iEC mice 
showed sprouts that increased in length and others that retracted and the pattern was similar 
for all mice analysed (Figure 3.8d). Overall, the average net sprout growth over the imaging 
period was 4 µm and this was similar between control and Hbo1iEC/iEC mice (Figure 3.8e). 
This distance is represented by the yellow spot in Figure 3.8f and is less than the length of 
extending filopodia. This suggests that overall, even in control mice the imaging technique 
does not allow for analysis of significant forward EC migration making it difficult to 
determine if the Hbo1iEC/iEC have a migratory defect.  
 
It could be possible that the blunt sprouting front in Hbo1iEC/iEC mice is due to increased 
sideways movement of sprouts and anastomosis with neighbouring vessels rather than 
directed movement outward into the avascular space. To measure the directionality of sprout 
growth, the angle at which each sprout grew was determined relative to the leading edge of 
the vasculature. In both control and Hbo1iEC/iEC mice, the most common sprout angle was 
forwards, directed into the avascular tissue (Figure 3.9a,b). Sprouts from both control and 
Hbo1iEC/iEC mice also showed sideways migration (parallel to the leading edge) as the second 
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most frequent direction (Figure 3.9b,c). Occasional sprouting back toward the vascular 
network was rare in both control and Hbo1iEC/iEC mice (Figure 3.9b). There was no statistical 
difference between control and Hbo1iEC/iEC mice for direction of sprout growth, suggesting 
this does not account for the phenotype observed (Figure 3.9b). 


















Figure 3.8. Both control and Hbo1iEC/iEC mice show limited migration during 
retinal explant live-imaging 
(a) Schematic of retina live-imaging protocol. Retinas were dissected and flat mounted 
onto 1% agarose with 10% FCS in DMEM. Retinas were live-imaged for 3.5 h with images 
acquired every 30 min. (b) Stills from live-imaging videos from control and Hbo1iEC/iEC 
mice expressing EGFP. Scale bar = 50 µm. Time (hh:mm) is shown above images. Yellow 
arrows indicate sprout that grows over imaging period, blue arrow indicates sprout that 
retracts over imaging period and orange arrow indicates sprout that does not grow over 
imaging period. (c) Examples of sprouts from control mice that show vessel 
growth/lengthening, growth & retraction, no growth or retraction. Scale bar = 25 µm. 
Time (hh:mm) is shown above images. Difference in sprout length from t0 to t3.5h is shown 
to right of each set of images. (d) Quantification of net sprout length over 3.5 h for control 
and Hbo1iEC/iEC retinas. Values less than zero indicate sprouts that retracted over imaging 
period. Each column represents an individual animal and each data point indicates an 
individual sprout from that animal. Data are mean ± SD. (e) Net change in sprout length 
for control (n = 4) and Hbo1iEC/iEC (n = 3) retinas over 3.5 h of imaging. Student’s two-
tailed t-test, ns p≥0.05. Data are mean ± SEM. Each circle represents one individual 
animal. (f) Yellow box = 4 µm x 4 µm to indicate net growth as shown in (e). White scale 
bar = 15 µm. 
 
 




Figure 3.9. Direction of sprout growth is normal in Hbo1iEC/iEC mice 
(a) Examples of control and Hbo1iEC/iEC sprouts that grow forwards. Scale bar = 25 µm. 
Time (hh:mm) is shown on images. Yellow line indicates net growth over imaging period. 
Dashed blue line indicates leading edge. (b) Quantification of proportion of sprouts 
growing forwards (purple), sideways (grey) or backwards (blue) for control (n = 4) and 
Hbo1iEC/iEC (n = 3) mice. Multiple t-tests with Holm-Sidak correction for multiple testing, 
ns p≥0.05. All data are mean ± SEM. (c) Examples of control and Hbo1iEC/iEC sprouts that 
grow sideways. Scale bar = 25 µm. Dashed blue line indicates leading edge. 
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3.2.9 Tip cell dependent pathological angiogenesis is reduced in the absence of 
HBO1 
The analysis of retinal vascular development suggests HBO1 is required for normal tip cell 
activity. In addition to normal angiogenesis, tip cell activity is also important for pathological 
vessel growth in the retina, as has been shown in the OIR model of ischaemia-induced 
neovascularisation (see Chapter 1.4) (Dubrac et al., 2016, Raimondi et al., 2014, Rama et al., 
2015). The OIR model was used to determine whether HBO1-dependent tip cell activity was 
also important for pathological vessel growth.  Hbo1iEC/iEC mice were exposed to high oxygen 
from P7 to P12, to induce vaso-obliteration. To induce Hbo1 deletion, Hbo1iEC/iEC and control 
pups were treated with 50 mg/kg tamoxifen at P12 and P13. Tamoxifen was administered 
and Hbo1 deleted after the oxygen exposure to allow vessel development prior to P7 to 
proceed normally and to prevent any unknown effects that deletion of Hbo1 may have on 
oxygen-induced vaso-obliteration. Retinas were then examined at the peak of neovascular 
growth at P17. Staining for collagen IV revealed a significant reduction in neovascular area 
in Hbo1iEC/iEC mice compared to controls (Figure 3.10a,b), suggesting that HBO1 was 
required for pathological vessel growth. Concurrent with pathological vessel growth, the 
vaso-obliterated central retina is revascularised by sprouting angiogenesis from the remaining 
peripheral vessels. Thus, the vaso-obliterated area remaining at P17 is a measure of normal 
sprouting angiogenesis. Consistent with the developmental angiogenesis defect, Hbo1iEC/iEC 
retinas had a significantly increased vaso-obliterated area compared to controls (Figure 
3.10c), indicating that normal angiogenesis was impaired in the OIR model. 





Figure 3.10. HBO1 is important for neovascularisation during the OIR model 
(a) Collagen IV images of P17 control and Hbo1iEC/iEC retinas. Neovascular lesions are 
outlined in yellow. Scale bar = 500 µm. Quantification of (b) neovascular area normalised 
to total retina area and (c) vaso-obliterated area normalised to total retina area in P17 
control (n = 7) and Hbo1iEC/iEC (n = 6) retinas following OIR. Student’s two-tailed t-test, 
**p<0.01. All data are mean ± SEM. Each circle represents one individual animal.  
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3.4 Discussion 
In this chapter, I have characterised the EC-specific role of the HAT HBO1 in normal and 
pathological angiogenesis. I found that HBO1 was required for angiogenic vessel growth by 
promoting normal tip cell activity and that its absence reduced both developmental and 
pathological angiogenesis. 
 
HBO1 has been previously shown to be the major HAT required for H3K14ac (Feng et al., 
2015, Kueh et al., 2011, Zou et al., 2013). Another HAT, GCN5, was shown to acetylate 
H3K14 in gene coding regions for transcriptional elongation but it does not compensate for 
the loss of HBO1 (Agalioti et al., 2002, Kueh et al., 2011). The variability in the level of 
H3K14ac within individual ECs in control mice likely reflects the dynamic nature of this 
mark, which has been previously shown to have a fast turnover rate with a reported half-life 
of about 1 h (Zheng et al., 2013). Histone deacetylases catalyse the removal of histone 
acetylation marks but what the purpose of fast turnover of H3K14ac means for cell 
behaviour or gene expression has not been previously established. H3K14ac levels were used 
as a marker of Hbo1 deletion efficiency. H3K14ac levels in Hbo1iEC/iEC ECs were reduced to 
about 50% of normal. While this could be interpreted as only partial deletion of HBO1, this 
is unlikely the case. Hbo1iEC/iEC mice showed reduced variability in the levels of H3K14ac 
between individual ECs. The remaining H3K14ac signal in the mutants may be due to 
acetylation by another HAT or is simply non-specific background staining. Comparing the 
level of H3K14ac in the postnatal retina of the conditional Hbo1iEC/iEC mutants with germline 
Hbo1 knockouts to establish true background signal is not possible due to the embryonic 
lethality of Hbo1–/– mice. 
 
Loss of HBO1 from the endothelium of the developing retina resulted in reduced vessel 
growth and vessel network density. To understand the cause of this reduction, I examined 
apoptosis, vessel regression, proliferation and tip cell activity. There was no difference 
between control and Hbo1iEC/iEC mice in terms of apoptosis or vessel regression, indicating 
that defects in the regulation of these processes does not underlie the Hbo1iEC/iEC phenotype. 
While the initial studies of HBO1 in non-ECs suggested a role in proliferation and replication 
licensing (Johmura et al., 2008, Wu & Liu, 2008), this was not recapitulated in Hbo1 null 
animals (Kueh et al., 2011). Mouse embryonic fibroblasts, another mesodermal derived cell 
type, isolated from Hbo1–/– embryos also did not exhibit a proliferation defect (Kueh et al., 
2011). Consistent with this, I found that EC proliferation was not significantly reduced in 
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Hbo1iEC/iEC mice compared to controls, but it was more variable. This variability was due to 
intra-litter variation as the proportion of proliferating ECs was highly similar between 
Hbo1iEC/iEC mice within individual litters. As only two mice showed a reduction in 
proliferation, Hbo1iEC/iEC mice did not exhibit a consistent proliferation failure. The role of 
HBO1 in regulating replication licensing and proliferation is contentious, but the data from 
this study are consistent with a non-essential role for HBO1 in proliferation. 
 
Loss of HBO1 from the endothelium resulted in a sprouting defect as evidenced by fewer 
filopodia, blunted sprouting front and increased EC density and vessel width in the sprouting 
front. In control mice, ECs within the sprouting zone had higher levels of H3K14ac than 
ECs in the remodelling zone. This indicates that HBO1 activity is highest in the sprouting 
zone, consistent with the sprouting zone being affected in Hbo1iEC/iEC retinas. Although 
initially hypothesised that HBO1 might be required for specification of distinct EC identities, 
I found that HBO1 was dispensable for specifying tip cell identity based on ESM1 and DLL4 
expression. Both ESM1 and DLL4 expression are upregulated in response to 
VEGFA/VEGFR2 signalling (Lobov et al., 2007, Rocha et al., 2014), suggesting that in the 
absence of HBO1, ECs can still sense VEGFA gradients normally. Instead the reduction in 
filopodia and failure to establish biased polarity for directed migration suggests that HBO1 
regulates tip cell activity. The blunted sprouting front found in Hbo1iEC/iEC retinas bears 
similarity to the EC-specific roles of several other genes in tip cell identity or migration. 
These include the transcription factors MEF2C (Sacilotto et al., 2016) and FOXO1 (Kim et 
al., 2019), the secreted ROBO ligand SLIT2 (Rama et al., 2015), the hypoxia-activated kinase 
MST1 (Kim et al., 2019) and the signalling adaptor proteins NCK1 and NCK2 (Dubrac et 
al., 2016). The molecular basis for the Hbo1 phenotype will be further explored in Chapter 
4.  
 
To validate a migratory defect as the cause of the tip cell phenotype, I attempted to live-
image tip cell activity during retinal angiogenesis. While this did not reveal a migratory defect 
in Hbo1-deficient tip cells, this was possibly due to technical limitations of the technique as 
control mice also did not show evidence of significant tip cell migration. Comparing the 
average radial outgrowth of P5 retinas from work previously generated in our laboratory to 
P6 control retinas in this thesis, the growth of the vessel network is about 330 µm per day 
or about 48 µm over 3.5 h. Therefore, the average net growth of 4 µm observed does not 
reflect normal growth. Only a few sprouts per mouse were able to grow by the normal 
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amount during the imaging period (Figure 3.8d). It was not possible to image the retinal 
explants for longer as the network fragmented with increased EC apoptosis. There were a 
number of limitations to the live-imaging. Firstly, this system requires retinal explants, which 
removes the vessels from their normal environment and blood flow. In culture, shear force 
can induce vessel sprouting (Galie et al., 2014). While intersegmental vessel sprouting in 
zebrafish is not affected by loss of blood flow (Watson et al., 2013), vessel sprouting and 
elongation within remodelling capillary plexus in avian embryos was shown to be regulated 
by flow dynamics (Ghaffari et al., 2015). This has not been conclusively shown in the retina 
but flow can drive vessel changes associated with cell migration during retinal vessel 
regression (Franco et al., 2015). Secondly, CO2 levels were controlled during imaging but 
oxygen levels were not. Retinal explants exposed to room air would be subjected to higher 
oxygen levels compared to normal tissue oxygen concentrations (21% vs. 1-11%, respectively 
(Carreau et al., 2011). How this change in oxygen would alter tissue hypoxia and levels of 
growth factors that respond to hypoxia and support vessel growth is unknown. Finally, 
although dissecting and flat-mounting were relatively quick procedures, the stress of these 
actions may affect normal sprouting behaviour in both control and Hbo1iEC/iEC mice. Future 
endeavours to understand migration in the absence of HBO1 could involve in vitro migration 
assays, such as scratch wound in 2D cultures (Liang et al., 2007), embryoid body sprouting 
(Nakatsu et al., 2003) or meta-tarsal sprouting assays (Song et al., 2015), all of which have 
been used to successfully live-image EC migration. However, given the in vitro nature of these 
systems, they may not reflect the normal sprouting angiogenesis that occurs in the retina or 
the environment that supports it, thus some of their limitations may overlap with those 
encountered in the ex vivo retina live-imaging. 
 
In the absence of live-imaging data, static imaging of the sprouting front of Hbo1iEC/iEC mice 
supported the notion of impaired/uncoordinated tip cell migration. In the absence of HBO1, 
tip cell front-rear polarity was disorganised relative to the direction of sprout elongation. 
Biased front-rear polarity has been shown to be important for EC migration and tip cell 
activity during sprouting angiogenesis (Dubrac et al., 2016). The adaptor protein NCK 
bridges VEGFR2 and ROBO1 to enable front-rear polarity downstream of CDC42 and 
PAK2 activity. In the absence of NCK1/2, tip cells fail to become front-polarised and the 
majority of mutant tip cells instead displayed rear-polarity (Dubrac et al., 2016). In Hbo1iEC/iEC 
mutants, tip cell polarity was random, with no skewing towards one polarised state or 
another. The discrepancy in polarity phenotype between Hbo1 and Nck mutant tip cells may 
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suggest a different underlying cause for the polarity defect or could be due to differences in 
the methods by which polarity was assigned. The reduced radial outgrowth suggests a delay 
in vessel migration rather than a failure. It is possible that in Hbo1iEC/iEC mice, the random 
chance of front-polarised tip cells allows successful migration of a given sprout but that 
migration proceeds at a delayed rate as the collective behaviour of EC migration is abnormal 
and ECs are not biased towards migrating. Increased density of ECs in the sprouting front 
of Hbo1iEC/iEC retinas, where tip cells would normally be emerging, suggests that ECs 
accumulate instead of growing out. Alternatively, the ability of Hbo1iEC/iEC retinal vessels to 
grow as well as they have may reflect the normal vessel growth that occurred before Hbo1 
was deleted at P1, or before existing HBO1 protein was decayed or diluted by cell division 
from ECs within the postnatal retina. It is possible that deletion of Hbo1 prior to birth would 
result in a more severe radial outgrowth phenotype due to failed directed migration.  
 
The creation of mosaic mice in which a gene of interest is deleted only in a fraction of ECs 
is a commonly used method to assess the fitness of mutant ECs to compete for the tip cell 
position and reveal tip cell deficiencies as a cause of angiogenic phenotypes. This method 
has been used to demonstrate a role for numerous genes in tip cell specification and 
behaviour (e.g.: (Aspalter et al., 2015, Lavina et al., 2018, Pitulescu et al., 2017)). Mosaic 
expression experiments were performed in Hbo1iEC/iEC;mTmG+ mice but unfortunately there 
was no correlation between Hbo1 deletion and EGFP expression using the low dose of 
tamoxifen required to generate EGFP mosaicism (data not shown), which precluded using 
this method to assess tip cell fitness. Nevertheless, in the absence of mosaic data, the 
differential distribution of H3K14ac between the sprouting and remodelling zones in control 
mice suggests that ECs with higher levels of HBO1 would be preferentially found in the 
sprouting front. 
 
Many genes and pathways that are important for normal vessel growth are also important 
for allowing vessels to grow in disease contexts (Dubrac et al., 2016, Raimondi et al., 2014, 
Xu et al., 2012). The OIR model can be used to study pathological vessel growth and is a 
commonly used model for retinopathy of prematurity and PDR. I found that HBO1 was 
necessary for pathological neovascular growth that occurs in the OIR model. Neovascular 
growth in the OIR model is a result of misdirected angiogenesis due in part to altered tip cell 
behaviour (Dubrac et al., 2016, Kim et al., 2019), supporting the idea that a tip cell defect 
underlies the Hbo1 phenotype. I also found that HBO1 was required for the normal 
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sprouting angiogenesis that revascularises the vaso-obliterated area, supporting the role of 
HBO1 during developmental angiogenesis observed in the early postnatal retina. 
 
The next chapter will detail the investigation into understanding the molecular mechanism 
of HBO1 during sprouting angiogenesis. 
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4 Chapter 4: Investigating the mechanism of HBO1 in the developing vasculature 
Chapter 4: Investigating the mechanism of HBO1 in the 
developing vasculature 
4.1 Introduction 
In the previous chapter, I showed that HBO1 was required for sprouting angiogenesis. I 
found that HBO1 was required for the normal behaviour of tip cells, which was shown by a 
reduction in tip cell filopodia and a failure to establish biased front-rear polarity that is 
required for tip cell migration. In this chapter, I have investigated the molecular mechanism 
by which HBO1 regulates tip cell activity. 
4.2 Results 
4.2.1 RNA-sequencing of lung ECs isolated from neonatal Hbo1iEC/iEC mice 
HBO1 is a HAT necessary for H3K14ac, a histone modification that is associated with 
transcriptionally active genes (Feng et al., 2015, Kueh et al., 2011, Zou et al., 2013). Histone 
acetylation levels affect chromatin conformation and gene expression (Rothbart & Strahl, 
2014). The cause of the Hbo1 phenotype would therefore likely be due to altered gene 
expression. To understand the transcriptional differences between control and Hbo1iEC/iEC 
ECs, RNA-sequencing was performed on ECs sorted from P6 heterozygote control 
(Hbo1iEC/+) and Hbo1iEC/iEC lungs. Heterozygote control mice were used to control for gene 
expression differences that may have arisen non-specifically due to the presence of active 
cre-recombinase. Unlike the retina, lungs contain a large number of ECs and were used in 
order to obtain sufficient cells and RNA for sequencing. Viable ECs based on DAPI 
exclusion were sorted as PECAM1hi ICAM2hi and CD45.2neg (Figure 4.1a). Reanalysis of 
sorted samples showed >95% purity for ECs. RNA was extracted and 120 ng per sample 
was used to generate sequencing libraries using the TruSeq library preparation kit (Illumina). 
Following NextSeq sequencing, differential expression analysis was performed by Dr Waruni 
Abeysekera and Prof Gordon Smyth (Figure 4.1a). Hbo1iEC/iEC mice showed significantly 
reduced Hbo1 levels compared to controls based on RPKM values from the RNA-
sequencing (Figure 4.1b). In a multi-dimensional scaling plot, which is a way to visualise 
similarities between samples, the samples segregated by genotype in the first dimension after 
adjusting for litter effect (Figure 4.1c). Using a Benjamini and Hochberg false discovery rate 
(FDR) cut off of less than 0.05, which accounts for multiple testing, deletion of Hbo1 resulted 
in upregulation of 520 genes and downregulation of 973 genes compared to control mice 
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with transcriptome-wide significance (Figure 4.1d). The top 20 downregulated genes and 
upregulated genes, ranked by significance, are shown in Table 4.1 and Table 4.2 respectively. 
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Figure 4.1. RNA-sequencing of lung ECs to understand the effects of the absence 
of HBO1 on transcriptome-wide mRNA levels 
(a) Experimental setup for lung EC RNA-sequencing experiment. ECs were isolated from 
total enzymatically dissociated lung cells by FACS and then RNA was extracted and 
sequenced. Dr Waruni Abeysekera and Prof Gordon Smyth mapped reads and performed 
differential expression analysis. (b) Hbo1 expression in control (n = 3) and Hbo1iEC/iEC (n 
= 3) lung EC RNA-sequencing samples based on reads per kilobase of transcript, per 
million mapped reads (RPKM). Data are mean ± SEM. Each data point represents one 
individual animal. Student’s two-tailed t-test, * p<0.05 (c) Multi-dimensional scaling plot 
showing control and Hbo1iEC/iEC mice segregated by genotype in dimension (dim) 1 and by 
an unknown factor on dimension 2. Each circle represents one mouse. (d) Mean difference 
plots of differentially expressed genes between Hbo1iEC/iEC v. control ECs. Each dot 
represents the average expression of a gene (x-axis) against its log-fold change (y-axis) in 
Hbo1iEC/iEC samples compared to controls. Red dots indicate genes that are significantly 
upregulated in Hbo1iEC/iEC (based on FDR<0.05) and blue dots represent genes that are 
significantly downregulated in Hbo1iEC/iEC (FDR<0.05). Black dots represent genes that are 
not statistically different.  
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Table 4.1. Top 20 downregulated genes in Hbo1iEC/iEC lung ECs compared to 
control lung ECs 
FDR = false discovery rate 





Cers4 0.50 5.99 1.50E-07 
Inhbb 0.56 6.40 1.50E-07 
Serpinb6a 0.53 6.08 1.57E-07 
Ptprf 0.42 4.69 1.83E-07 
Cd24a 0.55 6.63 1.94E-07 
Sdc4 0.52 5.65 1.94E-07 
Sbno2 0.65 8.57 4.12E-07 
Gpr4 0.37 4.10 8.58E-07 
Tnc 0.41 3.92 1.36E-06 
Emp2 0.61 8.41 1.58E-06 
Rgs5 0.42 4.34 1.58E-06 
Vegfc 0.62 6.68 2.03E-06 
Slc34a2 0.37 3.21 2.64E-06 
Mmrn2 0.65 7.79 3.16E-06 
Grik5 0.51 4.60 3.45E-06 
Pltp 0.54 7.98 3.59E-06 
Arrdc4 0.57 6.40 3.59E-06 
Enho 0.43 3.97 4.31E-06 
Samsn1 0.55 4.98 5.17E-06 
Hbb-bs 0.50 4.28 8.29E-06 
 
See Appendix Table 8.1 for all differentially expressed genes between Hbo1iEC/iEC and control 
lung ECs. 
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Table 4.2. Top 20 upregulated genes in Hbo1iEC/iEC lung ECs compared to control 
lung ECs 
FDR = false discovery rate 





Fn1 1.94 9.75 1.51E-09 
Adam23 2.05 6.36 3.84E-08 
Ltbp4 1.51 10.42 1.94E-07 
Plac8 1.71 6.00 1.36E-06 
Npr3 1.47 8.54 1.36E-06 
Vcam1 1.70 5.88 2.03E-06 
Lhfpl2 1.59 6.47 2.20E-06 
Plxnc1 1.68 5.95 2.62E-06 
Nid2 1.54 7.53 1.30E-05 
Tmod2 1.43 7.00 1.65E-05 
Dab2 1.55 5.69 3.01E-05 
Mettl24 1.61 5.28 4.76E-05 
Cxcl16 2.35 3.36 5.06E-05 
Hic1 1.68 5.49 6.07E-05 
Tril 1.52 5.49 6.07E-05 
Ccnd1 1.35 9.05 6.07E-05 
Igfbp7 1.36 9.12 8.76E-05 
Timp3 1.33 9.80 8.76E-05 
Trim47 1.48 6.07 8.92E-05 
Marcksl1 1.32 9.26 1.07E-04 
 
See Appendix Table 8.1 for all differentially expressed genes between Hbo1iEC/iEC and control 
lung ECs. 
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4.2.2 Pathway analysis showed that loss of HBO1 results in altered tip cell activity 
pathways 
To understand whether differentially expressed genes had common actions, KEGG pathway 
analysis was performed by Dr Waruni Abeysekera and Prof Gordon Smyth. This analysis 
takes into account changes in all genes related to a particular pathway and assigns a direction 
to the expression of this pathway. KEGG pathway analysis of the top 15 significantly 
downregulated pathways in Hbo1iEC/iEC mice compared to controls are shown in Figure 4.2a 
(see Appendix Table 8.2 for the complete list of genes within each pathway). Of interest, 
many of these pathways were specifically relevant to the action of tip cells (see Section 1.5 
for details), including ECM-receptor interaction, focal adhesion, cell adhesion molecules 
(CAMs), axon guidance and glycolysis/gluconeogenesis. The particular genes downregulated 
in each of these pathways are shown for reference in Table 4.3. In addition, a gene ontology 
(GO) analysis was performed. GO term analysis can provide information on cellular 
components, molecular functions and biological processes that are altered in a particular set 
of genes. The top 100 downregulated biological process terms in Hbo1iEC/iEC mice compared 
to controls is represented in Figure 4.2b. The y-axis separates terms by the proportion of 
genes included in that term that were downregulated. Related to the results in Chapter 3, GO 
terms relating to cell migration and cell motility were amongst the most downregulated terms 
(Figure 4.2b). See Appendix Table 8.3 for list of all biological processes represented on 
Figure 4.2b. Given the broad spectrum of pathways and processes identified that pertain to 
tip cell behaviour, the RNA-sequencing results supported the conclusion in Chapter 3 that 
HBO1 is required for normal tip cell activity.  
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Figure 4.2. Analysis of pathways and biological processes that are altered in ECs 
deficient for HBO1 
(a) Top 15 most significantly downregulated KEGG pathways in Hbo1iEC/iEC ECs (n = 3) 
compared to control (n = 3). Each bar represents one pathway that is significantly 
downregulated. For reference, the orange line represents FDR = 0.05, values above the 
line are FDR<0.05. For full list of genes that are downregulated in each pathway see 
Appendix Table 8.2 (b) Scatterplot showing the top 100 significantly downregulated 
biological processes gene ontology (GO) terms in Hbo1iEC/iEC ECs (n = 3) compared to 
control (n = 3). Each dot represents the significance of one biological process against the 
proportion of genes associated with that process that are downregulated in Hbo1iEC/iEC ECs 
compared to controls. For the full list of terms see Appendix Table 8.3. 
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Table 4.3. Downregulated genes in Hbo1iEC/iEC lung ECs for KEGG pathways 
associated with tip cell behaviour 
Pathway Downregulated genes 
ECM-receptor interaction Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, 
Col1a1, Itga3, Itgb5, Lama1, Lamc3, Itga4, Thbs1, 
Sdc4, Npnt, Tnc, Cd36, Reln, Itga9, Col4a5 
Focal adhesion Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Flt4, 
Col1a1, Itga3, Itgb5, Lama1, Lamc3, Itga4, Thbs1, 
Myl9, Src, Tnc, Reln, Ilk, Vegfc, Bcar1, Birc3, Itga9, 
Col4a5 
Axon guidance Sema4c, Epha4, Efnb3, Unc5a, Wnt5a, Sema5a, 
Plxnb2, Rnd1, Robo2, Sema6b, Sema6a, Ssh3, Rhod, 
Myl9, Src, Sema6c, Gnai1, Slit2, Plxna1, Ilk, Sema7a, 
Sema3f 
Cell adhesion molecules (CAMs) Cldn7, Nrcam, Cldn5, Alcam, Ptprm, Itga4, Sdc4, 
Cdh4, Ptprf, Sdc3, Cdh1, Jam3, Cd276, Cldn18, Itga9 
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4.2.3 Retina fibronectin patterning appears normal in the absence of HBO1 
Although the activity of HBO1 has generally been associated with transcriptional activation 
(Kueh et al., 2011), the most differentially expressed gene between Hbo1iEC/iEC and control 
mice was Fn1, which encodes fibronectin, and showed almost 2-fold upregulation (Table 
4.2). Fibronectin is a component of the ECM that contributes to angiogenic regulation by 
controlling the availability of growth factors and providing structural support for cell 
adhesion that allow ECs to migrate along the ECM (Stenzel et al., 2011b). As astrocytes are 
responsible for producing this scaffold for vessel growth, fibronectin is expressed in 
avascular regions of the retina. However, ECs also produce fibronectin and its importance 
is highlighted by the reduced vessel growth that occurs when fibronectin is specifically 
deleted from the endothelium (Turner et al., 2017). While too little fibronectin in the retina 
reduces vessel growth (Stenzel et al., 2011b, Turner et al., 2017), a possible hypothesis is that 
too much fibronectin could sequester growth factors and take up space that growing vessels 
would normally occupy during migration and therefore also prevent vessel growth. 
Supporting this hypothesis, other basement membrane components have been previously 
shown to limit tip cell formation (Stenzel et al., 2011a). To understand whether the increased 
in Fn1 mRNA corresponded to increased fibronectin production in the retina, the protein 
expression of fibronectin was detected in Hbo1iEC/iEC retinas. Both control and Hbo1iEC/iEC 
mice showed the same patterning of fibronectin in the avascular retina, which would be 
expected to be normal. Fibronectin was also normally distributed across the vasculature with 
increased density around sprouts and tip cell filopodia in both control and Hbo1iEC/iEC mice 
and did not appear to be upregulated in the absence of HBO1 (Figure 4.3a). It is possible 
that other components of EC-ECM communication were altered in the absence of HBO1. 
As mentioned in the previous section, ECM-receptor interaction was the most significantly 
downregulated pathway in Hbo1iEC/iEC mice. Enrichment analysis of both up and 
downregulated genes in this pathway showed that genes associated with this pathway are 
downregulated in Hbo1iEC/iEC mice (Figure 4.3b, see Appendix Table 8.4 for full list of genes), 
suggesting that in the absence of HBO1 ECs may have reduced capacity to interact with the 
ECM.  
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Figure 4.3. Fibronectin patterning is normal in the absence of HBO1 
(a) Representative images of fibronectin staining in the sprouting front of P6 control (n = 
3) and Hbo1iEC/iEC (n = 3) retinas. Images stained with PECAM1 (green) and fibronectin 
(magenta, greyscale) Scale bar = 50 µm. (b) Barcode plot showing enrichment of ECM-
receptor interaction pathway in Hbo1iEC/iEC ECs compared to control. At the bottom of 
the plot, genes differentially expressed in Hbo1iEC/iEC ECs compared to controls are 
represented by the blue, grey and pink boxes and are arranged according to t-statistic 
(downregulated, blue; upregulated, pink). The vertical lines (‘barcode’) represent ECM-
receptor interaction genes among the genes expressed in the ECs. At the top, the 
horizontal dotted line represents what is considered neutral or no enrichment and worm 
represents the enrichment of ECM-receptor interaction genes in Hbo1iEC/iEC ECs. The p-
value was determined by ROAST gene set testing and refers to the alternative hypothesis 
that pathway genes tend to be downregulated in the absence of HBO1. In this plot, ECM-
receptor genes are significantly enriched in downregulated genes of Hbo1iEC/iEC mice 
compared to controls, indicating this pathway is downregulated in the absence of HBO1. 
For full list of up- and downregulated genes in this pathway see Appendix Table 8.4. 
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4.2.4 Focal adhesions are formed normally in the absence of HBO1 
Integrins on the cell surface interact with the ECM and transmit signals from the extracellular 
environment inside the cell by assembling focal adhesions. In the absence of HBO1, Itga3, 
Itga4, Itgb5 and Itga9 were downregulated. These genes were common to both ECM-receptor 
interaction and focal adhesion KEGG pathways (Table 4.3), suggesting that Hbo1iEC/iEC ECs 
may not be able to bind the ECM and relay the relevant signals into the cell. Enrichment 
analysis of genes in the focal adhesion pathway showed that this pathway tended to be 
downregulated in Hbo1iEC/iEC mice (Figure 4.4a, Appendix Table 8.4). Focal adhesion 
complexes comprise structural proteins that link integrins to the cytoskeleton as well as 
proteins like paxillin that amplify focal adhesion signalling. This provides important signals 
to promote a range of cellular processes, including cell migration (Stutchbury et al., 2017). 
Phosphorylation of paxillin potentiates its localisation to focal adhesion complexes and thus 
can be used as a marker for focal adhesion (Brown et al., 1998). Staining for phosphorylated-
paxillin revealed a similar staining pattern across the sprouting front in control and 
Hbo1iEC/iEC mice (Figure 4.4b). Regardless of genotype, focal adhesions were largely 
associated with filopodia of tip cells, suggesting that focal adhesions form normally in the 
absence of HBO1.  
 
One of the genes downregulated in the focal adhesion pathway was Myl9 (p = 0.011) with a 
linear fold change of 0.56. Myl9 encodes myosin light chain 2 (MLC2), which is a regulatory 
light chain of non-muscle myosin complexes. Similar to their muscle myosin counterparts, 
non-muscle myosins are actin binding and have contractile properties to enable changes to 
the actin cytoskeleton (Vicente-Manzanares et al., 2009). This is key to generating forces 
required for processes involving cell shape changes such as cell migration. Non-muscle 
myosin complexes comprise of two heavy chains and two types of light chains. Actin binding 
and ATP-dependent motor action are generated by heavy chains and essential light chains 
stabilise the complex. Regulatory light chains, such as MLC2, are phosphorylated to greatly 
enhance the activity of the heavy chains (Vicente-Manzanares et al., 2009). Phosphorylated 
MLC2 has been implicated in EC migration during retinal angiogenesis (Franco et al., 2013, 
Kim et al., 2017). Encouragingly, others have shown that clear differences between control 
and mutant samples with abnormalities in myosin activity can be seen by 
immunofluorescence (Kim et al., 2017). Staining for phosphorylated MLC2 did not reveal 
any difference between control and Hbo1iEC/iEC mice (Figure 4.4c), suggesting that myosin 
contractility is normal in the absence of HBO1.  





















Figure 4.4. Tip cells form focal adhesions in the absence of HBO1 
(a) Barcode plot showing enrichment of focal adhesion pathway genes among genes 
downregulated in Hbo1iEC/iEC ECs compared to control. The p-value was determined by 
ROAST gene set testing and refers to the alternative hypothesis that pathway genes tend 
to be downregulated in the absence of HBO1. For full list of up- and downregulated genes 
in this pathway see Appendix Table 8.4. (b) Representative images of focal adhesion 
marker phosphorylated-paxillin (p-paxillin) staining in the sprouting front of P6 control 
(n = 3) and Hbo1iEC/iEC (n = 2) retinas. Images stained with PECAM1 (magenta) and p-
paxillin (cyan, greyscale). Arrowheads indicate endothelial focal adhesions. Scale bar = 30 
µm. (c) Representative images of phosphorylated-MLC2 (p-MLC2) staining in the 
sprouting front of P6 control (n = 3) and Hbo1iEC/iEC (n = 2) retinas. Images stained with 
PECAM1 (green) and p-MLC2 (magenta, greyscale). Scale bar = 50 µm. 
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4.2.6 Tip cells deficient for Hbo1 have normal adherens junctional activity 
Another significantly downregulated KEGG pathway was cell adhesion molecules (CAMs). 
Enrichment analysis of genes in this pathway showed that it was downregulated in Hbo1iEC/iEC 
mice (Figure 4.5a, Appendix Table 8.4). Downregulated genes in this pathway were related 
to different types of cell adhesion including those involved in tight junctions (eg. Cldn5) and 
adherens junctions (eg. Ptprm), as well as adhesion to the ECM (eg. Itga4).  
 
In terms of vessel growth, differential cell adhesion establishes the capacity of ECs to 
rearrange and migrate during angiogenesis (Bentley et al., 2014). Most tip cells establish active 
junctions, which are weakly adhesive to neighbouring cells to better allow migration.  In 
contrast, junctions that are more strongly adhesive and not correlated with cell migration are 
referred to as inhibited (Bentley et al., 2014). The characteristics of these junctions have been 
based on the endothelial specific adherens junction protein VE-cadherin. Active junctions 
have internalised VE-cadherin signal, which corresponds to VE-cadherin turnover occurring 
at unstable junctions such as during cell migration (Esser et al., 1998, Gavard & Gutkind, 
2006), and display junctional protrusions that can be observed as serrated irregular VE-
cadherin patterning (Hayer et al., 2016) (Figure 4.5b). Inhibited junctions do not display 
internalised VE-cadherin signal and have static junctions that appear as straight lines (Bentley 
et al., 2014) (Figure 4.5b). Cells can also take on an intermediate phenotype, referred to in 
Figure 4.5b as ‘mixed’, which have features of both active and inhibited junctions (Bentley 
et al., 2014).  
 
While Cdh5, which encodes VE-cadherin, was not downregulated in Hbo1iEC/iEC mice (linear 
fold-change 1.00), perturbations in other CAMs and regulators of VE-cadherin activity at 
junctions may lead to changes in adhesion dynamics, which may manifest in altered VE-
cadherin junction activity. Others have shown that changes in cell adhesion can be identified 
by analysing VE-cadherin morphology, where loss of the adaptor protein TSAd that links 
VEGFR signalling with VE-cadherin internalisation showed a shift towards inhibited 
junctions (Bentley et al., 2014, Gordon et al., 2016). VE-cadherin staining in the sprouting 
front for control and Hbo1iEC/iEC mice is shown in Figure 4.5c. The VE-cadherin morphology 
of ESM1+ tip cells was individually assessed and assigned as active, mixed or inhibited. 
Analysing the junctional activity of ESM1+ tip cells showed no difference between control 
and Hbo1iEC/iEC mice (Figure 4.5d). These results suggest no difference in the ability of tip 
cells to establish differential adhesion in the absence of HBO1. 




Figure 4.5. Tip cell junctions are normal in the absence of HBO1 
(a) Barcode plot showing enrichment of cell adhesion molecules (CAMs) pathway among 
genes downregulated in Hbo1iEC/iEC ECs compared to control. The p-value was determined 
by ROAST gene set testing and refers to the alternative hypothesis that pathway genes 
tend to be downregulated in the absence of HBO1. For full list of up- and downregulated 
genes in this pathway see Appendix Table 8.4. (b) Examples of tip cell junction 
morphology based on VE-cadherin. Scale bar = 15 µm. (c) Representative images of VE-
cadherin staining (greyscale) in the sprouting front of control and Hbo1iEC/iEC retinas. Also 
stained with FLI1 (magenta). Scale bar = 50 µm. (d) Quantification of junction activity for 
control (n = 3) and Hbo1iEC/iEC mice (n = 3). Data are mean ± SEM. Each data point 
represents one individual animal. Multiple t-tests with Holm-Sidak correction, ns p≥0.05. 
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4.3 Discussion 
In this chapter, I presented the work conducted to elucidate the molecular mechanism by 
which HBO1 promotes sprouting angiogenesis. RNA-sequencing was performed on lung 
ECs to profile transcriptome-wide differences in mRNA levels between Hbo1iEC/iEC and 
control mice that could account for the angiogenic defect characterised in Chapter 3. 
Pathway analysis of differentially expressed genes suggested several pathways controlling tip 
cell behaviour and migration were altered in the absence of HBO1, supporting the observed 
Hbo1iEC/iEC tip cell defect.  
 
As a HAT, HBO1 acetylates H3K14 required for transcriptional activation of critical cell 
differentiation genes during development (Kueh et al., 2011). As such, I aimed to understand 
the molecular mechanism of HBO1 by determining the transcriptional differences that occur 
in the absence of HBO1. RNA-sequencing is a widely used, high throughput method to 
understand gene expression changes (Hrdlickova et al., 2017). Although the vascular 
phenotype was characterised using the postnatal retina, the lung was chosen as the organ 
from which to isolate ECs for bulk population RNA-sequencing. The P6 retina contains 
around 15 000 ECs (Franco et al., 2015) and the number that can be isolated by FACS in my 
experience is around 500 ECs. In contrast, around 500 000 ECs were sorted from P6 lungs, 
which was sufficient RNA for bulk RNA sequencing. 
 
There were a large number of differentially expressed genes in the absence of HBO1. In 
Chapter 3, I showed that tip cells in Hbo1iEC/iEC mice failed to establish biased front-rear 
polarity required for normal directed cell migration. Therefore, I was particularly interested 
to study genes known to regulate cell behaviours required for migration. Most of the top 
differentially expressed genes do not have known roles during angiogenesis, including Cers4 
(downregulated), Serpinb6a (downregulated), Inhbb (downregulated), Adam23 (upregulated) 
and Plac8 (upregulated). Others, such as Ptprf that encodes a receptor-type tyrosine protein 
phosphatase PTPRF, have been implicated in cell migration in other cell types. But in 
contrast to what would be expected based on the Hbo1iEC/iEC phenotype, loss of PTPRF 
activity correlated with increased breast cancer invasiveness and migration (Du et al., 2013). 
For other differentially expressed genes, retinal angiogenesis has been examined with either 
no or a very mild phenotype. Vegfc was one of the most significantly downregulated genes in 
Hbo1iEC/iEC mice, but it has been previously shown that VEGFC is not expressed by ECs 
within the retina (Tammela et al., 2011); however, this does not discount the possibility that 
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it is important for lung vascular development. Tenascin C, encoded by Tnc, was found to 
have pro- and anti-angiogenic roles in glioblastoma; however, analysis of Tnc–/– retinas 
showed a very mild reduction in radial vessel outgrowth that did not phenocopy Hbo1iEC/iEC 
retinas (Rupp et al., 2016). Syndecan 4, Sdc4, was found to be important for angiogenesis 
during wound healing in mice (Echtermeyer et al., 2001); however, Sdc4–/– mice have normal 
retinal vasculature (Ju et al., 2014). While deletion of these genes individually does not 
phenocopy Hbo1iEC/iEC mice, this does not disqualify the reduction in their expression from 
contributing to the Hbo1 phenotype. Instead, the large number of differentially expressed 
genes in Hbo1iEC/iEC ECs suggests that it is the cumulative effect of altering these genes that 
perturbs sprouting angiogenesis.  
 
Given the large number of differentially expressed genes in Hbo1iEC/iEC lung ECs, I wanted 
to understand the cumulative effect on gene expression by looking at whether particular 
pathways were altered. Encouragingly, KEGG pathway analysis showed that multiple 
pathways relating to tip cell behaviour were downregulated in the absence of HBO1. 
However, investigating aspects of the ECM-receptor interaction, focal adhesion and cell 
adhesion molecules (CAMs) pathways did not reveal any differences in their regulation in 
retinal vasculature between control and Hbo1iEC/iEC mice. It is likely that the approaches taken 
to investigate these pathways were not sensitive enough for detecting differences. For 
example, using phosphorylated-paxillin as marker for focal adhesions, showed that while 
they could be formed in Hbo1iEC/iEC mice, it is possible that signalling downstream of paxillin 
was altered and undetected. Additionally, cell-cell adhesion was analysed by looking at the 
adherens junction protein VE-cadherin, but pathway analysis found that tight junction genes 
as well as integrins were also represented in downregulated genes. Using multiple markers 
for each of these altered pathways may reveal components that are changed in the retinas of 
Hbo1iEC/iEC mice. It is also possible that some of the other tip cell relevant pathways such as 
glycolysis/gluconeogenesis and axon guidance that were not studied may explain the retinal 
Hbo1iEC/iEC phenotype (see Table 4.3 for the differentially expressed genes giving rise to the 
annotations axon guidance and glycolysis/gluconeogenesis). 
 
Relative to other cells, all ECs generate most of their required ATP by glycolysis. Tip cells 
further increase their glycolytic flux during sprouting angiogenesis (De Bock et al., 2013b). 
The glycolysis pathway converts glucose into pyruvate through a series of intermediates, with 
each step requiring its own specific enzyme. Hexokinase (HK), phospho-fructokinase (PFK) 
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and pyruvate kinase (PK) are all rate-limiting enzymes in this pathway (Li et al., 2019). In 
Hbo1iEC/iEC lung ECs, HK2 and all three isoforms of PFK were downregulated. Loss of HK2 
from the endothelium stunts retinal vessel growth, reduces vessel density and reduces tip cell 
numbers (Yu et al., 2017). The outcome of EC specific loss of PFK is yet to be determined 
but loss of PFKFB3, which produces an allosteric activator of PFK, from the endothelium 
leads to reduced retinal radial vessel outgrowth and sprouting (De Bock et al., 2013b). Thus, 
the reduced sprouting in Hbo1iEC/iEC mice strongly correlates with a role for HBO1 in 
regulating glycolysis. One way to further investigate this possibility, would be to measure the 
glycolytic activity of ECs deficient for Hbo1. Seahorse XF analysers are commonly used for 
this purpose and measure the extracellular acidification rate based on lactic acid production, 
which is a by-product of glycolysis. Various substrates or inhibitors can be used during this 
procedure to determine the glycolytic capacity of cells (TeSlaa & Teitell, 2014). Assays that 
measure the enzymatic activity of HK and PFK in cell lysates using spectrophotometry 
approaches are also available (TeSlaa & Teitell, 2014) and could be applied to Hbo1 deficient 
ECs. 
 
Tip cells bear morphological resemblance to axonal growth cones that are responsible for 
axon guidance (Adams & Eichmann, 2010). Additionally, many of the signalling pathways 
that allow axon guidance also regulate normal sprouting angiogenesis, including 
SLIT/ROBO (Park et al., 2003, Rama et al., 2015), ephrin/Eph receptor (Wang et al., 2010b), 
netrin/UNC (Larrivee et al., 2007, Lu et al., 2004) and semaphorin/plexin/neuropilin 
signalling (Kim et al., 2011, Zygmunt et al., 2011). The appearance of axon guidance amongst 
KEGG pathways downregulated in Hbo1iEC/iEC mice is encouraging as it supports the notion 
that the phenotype is due to a tip cell defect. As mentioned in Chapter 3.3, the Hbo1 
phenotype strongly resembles the Slit2 phenotype (Rama et al., 2015) and Slit2 was amongst 
the downregulated axon guidance genes (Table 4.3), suggesting that HBO1 may regulate this 
signalling pathway in retinal ECs.  
 
The most differentially expressed gene in Hbo1iEC/iEC ECs was Fn1, encoding the extracellular 
protein fibronectin. Fibronectin provides a scaffold by which ECs migrate along during 
sprouting angiogenesis (Stenzel et al., 2011b). Lung ECs showed a two-fold increase in Fn1 
transcripts; however, the expression of fibronectin protein appeared normal in Hbo1iEC/iEC 
retinas. The expression intensity of fibronectin protein in the retina was not quantified as its 
non-uniform staining within the vasculature makes it difficult to analyse above surrounding 
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background. It may be that there is a difference in fibronectin protein expression that 
immunofluorescence is not sensitive enough to detect. Another possibility is that mRNA 
levels are also upregulated in retinal ECs but that there are other mechanisms to maintain 
normal protein expression, with transcript abundance not always reflected in protein 
abundance (Payne, 2015, Vogel & Marcotte, 2012). 
 
While the lung EC data revealed pathways that were altered in Hbo1iEC/iEC mice, there were 
limitations to using the lung for gene expression analysis. Firstly, an important difference is 
the method of vessel growth. In addition to vessel sprouting, the lung vasculature grows and 
remodels by intussusceptive angiogenesis that greatly increases the surface area of the 
vasculature (Schittny, 2017). As the molecular mechanism of intussusceptive angiogenesis is 
not well understood, it is possible that many of the genes that were changed in Hbo1iEC/iEC 
lungs were relevant to this type of vessel growth. I did not examine whether loss of HBO1 
from the lung endothelium impacted intussusceptive angiogenesis. In contrast to the retina 
that does not have any lymphatic vessels, the lung has an extensive lymphatic vessel network 
(Schraufnagel, 2010). Lymphatic ECs also express VE-cadherin, thus the Cdh5(PAC)-
creERT2 transgene would result in deletion of HBO1 from the lymphatic vasculature (Baluk 
et al., 2007). Lymphatic vessels also express PECAM1, albeit at lower levels than blood ECs 
(Baluk et al., 2007). To minimise the chance of collecting lymphatic ECs, cells with low 
PECAM1 expression were excluded from the cell sort, but it is possible that some lymphatic 
ECs were amongst the sorted blood ECs. A final disadvantage of using lung ECs to 
understand a phenotype in the retina is that even in wild-type mice, ECs have distinct gene 
expression patterns depending on the tissue in which they reside (Sabbagh et al., 2018, Tabula 
Muris et al., 2018). It is possible that the phenotype in the postnatal retina is due to 
aberrations in the same pathways as those from the lung, but that the specific genes that 
regulate those pathways differ between tissues. Thus, using the lung endothelium was not 
the appropriate source to understand gene expression differences that may contribute to the 
retinal phenotype of Hbo1iEC/iEC mice. 
 
To circumvent the limitations of assessing gene expression in the lung, it may be possible in 
the future to isolate RNA from retinal ECs. There are a number of approaches that have 
been previously used to isolate retinal ECs for gene expression studies, including laser 
capture microdissection (Strasser et al., 2010), dissociating the retina and capturing ECs using 
magnetic beads (del Toro et al., 2010) or the RiboTag method for isolation of ribosomal-
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associated mRNA (Jeong et al., 2017). The technological advances allowing single cell RNA-
sequencing also represents an exciting opportunity to better understand EC heterogeneity 
and has previously been used to interrogate other retinal cell subtypes (Rheaume et al., 2018, 
Shekhar et al., 2016). Given the heterogenous nature of ECs, bulk population RNA-
sequencing vastly underrepresents the complexity of gene expression changes that might 
occur in one subtype compared to another. As the Hbo1iEC/iEC phenotype appears to primarily 
affect tip cells, understanding the differences between control and Hbo1iEC/iEC ECs at a single 
cell level is desirable.  
 
There are no previously published accounts of roles for HATs in mammalian sprouting 
angiogenesis, however the role of HBO1 orthologue, kat7, in the developing zebrafish 
vasculature was published during the course of my PhD (Yan et al., 2018). There are two 
orthologues of HBO1 that exist in zebrafish, kat7a and kat7b, and the study by Yan et al 
focussed on kat7b, which shows greater sequence similarity to human HBO1. Morpholino 
knock-down of kat7b lead to impaired intersegmental vessel sprouting, which could be 
rescued by expressing human HBO1. They found HUVEC proliferation was reduced in the 
absence of HBO1, which was not consistent with the EdU results of my in vivo study 
presented in Chapter 3. siRNA knock-down of HBO1 impaired the ability of ECs to migrate 
using the scratch wound assay but contradicting this, in transwell migration assays HBO1 
siRNA HUVECs showed normal migration behaviour (Yan et al., 2018). Yan et al performed 
gene expression microarray analysis on HUVECS to understand transcriptional differences 
that occur with loss of HBO1. In the absence of HBO1, there were 263 differentially 
expressed genes (117 downregulated and 146 upregulated, based on p<0.05). In contrast, 
Hbo1iEC/iEC mice showed 1493 differentially expressed genes (973 downregulated and 520 
upregulated). This difference likely reflects the method for analysing transcripts as RNA-
sequencing has a higher dynamic range and greater sensitivity to detect low abundance 
transcripts (Wang et al., 2009). Yan et al also performed GO analysis for biological processes. 
Only two pathways in their top 12 GO terms, inflammatory response and defense response, 
were amongst the top 100 GO terms associated with Hbo1iEC/iEC mice. Yan et al concluded 
that dysregulated VEGFR signalling was responsible for their observed sprouting phenotype 
as VEGFR1 and VEGFR2 were significantly downregulated in the absence of HBO1. In 
contrast in Hbo1iEC/iEC mice, Vegfr1 and Vegfr2 were unchanged (linear fold change = 1.06 
and 0.98 respectively). Additionally, Hbo1iEC/iEC mice are able to upregulate VEGFA 
responsive genes such as ESM1 and DLL4, suggesting that at least some VEGFR2 signalling 
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outputs are normal. The disparate gene expression changes found in my study compared to 
Yan et al is likely to be due to differences in populations of ECs used and methods of 
analysing gene expression. In particular, it must also be noted that siRNAs can result in off 
target gene silencing (Fedorov et al., 2006, Jackson et al., 2003, Lin et al., 2005) and Yan et al 
did not include the appropriate control experiment trying to rescue the siRNA effect by 
expressing an siRNA-resistant HBO1 construct. Thus, it may be possible that gene 
expression changes in HBO1 siRNA HUVECs were due to off target effects.  
 
As mentioned in Chapter 3, the blunted sprouting front of the Hbo1 phenotype bears 
resemblance to other phenotypes associated with tip cell defects, including the transcription 
factors MEF2A/C (Sacilotto et al., 2016) and FOXO1 (Kim et al., 2019), the secreted ROBO 
ligand SLIT2 (Rama et al., 2015), the hypoxia-activated kinase MST1 (Kim et al., 2019) and 
the signalling adaptor proteins NCK1 and NCK2 (Dubrac et al., 2016). The MEF2 enhancer 
was shown to be acetylated by p300 required for normal expression of MEF2 target genes 
that promote sprouting angiogenesis (Sacilotto et al., 2016). It is possible that acetylation of 
H3K14 by HBO1 is also necessary for the normal expression of MEF2 or its target genes. 
In response to hypoxia, MST1 was shown to promote the nuclear import of FOXO1, where 
FOXO1 was suggested to regulate expression of polarity associated genes that are required 
for directed tip cell migration towards hypoxia (Kim et al., 2019). The phenotypic similarities 
of blunt vessels and increased EC density in the sprouting front as well as a front-rear polarity 
defect common to Foxo1, Mst1 and Hbo1 phenotypes suggest that HBO1 may function 
within this cascade and promote transcriptional activation of FOXO1 itself or its target 
genes. It should be noted that Hbo1iEC/iEC mice do not phenocopy the proliferation changes 
that both Mst1 (Kim et al., 2019) and Foxo1 (Wilhelm et al., 2016) deficient mice display, 
suggesting that HBO1 may modulate only some aspects of this signalling pathway. 
Interestingly, loss of Mst1 or Foxo1 have opposing effects on EC proliferation, supporting 
the notion that their roles in proliferation and migration are separately regulated. NCK 
proteins integrate signals from VEGFA/VEGFR2 and SLIT2/ROBO1&2 signalling and 
loss of NCK1&2 results in an EC polarity defect and failed directed migration (Dubrac et 
al., 2016). This raises the possibility that downstream NCK signalling may intersect with 
FOXO1 to promote tip cell polarity and that HBO1 is required for H3K14ac for genes 
associated with these pathways. While the Hbo1iEC/iEC retina phenocopies a number of 
mutations with tip cell defects, it should also be noted that the Hbo1 phenotype is less severe 
than other mutations associated with tip cell defects, such as the signalling adaptor protein 
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CDC42 (Lavina et al., 2018) or transcription co-activators YAP/TAZ (Kim et al., 2017, 
Sakabe et al., 2017). This is likely due to other EC behaviours being disturbed by the loss of 
these proteins, for example the YAP/TAZ phenotype also shows reduced proliferation (Kim 
et al., 2017, Sakabe et al., 2017). 
 
To summarise the findings of Chapter 3 and 4, I have found that HBO1 is required for the 
normal expression of a large number of genes within ECs that are associated with sprouting 
angiogenesis. Deletion of Hbo1 resulted in abnormal vascular growth, due to altered tip cell 
activity, which included failed biased migration. This was supported by RNA-sequencing 
analysis that showed pathways responsible for tip cell behaviour were altered in the absence 
of HBO1.  
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5 Chapter 5: Ischaemic retina revascularisation by ‘vessel reassembly’ following endothelial apoptosis blockade 
Chapter 5: Ischaemic retina revascularisation by ‘vessel 
reassembly’ following endothelial apoptosis blockade 
5.1 Preview 
Aberrant, neovascular retinal blood vessel growth is a vision-threatening complication in 
diseases such as retinopathy of prematurity, retinal vein occlusion and diabetic retinopathy. 
These are biphasic vascular diseases with neovascularisation typically occurring as a result of 
underlying tissue hypoxia that can be caused by capillary regression. In some diseases, 
particularly diabetic retinopathy, this vessel regression is associated with EC apoptosis. In 
this chapter, I have investigated the role of EC apoptosis in vessel regression that causes 
retinal hypoxia and neovascular disease using the mouse oxygen-induced retinopathy (OIR) 
model of biphasic ischaemic retinal neovascular disease. In this model, apoptotic regression 
of retinal capillaries causes it to become hypoxic, driving upregulation of pro-angiogenic 
factors and a subsequent neovascular response. To investigate the role of EC apoptosis in 
vessel regression in this model, I applied it to mice with EC-specific deletion of the apoptosis 
effector proteins BAK and BAX (Watson et al., 2016a). These mice are Bak-/- with Bax 
conditionally deleted from the endothelium and will be referred to as Bak-/-BaxEC/EC. This 
strategy was chosen as almost all Bak-/-Bax-/- mice are lethal at birth (Ke et al., 2018, Lindsten 
et al., 2000) and Bax-/- mice are infertile and have increased retinal neurons (Hahn et al., 2003, 
Knudson et al., 1995). I found that blocking EC apoptosis could not prevent the loss of 
blood flow to capillaries that normally regress in the OIR model. Furthermore, these retinal 
capillaries still underwent a delayed form of regression, likely because of the lack of blood 
flow support. Even though capillaries regressed when apoptosis was blocked, the ECs in 
them did not die as they normally would. Instead, they survived and retracted into isolated 
clusters within the ischaemic region. Combining in vivo time course data with live-imaging of 
retinal explants, I found that in response to hypoxia, these clusters underwent a sprouting 
angiogenesis response and reassembled themselves into an intact vascular network within 24 
h. This reassembled network was functional and restored blood flow, rapidly reducing retinal 
hypoxia, preventing subsequent pathological neovascular growth and reactive gliosis. These 
results suggest that even though blocking endothelial apoptosis may not prevent vessel 
regression, it can preserve ECs within ischaemic tissues that are capable of responding to 
hypoxia and assemble into a functional network, rapidly restoring blood supply.  
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This chapter represents a manuscript currently in revision following peer review by the 
Journal of Clinical Investigation and is presented in its submitted manuscript form and 
includes all supplementary figures (supplementary videos are shown as stills). 
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Abstract  
Aberrant, neovascular retinal blood vessel growth is a vision-threatening complication in 
ischemic retinal diseases. It is driven by retinal hypoxia frequently caused by capillary non-
perfusion and endothelial cell (EC) loss. We investigated the role of EC apoptosis in this 
process using a mouse model of ischemic retinopathy, in which vessel closure and EC 
apoptosis cause capillary regression and retinal ischemia followed by the up-regulation of 
vascular endothelial cell growth factor A (VEGFA) that drives retinal neovascularisation. 
Protecting ECs from apoptosis in this model did not prevent capillary closure or retinal 
ischemia. Nonetheless, it completely prevented the clearance of ECs from closed capillaries, 
delaying vessel regression and allowing ECs to persist in isolated clusters throughout the 
ischemic zone. In response to hypoxia, these preserved ECs underwent a vessel sprouting 
response through which they rapidly reassembled into a functional vascular network that 
alleviated retinal hypoxia, preventing subsequent pathogenic neovascularisation. This vessel 
reassembly was not limited by VEGFA neutralisation, suggesting it was not dependent on 
the excess VEGFA produced by the ischemic retina. Thus, blockade of endothelial cell 
apoptosis may promote ischemic tissue re-vascularisation by preserving ECs within ischemic 
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Introduction 
Angiogenesis is the growth of new blood vessels from pre-existing vessels and occurs 
through a tightly regulated response of endothelial cells (ECs) to pro-angiogenic factors (Betz 
et al., 2016, Geudens & Gerhardt, 2011, Potente et al., 2011, Siekmann et al., 2013). 
Insufficient vascular supply, which may arise due to impaired vessel growth (Hellstrom et al., 
2013), capillary loss (Stitt et al., 2016) or vessel obstruction (Herrington et al., 2016), causes 
tissue ischemia. While increased angiogenesis correlates with better outcomes in ischemic 
diseases like stroke (Zhang et al., 2000), ischemia and the upregulation of VEGFA can drive 
aberrant angiogenesis exacerbating certain diseases. This is particularly evident in retinal 
diseases, such as proliferative diabetic retinopathy, retinal vein occlusion and retinopathy of 
prematurity where aberrant angiogenesis (neovascularisation) increases the risk of severe 
vision loss and blindness (Miller et al., 2013). Current treatments for neovascular disease in 
the retina revolve around reducing the angiogenic stimulus either by decreasing the metabolic 
activity of the retina or by direct inhibition of VEGFA (Campochiaro et al., 2011, Good & 
Early Treatment for Retinopathy of Prematurity Cooperative, 2004, Mintz-Hittner et al., 
2011, Sivaprasad et al., 2017, Writing Committee for the Diabetic Retinopathy Clinical 
Research et al., 2015). While these approaches improve visual outcomes, many patients show 
either no or a sub-optimal response (Sivaprasad et al., 2017, Writing Committee for the 
Diabetic Retinopathy Clinical Research et al., 2015). Capillary regression and the loss of ECs 
from the microvasculature is commonly associated with progression to neovascular disease 
in the retina and can occur in response to metabolic dysregulation (Stitt et al., 2016), 
hyperoxia (Hartnett & Penn, 2012), or interrupted blood flow (Danis & Wallow, 1986, 
Frangieh et al., 1982). ECs die by apoptosis, a genetically programmed form of cell death 
(Fuchs & Steller, 2011), in settings where extensive vessel regression occurs (Korn & 
Augustin, 2015, Watson et al., 2017). Retinal capillaries in patients with diabetic retinopathy 
for example show elevated levels of EC apoptosis prior to progression to the proliferative 
phase (Mizutani et al., 1996, Stitt et al., 2016). Understanding the role of apoptosis in EC loss 
and vessel regression leading to retinal ischemia may therefore provide new insight into 
vascular changes associated with ischemia and potentially new avenues for preventing disease 
progression.  
Apoptosis is regulated by two pathways, one consisting of BCL2 family proteins, the 
other by cell surface ‘death receptors’. Previous studies have demonstrated a key role for the 
BCL2 family of proteins in the regulation of EC apoptosis (Watson et al., 2017). The BCL2 
family consists of opposing factions of pro-survival and pro-apoptotic members (Czabotar 
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et al., 2014), the balance of which determines whether the apoptosis effector proteins BAK 
and BAX become activated (Wei et al., 2001). Previous studies have shown that among the 
BCL2 family, the pro-survival protein MCL1 (Watson et al., 2016b), the pro-apoptotic 
protein BIM (Koenig et al., 2014, Wang et al., 2011), and the two effector proteins BAK and 
BAX (Watson et al., 2016a) have a central role in regulating EC apoptosis in the retina in vivo.  
Vessel regression is a normal process necessary for establishing hierarchic vessel 
patterning during angiogenesis and the removal of redundant or damaged vascular networks 
(Korn & Augustin, 2015, Watson et al., 2017). During angiogenic vessel remodelling, local 
differences in blood flow shear between neighbouring vessel segments determines which will 
be ‘pruned’ away (Chen et al., 2012, Kochhan et al., 2013, Lenard et al., 2015). This selective 
vessel pruning is driven by EC migration (Chen et al., 2012, Franco et al., 2015, Lenard et 
al., 2015), does not cause ischemia and does not require EC apoptosis (Watson et al., 2016a). 
In contrast, apoptosis does appear responsible for capillary regression in other contexts, 
including those that leave tissues with insufficient vascular supply, causing ischemia. Exactly 
how apoptosis contributes to vessel loss in this context and the outcomes of preventing it 
are not well understood.  
Here we have investigated the effect of blocking EC apoptosis in a mouse model of 
ischemia-induced neovascular disease (Stitt et al., 2016), in which blocking apoptosis is 
known to prevent capillary loss and subsequent neovascularisation (Wang et al., 2011). Our 
results show that EC apoptosis in this model is secondary to a vessel closure event that 
deprives downstream capillaries of blood flow. Rather than preventing this vessel closure or 
subsequent vessel degeneration, protecting ECs from apoptosis instead preserved ECs from 
these closed vessels within the ischemic region that were capable of rebuilding a functional 
vascular network in response to hypoxia-derived signals, restoring tissue oxygenation and 
mitigating the damaging effects of prolonged hypoxia on the retina.       
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Results 
Blocking BCL2 pathway apoptosis results in EC survival and delayed vessel 
regression  
To determine whether EC apoptosis was responsible for vessel regression causing ischemia, 
we investigated its role in the oxygen-induced retinopathy (OIR) model (Smith et al., 1994) 
(Supplementary Figure 1A). In this model, transient exposure of mice to high oxygen causes 
the apoptotic death of ECs and consequent regression of retinal capillaries in the centre of 
the retina, resulting in relative retinal hypoxia once the mice are returned to room air oxygen 
levels. This is followed by the development of abnormal vascular lesions that resemble those 
found in neovascular retinal diseases (Stitt et al., 2016). To block apoptosis, we used mice 
that we previously generated, in which apoptosis was inactivated in ECs through combined 
deletion of BAK and BAX (Bak-/-BaxEC/EC mice (Watson et al., 2016a)). Bak-/-BaxEC/EC mice 
lack BAK in all tissues and BAX only in ECs, a necessary strategy because Bak-/- mice are 
viable, whereas most Bak-/-Bax-/- double null mice die at birth due to a range of birth defects 
(Ke et al., 2018). Relevant to the age of mice studied here, Bak-/-BaxEC/EC mice develop a 
normal vascular network in the first few weeks following birth (Watson et al., 2016a). After 
24 h of exposure to high oxygen, control genotype mice contained extensive numbers of 
apoptotic ECs (active caspase 3+ PECAM1+ cells). In contrast, retinas from similarly treated 
Bak-/-BaxEC/EC mice were almost completely devoid of apoptotic ECs, confirming the central 
role of the BCL2-regulated apoptotic pathway in this response (Figure 1A & B). By contrast, 
other forms of programmed cell death, namely death receptor mediated apoptosis (caspase-
8-dependent) and MLKL-dependent necroptosis were dispensable for vaso-obliteration as 
casp8-/-Mlkl-/- double-knockout mice underwent normal vaso-obliteration when exposed to 
high oxygen (Supplementary Figure 1B & C).  
As a result of blocking apoptosis, Bak-/-BaxEC/EC retinas contained significantly more 
vasculature than control littermates following 24 - 48 h of high oxygen exposure (Figure 1C, 
Supplementary Figure 1D). Despite this, the vessel area in Bak-/-BaxEC/EC retinas declined 
with increasing duration of high oxygen exposure (Figure 1D). This loss of vasculature was 
due to vessel regression based on the reduced occupancy of collagen IV+ vascular basement 
membranes with PECAM1+ ECs (Phng et al., 2009) (Figure 1E & F, Supplementary Figure 
1E). By 48 h of exposure to high oxygen, ongoing vessel regression had caused the network 
in Bak-/-BaxEC/EC retinas to degenerate into isolated vessel fragments and endothelial clusters 
that in many cases remained linked by empty collagen IV sleeves (Figure 1E & G), evidence 
that they were once part of an interconnected vascular network. The Tie2-cre transgene used 
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to generate Bak-/-BaxEC/EC mice is active in hematopoietic cells as well as ECs. We confirmed 
that the vascular phenotype we observed was due to apoptosis suppression specifically in 
ECs by using an EC-specific, tamoxifen-inducible cre transgene (Cdh5-CreERT2 (Wang et 
al., 2010)) that is not active in hematopoietic cells (Watson et al., 2016b) to generate Bak-/-
BaxiEC/iEC mice. These mice showed the same fragmented vascular phenotype in their retinas 
after 48 h of high oxygen exposure (Supplementary Figure 1F-H), confirming the phenotype 
is due to apoptosis blockade specifically in ECs.  
 
Vessel regression is preceded by an EC apoptosis-independent loss of blood flow  
We sought to determine why apoptosis suppression could not prevent the loss of retinal 
capillary network integrity following high oxygen exposure. Reduced blood flow triggers the 
regression of immature retinal vessels (Franco et al., 2015, Lobov et al., 2011) and EC 
apoptosis in OIR has previously been proposed to occur secondary to loss of blood flow 
(Hughes & Chang-Ling, 2000, Lobov et al., 2011). Widespread EC apoptosis was evident in 
control mice 8 h after onset of exposure to high oxygen (Supplementary Figure 2A) and with 
few exceptions was localised to non-perfused vessels based on co-staining for active caspase 
3 and intravenously perfused L. esculentum lectin (Figure 2A), which binds to and marks ECs 
in patent vessels. Loss of flow was mostly observed downstream of arterial side-branches 
that had closed (Figure 2A & B). This pattern of vessel closure was also observed in Bak-/-
BaxEC/EC mice and the number of perfused arterial side branches remaining at 8 h was not 
different between Bak-/-BaxEC/EC mice and their littermate controls (Figure 2B & C). This 
demonstrates that apoptosis is not responsible for hyperoxia-induced arterial side-branch 
closure or deprivation of downstream capillaries of blood flow. Nonetheless, the regression 
of closed arterial side-branches was delayed in the absence of apoptosis as fewer non-
perfused side-branches in the Bak-/-BaxEC/EC mice had fully disconnected their lumens from 
the artery by 8 h (Figure 2D & E). There was also less regression occurring in non-perfused 
Bak-/-BaxEC/EC mutant capillaries relative to controls (Figure 2F & G), although the non-
perfused capillaries in Bak-/-BaxEC/EC mutants still showed slightly elevated levels of 
regression relative to the peripheral capillary plexus region that is unaffected by high oxygen 
exposure (Figure 2G). VEGFA promotes EC survival via the BCL2 pathway (Gerber et al., 
1998, Naik et al., 2011) and is down-regulated during exposure to high oxygen (Claxton & 
Fruttiger, 2003, Pierce et al., 1996, Uemura et al., 2006). However, EC-specific reduction of 
VEGFR2 expression, which is the major VEGFA receptor and is responsible for survival 
signalling by VEGFA (Simons et al., 2016), did not result in widespread loss of central retina 
  Mechanisms of angiogenesis in development & disease 
 123 
capillaries when deleted following tamoxifen administration from postnatal day (P)7 and 
followed by analysis at P10 (Supp. Figure 2B & C), which is consistent with previous studies 
(Lobov et al., 2011, Pan et al., 2007).  
Retinas vaso-obliterated by exposure to high oxygen become hypoxic on return to room 
air owing to the loss of the central capillary network (Scott & Fruttiger, 2010) and this was 
observed in control mice following either 24 or 48 h of exposure to high oxygen (Figure 2H 
& I). The extent of hypoxia in littermate Bak-/-BaxEC/EC retinas was equivalent to the controls, 
consistent with loss of blood flow to and fragmentation of the central retinal capillaries 
(Figure 2H & I). Collectively, these data suggest that EC apoptosis occurs secondary to the 
loss of blood flow and in the absence of apoptosis, vessel regression still occurs as a result 
of the blood flow loss.  
 
Preserved Bak-/-BaxEC/EC ECs rapidly reassemble the vessel network in response to 
hypoxia  
In WT mice, the onset of hypoxia following return to room air induces a sprouting 
angiogenic response from the remaining vasculature that gradually revascularises the central 
retina through centripetal growth of the network (Fukushima et al., 2011, Lee et al., 2013). 
To determine whether the preserved ECs in the central retina of Bak-/-BaxEC/EC mice could 
also respond to hypoxia, mice were exposed to high oxygen for 48 h to fragment the vascular 
network, returned to room air to induce hypoxia in the avascular retina, then examined 24 h 
later (referred to as 48 + 24 RA) (Supplementary Figure 3A). As expected, new vessel growth 
from the peripheral plexus and radial veins in control mice only partially revascularised the 
retina 24 h after onset of hypoxia (Figure 3A, B & C). In contrast, Bak-/-BaxEC/EC retinas 
showed a significant increase in vessel area accompanied by the cessation of vessel regression 
and reestablishment of an interconnected vascular network (Figure 3A, C - F).  
To understand how an intact vascular network was re-established in the Bak-/-BaxEC/EC 
mutant mice, we performed time-lapse imaging to track the fate of the preserved ECs. For 
this, the Cre-inducible, cell membrane-targeted EGFP reporter allele mTmG (Muzumdar et 
al., 2007) was intercrossed with the tamoxifen-inducible Bak-/-BaxiEC/iEC mice. Following 
tamoxifen administration, Bak-/-BaxiEC/iECmTmGki/+ pups were exposed to high oxygen for 48 
h, returned to room air for 12 h to initiate the hypoxic response, then retinas were explanted 
and immediately time-lapse imaged at 30 min intervals for 5 h (Supplementary Figure 3B & 
C). Time-lapse imaging showed that ECs in the isolated clusters adopted a migratory 
phenotype consistent with tip cell activity normally seen during sprouting angiogenesis 
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(Geudens & Gerhardt, 2011). Through this, the isolated ECs actively re-established 
connections with their neighbours, reassembling the network (Figure 3G, Supplementary 
Movie 1-3, black arrows). Vessel sprouts establishing new connections were also observed 
from already intact vessels (Supplementary Movie 1 & 2, red arrows). While in many cases 
migrating ECs extended multiple filopodial projections suggesting de novo pathfinding 
(Supplementary Movie 3, red arrows), in some cases ECs appeared to track along pre-
determined paths (Supplementary Movie 3, blue arrows).  
During normal sprouting angiogenesis in the retina, EC proliferation is coupled to new 
vessel growth (Ehling et al., 2013), and EC proliferation was observed during regrowth of 
the central retinal vasculature in control retinas 24 h after return to room air (Figure 4A & 
B, Supplementary Figure 3D). In contrast, reassembly of the network in Bak-/-BaxEC/EC 
retinas following return to room air required very little EC proliferation based on phospho-
histone H3(Ser10) staining (Figure 4A & B, Supplementary Figure 3D). EC proliferation in 
the peripheral vasculature was similar between mutants and controls, indicating that there 
was not a general EC proliferation defect in the mutants (Supplementary Figure 3E). 
Consistent with this, the number of ECs in the central retina of Bak-/-BaxEC/EC mice remained 
constant throughout the process of network fragmentation and reassembly (Figure 4C & D). 
Collectively, these data show that isolated EC clusters protected from apoptosis are active 
participants in the reestablishment of an intact vascular network and forego the need for new 
EC production during revascularisation of the ischemic tissue. 
 
The extent of network fragmentation influences vessel reassembly 
The degree of network fragmentation in Bak-/-BaxEC/EC mice was proportional to the time 
spent in the high oxygen environment. Those mice exposed to high oxygen for 24 h showed 
less extensive vessel regression and network fragmentation than those exposed for 48 h 
(Figure 1F & G, Supplementary Figure 4A). When mice exposed to high oxygen for 24 h 
were returned to room air for a further 24 h to stimulate hypoxia-driven vessel reassembly 
(24 + 24 RA), the vascular area, vessel width and network branch points were all closer to 
that of mice raised in normoxia than was observed in the Bak-/-BaxEC/EC mice exposed to 48 
+ 24 RA (Supplementary Figure 4 B – D). This finding suggests that the sooner tissue 
hypoxia manifests after flow interruption, the more efficiently apoptosis-resistant ECs can 
reassemble a functional vascular network. 
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Vessel reassembly facilitated by the blocking of apoptosis reverses retinal hypoxia, 
and associated pathological responses 
To assess whether reassembled vessels were functional, we investigated retinal hypoxia in 
Bak-/-BaxEC/EC and control mice subjected to 48 + 24 RA. There was significantly less hypoxia 
in the central retinas of Bak-/-BaxEC/EC mice compared either to similarly treated control 
retinas or Bak-/-BaxEC/EC retinas still in the fragmented state immediately following exposure 
to 48 h of high oxygen alone (Figure 5A & B). Retinal hypoxia in the OIR model following 
return to room air results in increased expression of VEGFA (Pierce et al., 1995, Pierce et 
al., 1996). Accordingly, VEGFA protein levels increased substantially in control mice 24 h 
after return to room air, but this was significantly impaired in the Bak-/-BaxEC/EC retinas 
(Figure 5C), consistent with there being less hypoxia due to reassembly of the vascular 
network and restoration of the vascular supply. As neovascular lesion formation is dependent 
on VEGFA (Aiello et al., 1995, Fukushima et al., 2011, Lee et al., 2013), we sought to 
determine whether the reduction in hypoxia-induced VEGFA brought about by vessel 
reassembly would also translate to a reduction in neovascular lesion formation. Whereas 
control genotype mice exposed to high oxygen and returned to room air for 5 days developed 
extensive neovascular lesion area, this was again significantly reduced in retinas from Bak-/-
BaxEC/EC mice (Figure 5D, E & F). Additionally, Müller cell gliosis, an indicator of retinal 
stress, was significantly reduced in Bak-/-BaxEC/EC mice compared to the control animals 
(Figure 5G & H). These findings demonstrate that reassembled vessel networks are 
functional and prevent pathological consequences of prolonged tissue hypoxia in the retina.  
 
Reducing VEGFA levels does not prevent vessel reassembly or its suppression of 
neovascular lesion formation  
As elevated VEGFA drives aberrant angiogenesis in ischemic retinas we sought to determine 
if it was also necessary for the vessel reassembly that occurred in the absence of EC 
apoptosis. To test this, Bak-/-BaxEC/EC mice were exposed to 48 + 24 RA to induce network 
fragmentation and reassembly and administered with either a VEGFA neutralising antibody 
(Liang et al., 2006) or isotype control on return to room air (Figure 6A). VEGFA 
neutralisation did not appear to prevent vessel reassembly as no difference was observed in 
central retinal vascular area between mice treated with anti-VEGFA or isotype control 
antibody (Figure 6B & C). Consistent with this, VEGFA inhibition did not interfere with the 
ability of vessel reassembly to prevent neovascular lesion formation 5 days after return to 
room air (Figure 6D, E & F). Vessel reassembly in Bak-/-BaxEC/EC mice reduced neovessel 
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area by 88% (Figure 6F). In contrast, the VEGFA neutralising antibody reduced neovessel 
lesion area by around 50% (Figure 6F). 
The mature retinal vasculature consists of three layers of vessels with the middle and 
deeper layers being generated by vessels that initially sprout from the superficial layer. 
Control genotype mice exposed to high oxygen followed by 5 days return to room air showed 
partial but incomplete revascularisation of the superficial and mid vascular layers, evident 
from residual vaso-obliterated area (Figure 6G & H), and also showed little formation of 
deep layer vasculature (Figure 6H & I). This was not altered when VEGFA was neutralised 
throughout the 5 day room air recovery period (Figure 6G, H & I). In contrast, Bak-/-BaxEC/EC 
littermates at the same time point showed extensive vascularisation in the superficial, middle 
and deep layers, none of which were affected when VEGFA was neutralised (Figure 6H, I 
& J). Taken together, these data show that vessel reassembly in the absence of EC apoptosis 
is not dependent on abnormally high VEGFA levels or impeded when VEGFA levels are 
reduced to a level sufficient to suppress aberrant neovascularisation.  
 
  
  Mechanisms of angiogenesis in development & disease 
 127 
Discussion 
We have demonstrated that in a model of ischemic retinal disease, blocking EC apoptosis 
due to the loss of BAX and BAK enables a process of hypoxia-induced vessel reassembly 
that restores oxygen supply to ischemic tissue faster than would occur through normal 
angiogenic vessel regrowth, thereby diminishing hypoxia-induced pathological responses. 
While blocking apoptosis has previously been shown to prevent neovascularisation in the 
OIR model (Wang et al., 2011), the way it does so was unknown. We show that protecting 
against apoptosis did not prevent against the initial loss of perfusion or breakdown of the 
vasculature through vessel regression that leads to areas of the retina becoming ischemic. 
Rather, it allowed those ECs that would ordinarily die during the process of vessel regression 
to survive and persist, not as intact or functional vessels, but instead as isolated clusters of 
cells scattered throughout the ischemic zones. As the tissue surrounding these isolated ECs 
became hypoxic, they underwent a sprouting angiogenic response through which they re-
established connections with each other and neighbouring vessels, reassembling into a 
functional network and restoring oxygen delivery (Supplementary Figure 4E).  
We found that ischemia in the OIR model was caused by EC apoptosis-independent 
vessel closure, predominantly in arterial side-branch vessels, and consequent loss of blood 
flow to downstream capillaries suggesting that loss of blood flow shear constitutes the major 
initiating event in vaso-obliteration and EC apoptosis, which is consistent with previous 
studies (Hughes & Chang-Ling, 2000, Lobov et al., 2011). When apoptosis was blocked, 
capillaries deprived of blood flow still initiated a vessel regression response in which vessels 
disassembled and ECs retracted into isolated clusters resulting in network fragmentation. 
The vessel regression seen in the absence of apoptosis likely involves a process of cell 
migration similar to that which occurs in normal angiogenic vessel pruning, which also occurs 
in response to blood flow changes (Chen et al., 2012, Franco et al., 2015, Kochhan et al., 
2013, Lenard et al., 2015) and is independent of EC apoptosis (Watson et al., 2016a).  
When protected from apoptosis, ECs in the fragmented, non-perfused vessels retained 
the capacity to initiate a sprouting angiogenesis phenotype in response to hypoxia. They 
displayed behavioural and morphological features typical of endothelial tip cells that guide 
the growth of new vessels during sprouting angiogenesis (Gerhardt et al., 2003), which is the 
process normally responsible for the vascularisation of the retina in response to physiologic 
hypoxia (Geudens & Gerhardt, 2011, Selvam et al., 2018). As such, the isolated cells were 
able to re-establish connections with neighbouring vessels and reassemble into a functional 
network. In some instances, ECs appeared to migrate along pre-determined paths. Empty 
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vascular basement membranes left behind during vessel regression can act as a scaffold for 
vessel regrowth (Baffert et al., 2006, Mancuso et al., 2006). It is likely this was occurring in 
our retinas as the PECAM1:collagen IV ratio returned to normal during vessel reassembly, 
suggesting it involves at least to some extent, recanalization of empty basement membranes. 
Unlike normal sprouting angiogenesis in which EC proliferation is coupled to new vessel 
growth (Ehling et al., 2013), the cell sprouting and network reassembly we observed in the 
absence of apoptosis proceeded largely without the need for EC proliferation. While the 
exact reasons for this lack of proliferation are unclear, the unchanging number of ECs 
throughout the process of network fragmentation and reassembly possibly suggests some 
form of feedback mechanism. Nonetheless, the formation of extensive deeper layer 
vasculature suggests reassembled vessels retain the capacity for further network growth that 
likely does require EC proliferation. Deep layer retinal vessels grow from vessel sprouts 
originating from the superficial vascular layer and are not yet formed when mice start the 
OIR procedure therefore do not reassemble from existing EC clusters in the apoptosis-
resistant mutants like the superficial layer. The presence of deep layer vasculature in our 
mutant mice 5 days after return to room air suggests that reassembled superficial layer vessels 
are competent to undergo further sprouting angiogenesis to give rise to the new vessel 
networks in the deeper layers. These vessels are important for normal retina function as 
defects in their formation are associated with diseases causing vision loss (Xu et al., 2004). 
The reassembly of vessel fragments we observed bears similarities to vessel formation 
in other contexts. During vasculogenesis, angioblasts coalesce into endothelial cords before 
establishing lumenised vessels (Betz et al., 2016); isolated clusters of lymphatic ECs 
incorporate into growing lymphatic vessel networks (Pichol-Thievend et al., 2018); and 
isolated vessel segments in the rat mesentery reconnect during network growth (Stapor et al., 
2013). We showed that isolated ECs protected from apoptosis driven by BAK and BAX can 
respond to hypoxic stimuli to reassemble themselves into a functional vessel network, 
resulting in rapid network repair and tissue reoxygenation. This had the effect of reducing 
hypoxia, pathological neovascularisation and reactive retinal gliosis. Manipulation of other 
pathways, such as ANG1 (Lee et al., 2013) and ATM signalling (Okuno et al., 2012), have 
also been shown to accelerate the repair of the retinal network and reduce neovascularisation 
in the OIR model. In these cases, vaso-obliteration proceeded normally and enhanced 
centripetal growth of the peripheral vascular network accounted for the vessel repair and 
took longer than the reassembly process we describe (Lee et al., 2013, Okuno et al., 2012). 
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Blocking apoptosis therefore enabled a fundamentally different and faster approach for 
restoring blood supply to the ischemic retina.  
Network reassembly became less efficient the longer ECs were exposed to high oxygen 
and therefore in the fragmented, flow-deprived state. While this reduced efficiency may 
simply reflect the fact that more fragmentation has occurred at these later time points, taking 
longer to repair, other factors may contribute to hinder the process. By 48 h, ECs had down-
regulated the transcription factor FLI1 and possibly other genes that may affect their 
responsiveness to angiogenic stimuli. Changes to the neurovascular unit over time likely also 
affect reassembly. Astrocytes promote retinal angiogenesis both in normal development 
(Uemura et al., 2006) and vessel regrowth in the OIR model (Dorrell et al., 2010, Lee et al., 
2013). The astrocyte network deteriorates rapidly beyond 24 h of exposure to high oxygen 
(Bucher et al., 2013). This may explain why revascularisation in our model was less efficient, 
but still effective, beyond 24 h of high oxygen exposure.  
Current treatments for neovascular disease in the retina revolve around reducing the 
angiogenic stimulus either by decreasing the metabolic activity of the retina or direct 
inhibition of VEGFA (Campochiaro et al., 2011, Good & Early Treatment for Retinopathy 
of Prematurity Cooperative, 2004, Mintz-Hittner et al., 2011, Sivaprasad et al., 2017, Writing 
Committee for the Diabetic Retinopathy Clinical Research et al., 2015). Our findings show 
that preventing EC apoptosis may provide a new approach for suppressing ischemia-induced 
neovascularisation in ischemic retinopathies such as diabetic retinopathy by accelerating 
revascularisation of the ischemic tissue and reducing the hypoxic stimulus that drives 
abnormal VEGFA expression. Furthermore, our data show that reducing VEGFA to levels 
that suppress pathological angiogenesis did not interfere with the vessel reassembly that 
occurs in the absence of EC apoptosis. While these findings do not necessarily exclude a role 
for low-level VEGFA in the reassembly process, they do show that it can occur at levels of 
VEGFA that are limiting for pathological angiogenesis. There have been calls to normalise 
VEGFA levels throughout the entire course of ischemic retinopathies such as diabetic 
retinopathy and retinal vein occlusion. Clinical and experimental evidence has shown that 
excessive VEGFA contributes not just to the neovessel formation phase of these diseases, 
but also exacerbates vessel non-perfusion in a feed-forward loop (Liu et al., 2017). Our data 
suggest the possibility that VEGFA inhibitors used in such a way would not interfere with 
vessel reassembly facilitated by concurrent apoptosis inhibition.  
As our data show that protecting ECs from apoptosis enables them to persist within 
ischemic tissue without the need for ongoing blood flow support and re-establish functional 
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vessels faster than normal angiogenic growth can achieve, these findings may also have 
implications for restoring blood flow in diseases such as stroke and myocardial infarction.  
  




Conditional Bax mice(Knudson et al., 1995), Bak null mice (Lindsten et al., 2000), Tie2-cre 
mice (Kisanuki et al., 2001), Cdh5(PAC)-creERT2 mice (Wang et al., 2010), caspase 8 null mice 
(Salmena et al., 2003), Mlkl null mice (Murphy et al., 2013), ROSA26Sortm4(ACTB-tdTomato,-EGFP)Luo 
(mTmG) mice (Muzumdar et al., 2007) have been previously described. Conditional Vegfr2 
mice crossed with Tie2-creERT2 have been described previously (Beazley-Long et al., 2018) 
and show 80% reduction of endothelial VEGFR2 protein along with loss of endothelial cells 
from non-retinal organs following tamoxifen administration (Beazley-Long et al., 2018, Ved 
et al., 2018). Animals were maintained on an inbred C57BL/6 background. The day of birth 
was termed P0. Mice of both genders were used. Bak-/-BaxiEC/iEC mice were injected with 50 
µg tamoxifen (MP Biomedicals, dissolved in sterile corn oil + 5% ethanol) by intragastric 
injection at postnatal day 2 (P2) and P3. For conditional Vegfr2 mice, tamoxifen (Sigma) was 
dissolved in ethanol and diluted in sterile corn oil to 1 µg/µL with mice administered 50 µg 
by intraperitoneal injection at P7, P8 and P9 with eyes dissected for analysis at P10. Control 
genotypes for experiments involving Bak-/-BaxEC/EC and Bak-/-BaxiEC/iEC mice were: Bak-/-
Baxflox/+;cre+, Bak-/-Baxflox/+;cre- and Bak-/-Baxflox/flox;cre-. 
 
Oxygen-induced retinopathy 
Nursing dams with P7 pups were housed in a Perspex chamber (BioSpherix) and exposed 
continuously to 74±1% oxygen in air maintained by a ProOx110 oxygen controller 
(BioSpherix). Duration of oxygen exposure and subsequent recovery time in room air is 
indicated in each figure. Pups were fostered to BALB/c females following exposure to 3 
days of high oxygen to prevent oxygen toxicity in dams.  
 
VEGFA neutralisation experiments 
Mouse anti-mouse/human VEGFA neutralising antibody B20-4.1.1 (Liang et al., 2006) 
(Genentech) and control mouse anti-human CD8a antibody OKT8 (WEHI Antibody 




For whole-mount immunohistochemistry, eyes were fixed for 2 h in 4% paraformaldehyde 
at 4OC before dissecting and blocking retinas for 1 h at room temperature in Dulbecco’s 
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phosphate buffered saline (DPBS) with 1% Triton X-100 and 2% donkey or goat serum. 
Retinas were stained with primary antibodies prepared in blocking solution overnight at 4˚C, 
washed in DPBS containing 0.01% Triton X-100, then stained overnight with secondary 
antibodies prepared in blocking solution. Primary antibodies were rat anti-PECAM1/CD31 
(BD Pharmingen, 553370), goat anti-PECAM1/CD31 (R&D Systems, AF3628), goat anti-
collagen IV (Merck, AB769), rabbit anti-cleaved (active) caspase 3 (Cell Signaling, 9664), rat 
anti-ICAM2/CD102 (BD Pharmingen, 553326), rat anti-VE cadherin (BD Pharmingen, 
555289), rabbit anti-pimonidazole (Hypoxyprobe, PAb2627AP), rabbit anti-NG2 (Merck, 
AB5320), rabbit anti-FLI1 (Abcam, ab15289), rabbit anti-GFAP (DAKO, Z0334) and rabbit 
anti-phospho H3 (Ser10) conjugated to AF488 (Merck, 06-570-AF488).  Secondary 
antibodies were donkey anti-rabbit-Cy3 (Jackson, 711-165-152), donkey anti-rabbit-AF647 
(Jackson, 711-605-152, donkey anti-rat-DL488 (Jackson, 712-485-153), donkey anti-rat-Cy3 
(Jackson, 712-165-150), donkey anti-rat-AF647 (Jackson, 712-605-150), donkey anti-goat-
DL405 (Jackson, 705-475-147), donkey anti-goat-Cy3 (Jackson, 705-165-147) and 
streptavdin-AF488 (Jackson, 016-540-084). For IsolectinB4 (Vector Laboratories, B-1205) 
staining, retinas were blocked in 1% BSA, 0.3% Triton-X 100 in DPBS then incubated with 
Isolectin B4 in 0.4% Triton-X 100 in Hank’s balanced salt solution. Retinas were incubated 
in 2 µg/ml Hoechst 33342 (Invitrogen, H3570) in 0.01% Triton-X 100 DPBS for 2 hours at 
room temperature and imaged same day. Retinas were mounted with Prolong Diamond 
(Invitrogen, P36961). For hypoxia detection, pups were administered 60 mg/kg 
pimonidazole (Hypoxyprobe) by intra-peritoneal injection either immediately after exiting 
the oxygen chamber (30 min labelling duration) or 24 h after exiting the chamber (2 h 
labelling duration). Pimonidazole was detected using rabbit anti-pimonidazole antibody and 
staining performed as above. For intravenous lectin perfusion, P7 pups were anaesthetised 
using Xylazil-20 (20 mg/kg) (Troy laboratories Pty Ltd) and Ketamine (100 mg/kg) (Hospira 
Australia Pty Ltd) via intraperitoneal injection, then 30 µl of DyLight488-conjugated 
Lycopersicon esculentum lectin (Vector Laboratories, DL-1174) was injected retro-orbitally and 
allowed to circulate for 2 min before retinas were fixed, dissected and stained as above. For 
cryosectioning, P18 retinas were fixed for 24 h, equilibrated in 30% sucrose in DPBS for at 
least one hour at room temperature and frozen in O.C.T. embedding compound (Scigen). 
20 µm cryosections were adhered to polysine slides, washed in DPBS then blocked and 
stained as for wholemount retinas.  
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Imaging & image analysis 
Retinas were imaged using a Leica TCS SP8 confocal microscope using 10x/0.4 NA, 
20x/0.75 NA or 40x/1.30 NA objectives and Leica Application Suite software. All image 
analysis was performed in the FIJI distribution of ImageJ software (Schindelin et al., 2012). 
Apoptotic ECs (defined as cleaved (active) caspase 3+/PECAM1+ cells enclosed by collagen 
IV signal) were quantified manually from confocal z stack images from the central retina at 
P8 and normalised to central retina area. Central retina vessel area was calculated based on 
PECAM1 signal from maximum intensity projection images following application of a 
median filter (2 pixels) and ‘despeckle’ filter prior to manually adjusting threshold and 
measuring area. Vessel area was normalised to total area of the central retina. Vessel 
regression was determined from equivalent areas as a ratio of PECAM1+ vessel segment 
length to collagen IV+ vessel segment length in a semi-automated fashion. Binary masks of 
both PECAM1 and collagen IV channel were made by various morphological filters and 
thresholding signal manually. Collagen IV+ PECAM1- vessel segment mask (i.e. regressing 
vessels) was generated by subtracting PECAM1 mask from collagen IV mask. Collagen IV+ 
PECAM1- mask and collagen IV mask were then skeletonised and length of vessels within 
each mask was measured. Collagen IV+ PECAM1-:collagen IV ratio generated automatically 
based on vessel length. Data represented as PECAM1:collagen IV ratio. ICAM2:collagen IV 
ratio calculated in same way, replacing PECAM1 with ICAM2 signal. Arterial side branches 
were counted as perfused if lectin signal overlapped continuously with ICAM2. Number of 
perfused arterial side branches within the central retina were counted and normalised to 
artery length. Non-perfused side branches were further categorised as ‘attached’, ‘disrupted’ 
or ‘detached’ based on ICAM2 signal. ‘Attached’ vessels were not perfused but had normal 
ICAM2 signal (identical appearance to perfused side branches). ‘Disrupted’ side branches 
had abnormal ICAM2 morphology compared to normal vessels, suggesting they were in the 
process of closing their lumen and detaching from the artery. ‘Detached’ side branches did 
not have continuous ICAM2 signal between side branch and major artery but did have 
continuous collagen IV signal. EC number was counted within equivalent regions of the 
same size and normalised to retina area. EC nuclei were counted manually based on Hoechst 
33342 or FLI1 nuclei in cells positive for vascular markers (Isolectin B4 or PECAM1). When 
using Hoechst 33342, NG2 staining was included to exclude pericyte nuclei. Number of 
FLI1 particles (nuclei) were counted after applying a median filter (2 pixels), removing noise 
with ‘despeckle’ function and analysing particles greater than 20 square-pixels. Particles were 
then manually checked through confocal Z-stacks to ensure all EC were counted. EC 
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proliferation was determined by manually counting phospho-histone H3 (Ser10)+ FLI1+ 
nuclei and normalised to total EC number in each region of the retina. ECs were then 
assigned as peripheral or central region based on demarcation described above. Network 
fragmentation, vessel branch points and vessel width were quantified from PECAM1 images 
of central retina vasculature. A median filter (2 pixels) was first applied to the PECAM1 
images, which were then segmented using the Trainable Weka Segmentation Plugin in FIJI 
(Arganda-Carreras et al., 2017). Segmented images were then skeletonised. The number of 
separate, independent network skeletons was used as a measure of network fragmentation. 
The number skeletons and vessel branch points were both normalised to central retina area. 
Vessel width was calculated as total vessel area divided by total vessel length calculated from 
Weka segmented images. Hypoxic area in the central retina was quantified from 
pimonidazole images. A 20-pixel median filter was applied to the images and a signal intensity 
threshold used to distinguish hypoxic signal from background. Hypoxic area was normalised 
to total central retina area. Neovascular tufts were quantified based on collagen IV signals 
which were segmented manually in Adobe Photoshop CC 2015 and area calculated in FIJI. 
Neovascular area per retina was normalised to total retina area. Where necessary, a despeckle 
filter was applied to select channels in images displayed in figures for clarity. 
 
Retina live-imaging 
Bak-/- BaxiEC/iEC mTmG mice were injected with tamoxifen as described above by intra-gastric 
injection at P2 and P3. Dam and pups were exposed to high oxygen for 48 h followed by 12 
h in room air. Retinas were then dissected immediately in cold DMEM, 5 radial incisions 
made and then flat-mounted with the internal limiting membrane face-down on a disc of 1% 
low-melting point agarose gel dissolved in DMEM containing 10% FCS and set in a 35 mm 
culture dish with cover glass bottom (Eppendorf, 0030740017). Nitex 50 µm filter mesh 
(Sefar, 03-50/31) dipped in molten 1% agarose/DMEM/10% FCS mixture was laid on top 
of the retina and allowed to set briefly to minimise retina movement during imaging. The 
dish was then fixed into in a custom 3D printed stage insert with inbuilt water reservoirs to 
maintain humidity. Retinas were live-imaged using an inverted Leica SP8 confocal 
microscope using a HyD detector and a 10x/0.4 NA objective. Retinas were maintained at 
37OC and 5% humidified CO2. Images were acquired every 30 min for 5 h. Post-acquisition, 
a mean filter (1 pixel) was applied to the images using FIJI software. 
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VEGFA ELISA 
VEGFA levels in whole retina lysates were quantified using a mouse VEGF Quantikine 
ELISA kit (R&D Systems, MMV00) as per the manufacturer’s instructions. Briefly, freshly 
dissected whole retinas were snap frozen in dry ice, thawed in 50 µl of DPBS and 
homogenised by manual trituration 20 times. Retina homogenates were subject to two 
freeze/thaw cycles then centrifuged at 5000 x g for 5 min. An equal volume of lysate was 
then assayed per retina. VEGFA concentrations were calculated from a standard curve 
generated by 4-parameter logistic regression analysis in R Version 3.4.4 using the drc package 
(Ritz et al., 2015).  
 
Statistics 
All data are shown as mean ± standard error of the mean (SEM). Statistical analyses were 




All experiments involving animals were performed with procedures approved by The Walter 
& Eliza Hall Institute of Medical Research Animal Ethics Committee or with University of 
Nottingham Animal Welfare and Ethical Review Board approval. 
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Figure 1. Blocking apoptosis prevents the loss of ECs from retinas exposed to high 
oxygen. (A and B) Representative images and quantification of EC apoptosis visualised by 
active caspase 3 staining (cyan) and PECAM1 (red) in control (n = 8) and Bak-/-BaxEC/EC (n 
= 3) retinas after 24 h in high oxygen. Arrow indicates rare apoptotic EC in Bak-/-BaxEC/EC 
retina. Scale bar = 100 µm. Student’s two-tailed t-test. (C) PECAM1 staining of control and 
Bak-/-BaxEC/EC retinas after 48 h in high oxygen, scale bar = 500 µm. Boxed region enlarged 
and rotated in E. (D) Quantification of central retina vessel area in mice exposed to high 
oxygen for 24 h (control n = 4, Bak-/-BaxEC/EC n = 5) or 48 h (control n = 6, Bak-/-BaxEC/EC 
n = 6) compared to 8 day old normoxic mice (control n = 2, Bak-/-BaxEC/EC n = 2). Multiple 
t-tests using Holm-Sidak correction for multiple comparisons. (E) PECAM1 (cyan) and 
collagen IV (red) staining within the central retina of Bak-/-BaxEC/EC mice raised in room air 
(normoxia) or for 48 h in high oxygen, scale bar = 80 µm. (F and G) Quantification of vessel 
regression and network fragmentation in the central retina of Bak-/-BaxEC/EC mice exposed to 
high oxygen for 24 h (n = 5) or 48 h (n = 6) compared to 8 day old normoxic mice (control 
n = 2, Bak-/-BaxEC/EC n = 2).  One-way ANOVA with Tukey’s multiple comparisons test. All 
data are mean ± SEM. Each circle represents one animal.  
  

















Figure 2. Blocking apoptosis delays, but does not prevent vessel regression (A) 
Control genotype retinas intravenously perfused with lectin (green) and stained for PECAM1 
(red) and active caspase 3 (cyan). Arrowheads indicate representative down-stream vessel 
closure points. Arrows indicate apoptotic ECs. Scale bar = 100 µm. (B) Collagen IV and 
perfused lectin staining in control and Bak-/-BaxEC/EC central retinas. Yellow arrows indicate 
arterial side branch closure, pink arrowheads indicate representative down-stream vessel 
closure points. Scale bar = 100 µm. (C) Quantification of perfused arterial side branches in 
control (n = 6) and Bak-/-BaxEC/EC mice (n = 5). Student’s two-tailed t-test. (D and E) 
Representative examples and quantification of perfused (lectin+, cyan) and types of 
unperfused arterial side branches in retinas from control (n = 4) and Bak-/-BaxEC/EC mice (n 
= 3) co-stained for ICAM2 (red) and collagen IV (blue). Scale bar = 10 µm. Multiple t-tests 
using Holm-Sidak correction for multiple comparisons. (F) Representative regions of non-
perfused capillaries from the central retinas of control and Bak-/-BaxEC/EC mice stained for 
collagen IV (red), ICAM2 (cyan) and perfused lectin (green). Scale bar = 50 µm. (G) 
Quantification of vessel regression in the peripheral and central retina capillaries from 
control (n = 4) and Bak-/-BaxEC/EC (n = 3) mice. Two-way ANOVA using Tukey’s multiple 
comparisons test. (H) Hypoxia visualised by pimonidazole (red) staining and ECs by 
PECAM1 (cyan) in control and Bak-/-BaxEC/EC retinas following 48 h of high oxygen 
exposure. Scale bar = 500 µm. (I) Quantification of central retina hypoxic area in mice 
exposed to high oxygen for 24 h (control n = 4, Bak-/-BaxEC/EC n = 3) or 48 h (control n = 
6, Bak-/-BaxEC/EC n = 5). Multiple t-tests using Holm-Sidak correction for multiple 
comparisons. Animals in panels A-G were exposed to high oxygen for 8 h. All data are mean 
± SEM. Each circle represents one animal.  
 
  


















Figure 3. Isolated endothelial cells protected from apoptosis rapidly reassemble to 
revascularize hypoxic retinas. (A and B) PECAM1 staining of control and Bak-/-BaxEC/EC 
retinas exposed to high oxygen for 48 h followed by 24 h in room air (48 + 24 RA). Scale 
bars: A = 500 µm, B = 60 µm. Arrows indicate sprouting vessels. Yellow boxes enlarged in 
B, pink box enlarged in D. (C) Quantification of central retina vessel area in control (n = 11) 
and Bak-/-BaxEC/EC (n = 12) mice exposed to 48 + 24 RA. Data for mice raised in normoxia 
or exposed only to 48 h of high oxygen from Figure 1D are included for comparison. Two-
way ANOVA using Tukey’s multiple comparisons test. (D) Representative area of central 
retinal vasculature from a 48 + 24 RA treated Bak-/-BaxEC/EC mouse stained for collagen IV 
(red) and PECAM1 (cyan). Scale bar = 80 µm. (E and F) Quantification of network 
fragmentation and vessel regression in the central retina of Bak-/-BaxEC/EC mice (network 
fragmentation n = 10, vessel regression n = 4) exposed to 48 + 24 RA. Data for mice raised 
in normoxia or exposed only to 48 h of high oxygen from Figure 1F & G are included for 
comparison. One-way ANOVA with Tukey’s multiple comparisons test. (G) Static images 
from live-imaging of retinal explants showing vessels reassembling starting 12 h after return 
to room air following 48 h exposure to high oxygen. Four independent clusters are shown. 
Time stamp is hh:mm (t0 = 12 h after return to room air). Arrows indicate where sprouts 
form new connections. Scale bar = 50 µm. All data are mean ± SEM. Each circle represents 
one animal. 
  



















Figure 4. Vessel reassembly in Bak-/-BaxEC/EC retinas utilises pre-existing, apoptosis-
protected ECs (A) EC proliferation in 48 + 24 RA control and Bak-/-BaxEC/EC retinas 
visualised by staining for pH3(Ser10) (cyan) and PECAM1 (red). Dotted line demarcates 
boundary between peripheral and central retina. Scale bar = 200 µm. (B) Quantification of 
proliferating ECs within central retina of 48 + 24 RA control (n = 3) and Bak-/-BaxEC/EC (n 
= 3) mice. Student’s two-tailed t-test. (C and D) Representative images and quantification of 
EC number in Bak-/-BaxEC/EC central retina vessels from normoxic mice (n = 3) or mice 
exposed to 48 h high oxygen alone (n = 3) or with 24 h recovery in room air (48 + 24 RA) 
(n = 3). EC number quantified based on EC nuclei (co-staining of FLI1 or Hoechst 33342 
with EC markers PECAM1+ or isolectin B4). Hoechst 33342 used at 48 h high oxygen as 
FLI1 was downregulated. Scale bar = 20µm. One-way ANOVA. All data are mean ± SEM. 
Each circle represents one animal. 
  





















Figure 5. Reassembled vessels in Bak-/-BaxEC/EC retinas are functional and limit 
neovascularisation and retinal injury. (A) Hypoxia visualised by pimonidazole (red) 
staining and ECs with PECAM1 (cyan) in retinas from control and Bak-/-BaxEC/EC mice 
exposed to high oxygen for 48 h followed by 24 h in room air (48 + 24 RA). Scale bar = 500 
µm. (B) Quantification of central retina hypoxia in 8 day old normoxic mice (control n = 2, 
Bak-/-BaxEC/EC n = 2), following 48 h in high oxygen (control n = 6, Bak-/-BaxEC/EC n = 5) or 
48 + 24 RA (control n = 6, Bak-/-BaxEC/EC n = 4). Multiple t-tests using Holm-Sidak 
correction for multiple comparisons. (C) Quantification of VEGFA protein in whole retina 
extracts from 48 + 24 RA treated control (n = 4) and Bak-/-BaxEC/EC (n = 4) mice and age-
matched normoxic controls (control n = 4, Bak-/-BaxEC/EC n = 4). Two-way ANOVA using 
Tukey’s multiple comparisons test. D) Experimental overview of OIR procedure time course 
used for analysis in E – H. (E and F) Representative examples and quantification of 
neovascular area in control (n = 8) and Bak-/-BaxEC/EC (n = 5) retinas at P15 stained for 
collagen IV. Yellow lines outline neovascular lesions. Scale bar = 500 µm. Student’s two-
tailed t-test. (G and H) Representative images and quantification of Müller cell gliosis 
visualised by GFAP (grey) staining comparing mice subjected to the OIR procedure shown 
in D (control n = 6, Bak-/-BaxEC/EC n = 6) or age-matched controls raised in room air 
(normoxia, control n = 2, Bak-/-BaxEC/EC n = 2). Isolectin B4 labels endothelial cells 
(magenta). Scale bar = 100 µm. One-way ANOVA with Tukey’s multiple comparisons test. 
All data are mean ± SEM. Each circle represents one animal. 
  


















Figure 6. Vessel reassembly is insensitive to VEGFA neutralisation. (A) Experimental 
overview of mice analysed in B and C. (B and C) Representative images and quantification 
of central retinal vasculature in mice subjected to the time course shown in A and treated 
with isotype control (control n = 4, Bak-/-BaxEC/EC n = 5) or anti-VEGFA (control n = 3, 
Bak-/-BaxEC/EC n = 5). Stained for collagen IV (grey). Scale bar = 500 µm. Two-way ANOVA 
with Tukey’s multiple comparisons test. (D) Experimental overview for mice analysed in E 
– H. (E) Representative examples of neovascularisation (yellow outline) in control and Bak-
/-BaxEC/EC retinas treated with anti-VEGFA or isotype control antibodies. Scale bar = 500 
µm. (F) Quantification of neovascular area in retinas from control (isotype n = 5, anti-
VEGFA n = 4) and Bak-/-BaxEC/EC mice (isotype n = 6 & anti-VEGFA n = 7). Two-way 
ANOVA with Tukey’s multiple comparisons test. (G) Quantification of vaso-obliterated area 
in control mice treated with isotype control (n = 5) or anti-VEGFA (n = 4). Bak-/-BaxEC/EC 
retinas do not have vaso-obliterated areas and are not shown. Student’s two-tailed t-test. (H 
– J) Representative images and quantification of vascular area in separate layers from the 
same field of view of the central retinas of control (isotype control n = 4, anti-VEGFA n = 
4) and Bak-/-BaxEC/EC mice (isotype control n = 6, anti-VEGFA n = 6). Scale bar = 100 µm. 
Student’s two-tailed t-test. 
 
  

















Supplementary Figure 1. (A) Experimental overview of entire oxygen-induced retinopathy 
procedure (B) PECAM1 staining control and Caspase 8-/-Mlkl-/- mice after 48 h high oxygen. 
Yellow lines demarcate avascular from vascularised regions. Scale bar = 500 µm. (C) 
Avascular area normalised to total retina area for control (n = 4) and Caspase 8-/-Mlkl-/-  (n = 
4) mice after 48 h high oxygen. Student’s two-tailed t-test. (D) Experimental overview of 
mice subjected to 24 h high oxygen. PECAM1 stained retinas of control and Bak-/-BaxEC/EC 
mice after 24h high oxygen, scale bar = 500 µm. (E) Collagen IV (red) and PECAM1 (cyan) 
staining in 24 h high oxygen Bak-/-BaxEC/EC central retina. Scale bar = 80 µm. (F) 
Experimental overview of mice treated with tamoxifen and subjected to 48 h high oxygen. 
PECAM1 stained retinas of control and Bak-/-BaxiEC/iEC mice after 48 h high oxygen, scale 
bar = 500 µm. Deletion was induced by administering tamoxifen at P2 and P3. (G) Collagen 
IV (red) and PECAM1 (cyan) staining within Bak-/-BaxiEC/iEC central retina. Scale bar  = 80 
µm. (H) Central retina vessel area normalised to central retina area in control (n = 4) and 
Bak-/-BaxiEC/iEC (n = 4) mice after 48 h high oxygen. Student’s two-tailed t-test. All data are 
mean ± SEM. Each circle represents one animal.  






Supplementary Figure 2. (A) PECAM1 (red) and active caspase 3 (cyan) stained images of 
P7 wild type retinas after 4, 8 and 12 h high oxygen and quantification of apoptotic ECs at 
each time point (0 h n = 2, 4 h n = 2, 8 h n = 2, 12 h n = 2). Scale bar = 500 µm. Line 
indicates mean. Each circle represents one animal. A PECAM1 mask was applied to the 
active caspase 3 signal to exclude non-EC apoptosis (B) PECAM1 staining of P10 control 
and Vegfr2iEC/iEC central retinas. Scale bar = 100 µm. (C) Quantification of central retina 
vessel area normalised to central retina area. Control n = 7, Vegfr2iEC/iEC n = 6. Student’s two-
tailed t-test. Data are mean ± SEM. Each circle represents one animal.  








Supplementary Figure 3. (A) Experimental overview of mice subjected to 48 h high oxygen 
or 48 h high oxygen followed by a further 24 h in room air (48 + 24 RA). (B) Experimental 
overview of Bak-/-BaxiEC/iECmTmGki/+ mice treated with tamoxifen and subjected to 48 h high 
oxygen followed by 12 h in room air (48 + 12 RA). (C) Schematic diagram of ex vivo retina 
live imaging setup. (D) 48 + 24 RA control retina stained for FLI1 (magenta) and pH3(Ser10) 
(cyan) to visualise proliferating ECs. Also stained with PECAM1. Arrows point to 
proliferating ECs in “plexus” region. Scale bar = 50 µm. (E) Proportion of ECs proliferating 
within peripheral retina of 48 + 24 RA control (n = 3) and Bak-/-BaxEC/EC (n = 3) mice. 
Student’s two-tailed t-test. Data are mean ± SEM. Each circle represents one animal.  





Supplementary Figure 4. (A) Experimental overview of mice subjected to 24 h high oxygen 
or 24 h high oxygen followed by a further 24 h in room air (24 + 24 RA). PECAM1 stained 
P8 normoxic, 24 h high oxygen and 24 + 24 RA Bak-/-BaxEC/EC retinas. Scale bar = 50 µm. 
(B) Comparison of central retina vessel area between mice exposed to high oxygen for 24 h 
or 48 h. Multiple t-tests using Holm-Sidak correction for multiple comparisons. (C) Branch 
points per mm2 of vessel area in P8 normoxic mice (control n = 2, Bak-/-BaxEC/EC n =2) and 
24 + 24 RA (n = 5) and 48 + 24 RA (n = 10) Bak-/-BaxEC/EC retinas. Control retinas are 
devoid of capillaries after exposure to high oxygen and hence not shown. One-way ANOVA 
with Tukey’s multiple comparisons test. (D) Vessel width in P8 normoxic mice (control n = 
2, Bak-/-BaxEC/EC n = 2) and 24 + 24 RA (n = 5) and 48 + 24 RA (n = 10) Bak-/-BaxEC/EC 
retinas. One-way ANOVA with Tukey’s multiple comparisons test. All data are mean ± 
SEM. Each circle represents one animal. (E) Overview model of vessel reassembly that 














Supplementary Movie 1. 
 
  








Supplementary Movie 2. 
 
  








Supplementary Movie 3. 
  
  Mechanisms of angiogenesis in development & disease 
 162 
  












Chapter 6:  








  Mechanisms of angiogenesis in development & disease 
 165 
6 Chapter 6: Discussion & Conclusions 
Chapter 6: Discussion and Conclusions 
6.1 Summary of major findings 
Angiogenesis is an essential developmental process necessary for tissue homeostasis but can 
become dysregulated in a range of diseases. In some diseases such as PDR, vessel loss due 
to EC death and vessel regression cause focal ischaemia that promotes an angiogenic 
response and contributes to disease progression. In this thesis, I investigated the mechanisms 
by which blood vessel growth and regression are regulated during development and disease. 
In the first part of this thesis, I investigated the role of the histone acetyltransferase (HAT) 
HBO1 in promoting gene expression changes necessary for EC differentiation and function 
during angiogenic blood vessel growth in development and disease. The major findings from 
this part of my thesis were: 
1. The HAT activity of HBO1 is increased in ECs undergoing sprouting angiogenesis 
and is necessary for normal sprouting angiogenesis  
2. Tip cells lacking HBO1 are unable to undergo directed or biased migration necessary 
for the formation of new vessel sprouts 
3. HBO1 activity is necessary for pathological retinal vessel growth that is known to 
depend on tip cell migration 
 
In the second part of my thesis, I investigated the contribution of EC apoptosis to 
pathological vessel regression, modelled using the OIR model that causes retinal ischaemia 
followed by pathological blood vessel growth. The major findings from this part of my thesis 
were: 
1. EC apoptosis in the OIR model does not cause the vessel closure that deprives the 
retina of blood flow, nor does it initiate vessel regression leading to vaso-obliteration  
2. Apoptosis clears ECs from vessels undergoing regression in the OIR model, and in 
its absence, these cells persist within the ischaemic region of the retina as non-
functional clusters of cells 
3. ECs preserved within the ischaemic retina are able to respond to hypoxic stimuli by 
reassembling a functional vessel network that restores blood supply and reduces 
retinal hypoxia 
4. Vessel reassembly does not depend on the high levels of VEGFA produced by the 
hypoxic retina 
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5. In the absence of EC apoptosis, reassembly of the retinal vascular network prevents 
neovascularisation and reduces damage to the underlying neural retina  
 
As the interpretation and experimental limitations of my results were discussed at the end of 
each results chapter, this discussion will mainly provide an overview of the future directions 
of the work as well as clinical implications of these findings and considerations for their use 
as therapeutic targets.  
 
6.2 HBO1 promotes both normal and pathological angiogenesis 
The pathways that blood vessels rely on to undergo normal angiogenic vascular growth can 
also contribute to inappropriate angiogenesis in disease. I found that HBO1 was required for 
the normal directed migratory behaviour of tip cells during developmental angiogenesis. 
Similarly to other genes that affect tip cell migration in both developmental and pathological 
contexts of vessel growth (Dubrac et al., 2016, Raimondi et al., 2014, Rama et al., 2015), I 
found that HBO1 was also required during pathological vessel growth in the OIR model. 
While the cause of the abnormal migratory behaviour at the molecular level remains 
inconclusive and is likely to be due to the collective change in a number of genes or pathways, 
the promising results in the OIR model suggest it as a potential therapeutic target for 
preventing angiogenesis in disease. The catalytic MYST domain that defines the MYST 
family of HATs including HBO1 was recently shown to be amenable to inhibition by small 
molecules (Baell et al., 2018). These inhibitors were developed in the Voss/Thomas 
laboratory at the Walter and Eliza Hall Institute and displayed varying affinity and specificity 
for the different MYST family members. One such inhibitor is WM1119, which has greatest 
affinity for MOZ (Kd = 0.002 µM) but can also inhibit HBO1 (Kd = 0.5 µM) (Baell et al., 
2018), suggesting that it may be feasible to generate small molecule inhibitors selective for 
HBO1. Another strategy to inhibit HBO1 could be to target members of the complexes that 
associate with and direct the activity of HBO1, such as BRPF and JADE scaffold proteins. 
While I did not determine which scaffold protein was responsible for the HAT activity of 
HBO1 within the endothelium, I found that H3K14ac was reduced in the absence of HBO1 
and BRPF proteins have been previously shown to direct HBO1 to H3K14 (Feng et al., 
2015, Lalonde et al., 2013, Mishima et al., 2011, Tao et al., 2017). Small molecule inhibitors 
against BRPF proteins have been developed (Bennett et al., 2016, Igoe et al., 2017), raising 
the possibility that these inhibitors could be used to prevent the action of HBO1. However, 
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a limitation to this approach is that BRPF proteins also form part of other MYST HAT 
complexes (Doyon et al., 2006, Ullah et al., 2008). The role of HBO1 in adult tissues has so 
far been limited to studying T lymphocyte development, where loss of HBO1 activity 
affected the development of natural killer T cells and survival of peripheral T cells (Newman 
et al., 2017); thus, it is not known what the wider consequences of HBO1 deficiency would 
be for adult homeostasis. Indeed, I did not investigate the role of HBO1 in the adult 
vasculature. The outcome of reducing HBO1 in adult tissues remains to be determined to 
recommend this as a possible therapeutic.  
 
6.2.1 Future directions 
I have shown that HBO1 is necessary for normal tip cell activity during sprouting 
angiogenesis, an event that is transcriptionally regulated. As the lung endothelium RNA-
sequencing data failed to elucidate the mechanism by which HBO1 is important for tip cell 
activity and sprouting angiogenesis, a high priority future direction will be to obtain RNA-
sequencing data from the retinal endothelium of control and Hbo1iEC/iEC mice. As described 
in Chapter 4, single cell RNA-sequencing represents the best method to interrogate the 
heterogeneity of the endothelium and understand the tip-cell specific consequence of 
deletion of Hbo1. In addition to sprouting angiogenesis, there are other contexts in which 
ECs undergo transcriptionally regulated fate-switching, for example during endothelial-to-
mesenchymal transition. This involves loss of EC identity, with cells instead adopting a 
mesenchymal fate (Dejana et al., 2017). Interestingly, this process bears resemblance to the 
actions of tip cells during angiogenesis, including establishing front-rear polarity for directed 
migration (Wesseling et al., 2018). Thus, HBO1 may be required for transcriptional 
regulation of genes that enable this process and future studies could address this possibility. 
Endothelial-to-mesenchymal transition can be activated in diseases, including atherosclerosis 
(Chen et al., 2015, Evrard et al., 2016) and vascular malformations (Bravi et al., 2016, 
Maddaluno et al., 2013), highlighting the importance of understanding this process.  
Similarly, it is possible that HBO1 is involved in other contexts of pathological vessel growth, 
which were not examined in this thesis. For example, future studies may investigate a role 
for HBO1 in regulating vessel network expansion necessary for tumour growth. Finally, the 
role of HBO1 in the adult vasculature and other organs should be studied to better 
understand the therapeutic potential and consequences of inhibiting the activity of HBO1. 
These studies may be aided by the development of a high affinity, specific HBO1 small 
molecule inhibitor.   
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6.3 Blocking the BCL2-regulated pathway of apoptosis in endothelial cells 
promotes revascularisation of ischaemic retinas 
I found that the BCL2-regulated pathway of apoptosis was required to remove ECs from 
regressing vessels during the vaso-obliteration phase of the OIR model. Reduced blood flow 
is the trigger for vessel regression during angiogenic pruning and this form of vessel 
regression requires EC movement, not apoptosis, as ECs in the vessel retract from each 
other, thereby dissolving the vessel (Franco et al., 2015, Watson et al., 2017). ECs survive 
angiogenic vessel pruning because they move short distances into neighbouring, perfused 
vessel segments that support EC survival (Zhang et al., 2018). In the OIR model however, 
whole capillary beds are simultaneously deprived of blood flow. Blocked blood flow and 
vessel regression still occurred in retinas of Bak–/–BaxEC/EC mice exposed to high oxygen. My 
results suggest that the loss of blood flow that occurs in the OIR model, triggers EC 
retraction and vessel regression, and that these ECs undergo apoptosis because they are not 
connected to a neighbouring, perfused vessel into which they can easily move. While 
apoptosis accelerated the vessel regression process, it did not cause the loss of blood flow 
that starts the regression process. My results showed that blocking apoptosis can protect the 
ECs in the regressing vessels, but cannot stop the cells retracting into isolated clusters. Thus, 
consistent with the role of apoptosis in clearing redundant cells, apoptosis in the OIR model 
serves to remove excess ECs from non-functional vessels.  
 
Blocking EC apoptosis may be a novel strategy for preventing the progression of biphasic 
retinal vascular diseases to the proliferative, neovascular stage because it facilitates the rapid 
revascularisation of the ischaemic retina. The relevance of understanding the contribution of 
EC apoptosis to human disease is highlighted by diabetic retinopathy pathogenesis where 
EC death is evident prior to progression to the proliferative phase. This was shown by 
TUNEL staining (Mizutani et al., 1996), however this assay detects cell death caused by either 
the BCL2-regulated or death receptor pathways and cannot discriminate between apoptosis 
and necroptosis (Grasl-Kraupp et al., 1995). While I found no involvement of death receptor 
apoptosis or necroptosis in vaso-obliteration using Casp8–/–Mlkl–/– double knockout mice in 
the OIR model, it remains possible that these forms of cell death contribute to EC apoptosis 
in diabetes.  
 
The phenotype of the Bak-/-BaxEC/EC mice is similar to Bim–/– mice, which have also been 
shown to be protected from vaso-obliteration and subsequent neovascularisation in the OIR 
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model (Wang et al., 2011). Interestingly, deletion of Bim specifically from the endothelium 
does not recapitulate the vaso-obliteration protective phenotype of Bim–/– mice (Wang et al., 
2017a), despite BIM being responsible for almost all EC apoptosis in the developing retina 
(Koenig et al., 2014). It is possible that loss of BIM, which is not as protective as loss of 
BAK and BAX, can only exert a protective effect if lost from both ECs and other cells that 
contribute to the retinal neurovascular unit, such as pericytes and astrocytes. While deletion 
of Bim cell-autonomously prevented pericyte apoptosis, this was unable to protect the 
endothelium from vaso-obliterating upon exposure to high oxygen (Wang et al., 2017a). 
Astrocytes also undergo apoptosis in the central retina during the OIR procedure (Bucher et 
al., 2013); however, the effect of protecting astrocytes from apoptosis during OIR is 
unknown.  
 
The general mechanisms of vessel regression that occur during diabetic retinopathy are not 
well understood. Whether the initiating event is due to loss of blood flow or caused by other 
stimuli like the loss of pericytes (Gardiner et al., 1994, Mizutani et al., 1996) or direct toxicities 
to ECs associated with high glucose (Ido et al., 2002, Yang et al., 2008) is not well 
understood. Patients with diabetic retinopathy have high levels of VEGFA in the eye, which 
may exacerbate vessel occlusion and regression due to leukostasis. Elevated VEGFA in 
experimental models causes leukostasis and vessel obstruction in mouse retinas, and clinical 
experience shows that anti-VEGFA therapy can improve capillary recanalisation in diabetic 
retinopathy (Liu et al., 2017). In the adult mouse brain, elevated VEGFA signalling also 
reduces recanalisation rates following capillary microsphere obstruction (Reeson et al., 2018). 
Vessel reassembly may represent a novel mechanism of preventing progression of diabetic 
retinopathy as it prevents the retina becoming hypoxic, thereby reducing the levels of 
VEGFA that would normally cause further vessel closure and proliferative vessel growth. It 
may even be possible to use apoptosis and anti-VEGFA therapy in conjunction, as blocking 
high levels of VEGFA in Bak–/–BaxEC/EC mice did not impede vessel reassembly. In addition, 
I found that inhibition of VEGFA did not impede deep vessel layer formation in Bak-/-
BaxEC/EC mice. It is possible that this is due to other hypoxia-induced pro-angiogenic factors 
that compensate for lack of VEGFA or that this process is insensitive to VEGFA dosage 
and can still proceed with only low levels of VEGFA present, ie: levels not inhibited at the 
given dose of anti-VEGFA.  
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While the retinal explant live-imaging did not allow normal vessel growth in P6 control and 
Hbo1iEC/iEC mice, this method was successfully used to live-image vessel reassembly in P9 
Bak–/–BaxEC/EC mice. This may be due to a number of reasons. Firstly, EC apoptosis was 
evident in the P6 retinas, but vessel reassembly was live-imaged in mice with ECs that are 
unable to undergo apoptosis and therefore cannot respond to stress in the same way that the 
P6 ECs did. Secondly, there may be differences in how P9 ECs within the remodelling zone 
are able to behave ex vivo compared to P6 ECs within the sprouting zone. For example, vessel 
reassembly is a process that normally occurs in the absence of blood flow and is therefore 
unlikely to be perturbed when the retina was removed from its blood supply. Finally, the 
factors influencing vessel reassembly are not understood and may be differently regulated to 
normal sprouting angiogenesis. It remains to be determined which growth factors and/or 
surrounding cells/ECM components enable EC clusters to reassemble. 
 
6.3.1 Challenges with inhibiting apoptosis in diabetic retinopathy patients 
While the OIR model recapitulates the biphasic nature of PDR, it occurs in the absence of 
high glucose or metabolic changes that influence disease progression in diabetes patients 
(Stahl et al., 2010). Whether the reassembly process can still occur in the retinas of patients 
with co-morbidities such as age or the metabolic changes associated with diabetes, which 
generally suppress angiogenesis (Stitt et al., 2005), remains to be determined.  
 
Diabetic retinopathy has a long-latency before progressing to PDR (Ting et al., 2016). A 
significant challenge to blocking apoptosis in the first phase of diabetic retinopathy would 
be knowing the correct time to treat patients. The time course and factors that influence the 
rate of capillary drop-out and ischaemia proceeding disease progression are not well 
understood. Optical coherence tomography angiography (OCT-A) is a newly developed 
technology that provides unprecedented detail of retinal vascularisation by measuring vessel 
perfusion in a non-invasive manner (Fingler et al., 2008). Longitudinal studies using OCT-A 
could help to understand the progression of capillary drop-out in diabetic retinopathy. This 
may help define the right time to treat patients, which would presumably be at a point where 
vessel loss becomes accelerated. Diabetes patients are already recommended to undergo 
routine retina screening for signs of disease progression (Stitt et al., 2016) and artificial 
intelligence-based approaches for assessing fundus images and diagnosing diabetic 
retinopathy have been FDA approved enabling high-throughput screening (van der Heijden 
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et al., 2018). Similar artificial intelligence strategies may be developed to automate the analysis 
of OCT-A images, which would expedite longitudinal progression studies.   
 
A further question relates to the availability of apoptosis inhibitors. There are no anti-
apoptotic agents currently in clinical use, however small molecule inhibitors of apoptosis 
have been developed with varying mechanisms of actions (Ben-Hail et al., 2016, Jiang et al., 
2016, Niu et al., 2017). For example, inhibitors of BAK/BAX oligomerisation at the 
mitochondrial outer membrane were shown to protect against neuronal cell death in vitro 
(Niu et al., 2017) and protecting the integrity of the mitochondrial electron transport chain 
could prevent neuronal cell death in a rat model of Parkinson’s disease (Jiang et al., 2016). 
As yet, these inhibitors have not been widely validated as bona fide BAK/BAX or apoptosis 
inhibitors. 
 
Relevant to the treatment of vascular eye diseases is the duration of treatment with apoptosis 
inhibitors. Long-term absence of BAK and BAX from the haematopoietic compartment 
results in multi-organ autoimmunity, characterised by reactive auto-antibodies and 
lymphocyte infiltration (Mason et al., 2013). Surviving Bak–/–Bax–/– mice show the same 
haematopoietic cell accumulation and autoimmunity but no additional detrimental defects 
(Ke et al., 2018, Lindsten et al., 2000). Long-term, systemic administration of apoptosis 
inhibitors may therefore be expected to induce autoimmunity. Localised administration into 
the eye by ocular implants or eye drops may help avoid this but remains to be tested.  
 
6.3.2 Future directions 
Vessel reassembly in the OIR model was not dependent on high levels of VEGFA produced 
by the hypoxic retina. Furthermore, vessel reassembly occurred without the need for EC 
proliferation, but how ECs sense their number and know to form sprouts without the need 
for accompanying proliferation is unclear. Understanding the molecular signals that stimulate 
vessel reassembly remain to be determined. This thesis focussed on the contribution of EC 
apoptosis to vessel loss causing ischaemic eye disease. It will be exciting to further investigate 
whether vessel reassembly could be useful in improving restoration of blood supply in other 
types of ischaemic disease such as heart failure, myocardial infarction or ischaemic stroke.  
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6.4 Concluding remarks 
In this thesis, I have investigated two distinct mechanisms regulating normal and pathological 
vessel growth and regression. In the first part of my thesis, I investigated the role of the HAT 
HBO1 during sprouting angiogenesis. I found that HBO1 is required for normal tip cell 
behaviour that allows directed migration necessary for both developmental and pathological 
angiogenesis. In the second part, I studied the role of EC apoptosis in vessel regression that 
occurs in the context of biphasic retinal vascular disease. I showed that blocking EC 
apoptosis does not protect against vessel regression, but preserves a reservoir of ECs 
embedded within the ischaemic retina capable of rapidly re-establishing a functional vascular 
supply and preventing disease progression. Overall, these results provide exciting new 
insights into how blood vessel growth and regression are regulated and suggest two novel 
ways for controlling vascular contribution to eye disease.  
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Table 8.1. Differentially expressed genes in Hbo1iEC/iEC  lung ECs compared to 
control lung ECs 
FDR = false discovery rate 





Fn1 1.94 9.75 1.51E-09 
Adam23 2.05 6.36 3.84E-08 
Cers4 0.50 5.99 1.50E-07 
Inhbb 0.56 6.40 1.50E-07 
Serpinb6a 0.53 6.08 1.57E-07 
Ptprf 0.42 4.69 1.83E-07 
Cd24a 0.55 6.63 1.94E-07 
Ltbp4 1.51 10.42 1.94E-07 
Sdc4 0.52 5.65 1.94E-07 
Sbno2 0.65 8.57 4.12E-07 
Gpr4 0.37 4.10 8.58E-07 
Plac8 1.71 6.00 1.36E-06 
Npr3 1.47 8.54 1.36E-06 
Tnc 0.41 3.92 1.36E-06 
Emp2 0.61 8.41 1.58E-06 
Rgs5 0.42 4.34 1.58E-06 
Vcam1 1.70 5.88 2.03E-06 
Vegfc 0.62 6.68 2.03E-06 
Lhfpl2 1.59 6.47 2.20E-06 
Plxnc1 1.68 5.95 2.62E-06 
Slc34a2 0.37 3.21 2.64E-06 
Mmrn2 0.65 7.79 3.16E-06 
Grik5 0.51 4.60 3.45E-06 
Pltp 0.54 7.98 3.59E-06 
Arrdc4 0.57 6.40 3.59E-06 
Enho 0.43 3.97 4.31E-06 
Samsn1 0.55 4.98 5.17E-06 
Hbb-bs 0.50 4.28 8.29E-06 
Mapt 0.57 4.98 1.30E-05 
Dapk1 0.55 5.04 1.30E-05 
Nid2 1.54 7.53 1.30E-05 
Rab27b 0.49 4.62 1.30E-05 
Serpinb1a 0.51 4.38 1.30E-05 
Flot2 0.56 5.10 1.53E-05 
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Rgs4 0.43 3.62 1.53E-05 
Lilrb4a 0.23 2.13 1.56E-05 
Tspan8 0.65 5.93 1.65E-05 
Tmod2 1.43 7.00 1.65E-05 
Ptk7 0.64 6.45 1.70E-05 
Fendrr 0.69 8.61 1.70E-05 
Loxl2 0.62 5.89 1.76E-05 
Rbms3 0.52 4.20 2.86E-05 
Prx 0.75 9.59 2.86E-05 
Cxcl15 0.40 2.68 2.87E-05 
Dab2 1.55 5.69 3.01E-05 
Pllp 0.63 5.39 3.12E-05 
Ctgf 0.65 6.41 3.15E-05 
Ccm2l 0.72 7.76 3.96E-05 
Ybx3 0.73 7.85 3.96E-05 
Scarf2 0.59 4.76 4.70E-05 
Mettl24 1.61 5.28 4.76E-05 
Abcc3 0.46 3.69 4.76E-05 
Atp8a1 0.59 5.94 4.99E-05 
Tbx2 0.67 7.72 4.99E-05 
Cxcl16 2.35 3.36 5.06E-05 
Hic1 1.68 5.49 6.07E-05 
Tril 1.52 5.49 6.07E-05 
Ccnd1 1.35 9.05 6.07E-05 
Asxl3 0.37 2.92 6.07E-05 
Camk4 0.67 5.81 8.14E-05 
Fam107b 0.66 5.30 8.46E-05 
Apbb1 0.51 3.83 8.46E-05 
Mgat4b 0.71 7.13 8.46E-05 
Itm2a 0.47 3.57 8.46E-05 
Dse 0.46 3.67 8.46E-05 
Malat1 0.74 7.27 8.46E-05 
Igfbp7 1.36 9.12 8.76E-05 
Timp3 1.33 9.80 8.76E-05 
Trim47 1.48 6.07 8.92E-05 
Gpm6b 0.57 4.50 9.03E-05 
Inf2 0.59 6.22 9.62E-05 
Cul9 0.43 3.15 9.70E-05 
Dvl1 0.73 6.66 1.06E-04 
Marcksl1 1.32 9.26 1.07E-04 
Cbr2 0.35 1.97 1.07E-04 
Gnao1 0.72 6.58 1.09E-04 
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Lhfp 0.71 6.68 1.10E-04 
Inpp4a 0.58 4.43 1.25E-04 
Mycn 1.88 3.80 1.40E-04 
Igfbp3 0.46 3.45 1.40E-04 
Als2cl 0.73 7.81 1.40E-04 
Zc3h12a 0.67 5.43 1.42E-04 
Ddx3x 1.32 10.14 1.42E-04 
Carmil1 0.64 5.30 1.47E-04 
Gucy1b3 0.55 4.03 1.49E-04 
Ndn 0.64 5.08 1.49E-04 
Ptprd 0.64 5.41 1.49E-04 
Pde2a 0.61 4.78 1.49E-04 
Fat1 0.68 5.60 1.49E-04 
Atp13a3 1.43 7.66 1.49E-04 
Fgfr2 1.38 6.47 1.49E-04 
Glp1r 0.74 6.94 1.49E-04 
Fzd4 1.32 8.12 1.49E-04 
Igsf10 0.36 2.77 1.49E-04 
Tbxa2r 0.61 4.53 1.49E-04 
Mier2 0.55 4.16 1.52E-04 
Tmem71 0.62 4.71 1.54E-04 
Camk1 0.67 5.43 1.54E-04 
Atp2a3 0.77 8.34 1.54E-04 
Rab11fip5 0.65 5.13 1.54E-04 
Grina 0.63 5.16 1.60E-04 
Rrm2 1.33 7.02 1.76E-04 
Stox2 1.35 6.98 1.80E-04 
Tns3 0.69 6.87 1.86E-04 
Ankrd44 0.73 6.62 1.90E-04 
Mras 0.61 5.77 2.04E-04 
Lyz2 0.45 2.93 2.10E-04 
Pkia 0.61 4.41 2.17E-04 
Napsa 0.31 1.08 2.22E-04 
Pfkp 0.62 5.01 2.34E-04 
Tspan7 0.75 9.62 2.34E-04 
Gprc5b 0.52 3.62 2.37E-04 
Dopey2 0.73 6.28 2.40E-04 
Exoc3l 0.75 6.98 2.40E-04 
Ehd3 0.45 2.97 2.40E-04 
Mcf2l 1.30 7.69 2.42E-04 
Nckap5 0.75 7.70 2.43E-04 
Osbpl5 0.65 4.88 2.55E-04 
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Diaph3 1.45 5.37 2.55E-04 
Arc 0.37 3.21 2.55E-04 
Oxct1 1.39 6.06 2.56E-04 
Fgf1 0.65 5.00 2.60E-04 
Rasgrp4 0.59 4.24 2.64E-04 
Mgll 0.72 7.41 2.65E-04 
Bcl3 0.74 6.63 2.65E-04 
Aebp1 0.63 4.72 2.69E-04 
Tbc1d2b 0.75 6.64 2.69E-04 
Lrch2 0.44 2.92 2.69E-04 
Calcrl 0.81 10.99 2.71E-04 
St6galnac2 0.68 5.30 2.76E-04 
Mfap2 0.75 7.22 2.76E-04 
Lifr 0.76 6.76 2.83E-04 
Lilr4b 0.21 1.25 2.83E-04 
Irf8 0.61 4.74 2.88E-04 
Frem1 0.48 3.57 2.88E-04 
Tbc1d16 0.74 6.18 2.90E-04 
Greb1 0.57 4.05 2.92E-04 
1810011O10Rik 1.41 7.45 2.92E-04 
Kctd17 0.63 5.02 2.94E-04 
Sec14l3 0.47 3.00 2.94E-04 
Serpina3g 0.34 3.17 3.07E-04 
Tm4sf1 1.30 8.89 3.07E-04 
Cyp1a1 0.39 2.50 3.15E-04 
Firre 0.72 6.02 3.15E-04 
Hc 0.42 1.95 3.15E-04 
Rdx 1.27 8.98 3.17E-04 
Pfkm 0.61 4.49 3.34E-04 
Cenpe 1.34 6.35 3.34E-04 
Man1a 0.65 4.70 3.39E-04 
Lmo7 0.69 5.30 3.39E-04 
Hmgn5 1.47 5.12 3.71E-04 
Itga1 1.28 7.86 3.75E-04 
Fosl2 0.79 8.14 3.76E-04 
Rnase4 0.60 4.11 3.81E-04 
Wif1 0.63 5.64 3.85E-04 
Sft2d2 0.73 6.12 4.09E-04 
Ssh3 0.51 3.33 4.25E-04 
Ano8 0.74 6.13 4.25E-04 
Hsph1 1.33 6.60 4.25E-04 
Pdlim3 1.47 5.31 4.32E-04 
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Arap1 0.75 6.42 4.32E-04 
Rrm1 1.31 7.21 4.32E-04 
Chst1 0.65 4.60 4.34E-04 
Sema7a 0.69 8.14 4.51E-04 
Pik3r6 0.65 4.70 4.51E-04 
Col4a5 0.50 3.40 4.51E-04 
Sqor 0.44 2.97 4.51E-04 
Map4k2 0.78 7.69 4.51E-04 
Cpd 1.25 9.63 4.61E-04 
Arhgef10 0.75 6.39 4.78E-04 
Kif23 1.31 6.66 4.78E-04 
Mfng 0.77 7.12 4.78E-04 
Mfap4 0.69 4.72 4.82E-04 
B3gnt3 1.34 6.25 4.99E-04 
Agtrap 0.65 5.09 5.03E-04 
Dpp4 1.29 7.74 5.03E-04 
Tsc22d1 1.25 9.07 5.03E-04 
Podxl2 0.63 4.35 5.19E-04 
A430105I19Rik 0.73 6.25 5.19E-04 
Bmx 1.45 5.04 5.59E-04 
Comp 5.38 0.77 5.59E-04 
Ctsl 0.77 6.93 5.65E-04 
Fndc4 0.46 2.91 5.79E-04 
Slc35f2 0.26 1.35 5.80E-04 
Gm20559 1.48 5.21 5.82E-04 
Pik3r3 1.27 7.43 5.82E-04 
Rcc2 1.27 7.69 5.85E-04 
Ctsz 0.73 5.71 5.91E-04 
Egflam 0.62 4.20 5.93E-04 
Cltb 0.73 6.66 6.23E-04 
Flrt3 0.47 2.97 6.26E-04 
Emcn 1.29 8.08 6.27E-04 
Myh14 0.41 2.85 6.40E-04 
Ccdc8 0.55 3.53 6.40E-04 
Col4a4 0.29 1.94 6.48E-04 
Asb4 0.49 4.01 6.65E-04 
Dnaja4 0.55 3.55 6.80E-04 
Klk8 0.59 4.15 7.11E-04 
Lbh 0.73 5.66 7.12E-04 
Ephx1 0.70 5.50 7.29E-04 
Edil3 0.71 6.34 7.35E-04 
Kdm6a 1.41 6.61 7.38E-04 
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Bcar3 0.69 5.34 7.39E-04 
Klhdc10 1.30 6.71 7.70E-04 
Tpcn1 0.76 6.56 8.07E-04 
Fibin 0.62 3.99 9.01E-04 
Gdpd1 0.72 5.34 9.28E-04 
Bub1 1.37 5.53 9.28E-04 
Col5a1 0.77 6.97 9.56E-04 
Brip1 1.51 4.51 9.57E-04 
Ier3 0.78 8.68 9.58E-04 
Gmfg-ps 0.63 4.07 9.60E-04 
Slc35e4 1.41 5.12 9.60E-04 
Alcam 0.41 2.31 9.71E-04 
Fxyd5 0.72 5.48 1.04E-03 
Hap1 1.55 5.15 1.04E-03 
Gnai1 0.72 5.28 1.05E-03 
Vopp1 0.76 6.10 1.05E-03 
Rasgef1a 0.79 7.13 1.07E-03 
Meis2 0.75 6.17 1.07E-03 
Frat2 1.53 4.88 1.08E-03 
Stil 1.34 5.72 1.08E-03 
C330027C09Rik 1.34 5.92 1.08E-03 
Zfp579 0.64 4.33 1.10E-03 
Pdzrn3 0.44 2.49 1.12E-03 
Cacna2d1 0.56 4.28 1.13E-03 
Cd82 0.57 3.66 1.13E-03 
Nbeal2 0.78 6.55 1.13E-03 
Lima1 0.77 6.81 1.13E-03 
Emp1 1.23 10.70 1.14E-03 
Cttnbp2 0.69 4.78 1.15E-03 
Tbc1d9 0.65 4.51 1.16E-03 
Axin2 0.69 4.71 1.16E-03 
Grk3 0.33 1.65 1.16E-03 
Arl4c 1.26 7.55 1.16E-03 
Spint2 0.44 2.37 1.20E-03 
Evc2 0.38 1.95 1.20E-03 
Stxbp2 0.39 2.29 1.21E-03 
Cblb 0.74 5.55 1.21E-03 
Peg3 0.79 9.11 1.22E-03 
Acta2 0.53 3.11 1.22E-03 
Gas1 2.29 2.62 1.22E-03 
Rps6ka3 1.32 6.25 1.22E-03 
Evc 0.38 1.96 1.22E-03 
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Dusp5 0.65 4.27 1.26E-03 
Gga2 0.74 5.53 1.26E-03 
Nova1 0.60 4.13 1.27E-03 
C630043F03Rik 0.56 3.54 1.27E-03 
Bora 1.36 5.50 1.27E-03 
Eml2 0.52 3.00 1.29E-03 
Guk1 0.79 6.79 1.29E-03 
Zfp641 0.54 4.11 1.30E-03 
Slco3a1 1.29 6.74 1.30E-03 
Reep2 0.58 3.54 1.31E-03 
Sat1 1.27 6.86 1.31E-03 
Itgb5 0.59 4.44 1.33E-03 
Chst2 0.71 5.00 1.33E-03 
Gramd4 0.72 5.07 1.33E-03 
H2-T22 1.38 6.61 1.33E-03 
Pdzd2 1.31 7.36 1.33E-03 
Mid1ip1 1.31 6.16 1.36E-03 
Il1rap 0.55 3.43 1.39E-03 
Osmr 0.68 5.11 1.40E-03 
Cdh4 0.69 4.74 1.45E-03 
Galc 0.59 3.78 1.47E-03 
Car12 1.86 3.17 1.47E-03 
Casc4 0.70 6.44 1.47E-03 
Isoc1 0.70 5.04 1.47E-03 
Dtx3 0.72 5.29 1.47E-03 
Lgmn 0.74 5.47 1.47E-03 
Fkbp11 0.44 2.42 1.47E-03 
Foxn2 1.28 6.43 1.47E-03 
Plxnb2 0.79 6.87 1.47E-03 
Chil1 0.40 1.15 1.47E-03 
Stau2 0.33 1.48 1.47E-03 
Capn1 0.73 5.77 1.48E-03 
Slc18b1 0.46 2.98 1.49E-03 
Grrp1 0.79 7.19 1.54E-03 
Kcnj2 0.61 4.77 1.55E-03 
Kank4 0.55 3.18 1.55E-03 
Trim12c 1.38 5.24 1.55E-03 
Peg3os 0.79 6.71 1.55E-03 
Pcolce 0.37 1.74 1.56E-03 
Nfkbid 0.65 4.13 1.57E-03 
Abca3 0.79 6.95 1.58E-03 
S1pr4 0.56 3.91 1.58E-03 
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Tmem158 1.40 5.03 1.58E-03 
Casz1 0.81 7.95 1.59E-03 
Rffl 0.66 4.27 1.61E-03 
Ccdc68 0.54 3.07 1.61E-03 
Myo5a 0.73 5.20 1.61E-03 
Tmem200b 1.91 3.05 1.62E-03 
Sdc3 0.78 7.83 1.62E-03 
Gbp8 2.13 2.53 1.63E-03 
Stab2 1.46 4.58 1.64E-03 
Tusc2 0.75 5.68 1.65E-03 
Nkd2 0.36 1.70 1.65E-03 
Serpinb9 0.77 6.26 1.66E-03 
Olfm1 0.75 5.64 1.66E-03 
Agpat5 0.69 4.72 1.67E-03 
Carhsp1 0.81 8.10 1.69E-03 
Zfp970 0.54 3.18 1.72E-03 
E2f8 1.33 5.58 1.73E-03 
Insig1 1.31 6.28 1.73E-03 
Frk 0.48 2.74 1.73E-03 
Endod1 0.72 5.01 1.73E-03 
Tmem88 1.26 6.73 1.79E-03 
St5 0.80 7.94 1.80E-03 
Per2 0.67 4.46 1.80E-03 
Trip6 0.61 3.73 1.86E-03 
Lamc2 0.45 2.16 1.89E-03 
Reep1 0.79 6.83 1.90E-03 
Reck 0.69 4.50 1.90E-03 
Man2b2 0.73 5.36 1.90E-03 
Lrg1 0.62 3.82 1.90E-03 
Tiam1 1.35 5.88 1.90E-03 
Sncaip 1.53 4.11 1.93E-03 
Emid1 0.78 6.19 1.94E-03 
Man1c1 1.28 6.25 1.95E-03 
Pld2 0.72 4.98 1.96E-03 
Timeless 0.81 7.47 1.96E-03 
BC064078 2.81 1.59 1.96E-03 
Adamts4 1.41 4.78 1.98E-03 
Enc1 1.24 7.23 1.98E-03 
Rab6b 0.68 4.60 1.98E-03 
Mylip 0.76 5.84 1.98E-03 
Phactr1 0.72 5.33 1.99E-03 
Gsn 0.62 3.68 2.00E-03 
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Tmem119 0.45 2.45 2.01E-03 
Acap3 0.77 6.21 2.04E-03 
Dhx32 0.64 4.30 2.05E-03 
Pitpnm3 0.56 3.35 2.07E-03 
Wwc1 0.28 0.89 2.07E-03 
Dnajb2 0.58 3.34 2.08E-03 
Il13ra1 0.68 4.93 2.08E-03 
Mlkl 1.39 5.09 2.08E-03 
Slc41a1 0.78 6.26 2.10E-03 
Whrn 0.45 2.42 2.13E-03 
Erap1 1.37 7.35 2.13E-03 
Pmp22 0.76 7.98 2.13E-03 
Ubr7 1.25 6.82 2.13E-03 
Akap5 0.52 3.00 2.13E-03 
Pitpnm1 0.60 3.63 2.14E-03 
Tbcel 0.73 5.08 2.18E-03 
39692 0.80 7.09 2.19E-03 
Pim3 0.82 9.14 2.22E-03 
Sec14l2 0.50 2.91 2.29E-03 
Bex3 0.64 4.17 2.29E-03 
Pmaip1 0.63 3.84 2.31E-03 
Cobll1 0.71 4.87 2.31E-03 
Ttk 1.45 4.79 2.35E-03 
Dram1 0.56 2.98 2.38E-03 
Sema4c 0.81 7.74 2.38E-03 
Plau 0.71 4.98 2.38E-03 
Kcnh1 0.74 7.14 2.40E-03 
Zfp423 1.39 5.07 2.40E-03 
Top2a 1.23 8.46 2.43E-03 
Tspan6 0.72 6.15 2.43E-03 
Oplah 0.51 2.73 2.44E-03 
Jam3 0.65 4.08 2.48E-03 
Cenpf 1.27 6.91 2.48E-03 
Sik1 0.81 7.01 2.51E-03 
Dusp8 0.81 7.06 2.55E-03 
Bace2 0.66 4.28 2.58E-03 
Tmc6 1.24 6.90 2.58E-03 
Astn1 0.08 -2.34 2.58E-03 
A630072M18Rik 1.36 5.28 2.59E-03 
Taok3 0.69 4.44 2.63E-03 
Fbn1 1.22 8.17 2.65E-03 
Tpd52 0.61 3.96 2.65E-03 
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Sftpa1 0.40 3.19 2.67E-03 
Hs3st1 0.63 3.77 2.67E-03 
Cavin3 0.77 5.88 2.67E-03 
Lin54 1.33 5.39 2.69E-03 
Sgpp1 0.62 3.73 2.70E-03 
Myo1d 0.78 6.28 2.70E-03 
Eva1a 0.70 4.51 2.73E-03 
Nipsnap1 0.55 3.00 2.76E-03 
Nacc1 1.23 7.14 2.76E-03 
Sema5a 0.45 2.26 2.81E-03 
Sema6c 0.62 4.01 2.82E-03 
Cyb5r3 0.82 7.95 2.85E-03 
Cops2 1.26 6.54 2.93E-03 
Iqgap3 1.24 6.93 2.93E-03 
Epha4 0.75 5.48 2.96E-03 
Serpine2 0.70 4.60 2.97E-03 
Spon2 0.32 0.97 2.97E-03 
Prc1 1.24 6.93 3.05E-03 
Pde9a 0.77 6.15 3.07E-03 
Mbnl3 1.31 6.80 3.07E-03 
As3mt 0.68 4.48 3.08E-03 
B4galt7 1.41 4.75 3.10E-03 
Pgd 1.28 5.96 3.12E-03 
Cyp2j6 0.65 4.01 3.16E-03 
Itga9 0.77 5.66 3.16E-03 
Adk 1.31 5.69 3.16E-03 
Traf7 0.83 8.03 3.16E-03 
Bmf 0.71 4.62 3.16E-03 
Slc26a2 0.71 4.70 3.17E-03 
Gm2223 1.43 6.11 3.20E-03 
Elovl5 1.21 8.34 3.20E-03 
Jak3 0.79 7.18 3.21E-03 
Plec 0.83 9.64 3.21E-03 
Slc6a2 0.71 6.97 3.27E-03 
Upp1 0.75 5.39 3.29E-03 
Ntn1 1.26 7.90 3.31E-03 
Micall2 0.53 2.83 3.32E-03 
Cdh1 0.37 1.05 3.32E-03 
Cyp26b1 0.78 6.90 3.36E-03 
Psma1 1.24 6.53 3.36E-03 
Sertad4 2.85 2.15 3.39E-03 
Gbp9 1.29 7.75 3.46E-03 
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Slc38a2 1.23 9.54 3.46E-03 
S1pr3 0.36 1.17 3.46E-03 
Anxa4 0.73 5.04 3.49E-03 
Tub 0.33 1.20 3.49E-03 
Nipal2 0.71 4.60 3.51E-03 
Slc12a4 0.81 6.73 3.58E-03 
Itga2 1.21 7.85 3.58E-03 
Ptgis 0.64 4.33 3.62E-03 
Col25a1 2.27 2.74 3.63E-03 
Cep192 1.24 6.61 3.64E-03 
Ahdc1 1.33 5.44 3.67E-03 
Plxna4 1.36 6.07 3.70E-03 
Ctso 0.77 5.50 3.70E-03 
Gpd2 0.76 5.70 3.70E-03 
Trim2 1.43 4.41 3.71E-03 
Pdcd7 1.36 4.86 3.71E-03 
Nrcam 0.36 1.46 3.71E-03 
Wfdc2 0.36 0.86 3.71E-03 
Dusp2 0.72 4.72 3.77E-03 
Ptpn4 0.76 5.38 3.77E-03 
Haus3 1.53 4.02 3.77E-03 
Angptl2 0.63 3.81 3.79E-03 
Sgk1 1.19 9.28 3.81E-03 
Arhgap42 0.65 4.02 3.83E-03 
Irs1 0.57 3.22 3.88E-03 
Pde8b 0.64 3.76 3.89E-03 
Lamc3 0.36 3.99 3.93E-03 
Cpq 0.67 4.03 3.93E-03 
Has2 1.25 6.23 3.93E-03 
Sytl4 0.46 2.31 3.98E-03 
Hid1 0.78 5.82 3.98E-03 
Pdia3 1.19 9.29 3.98E-03 
Sfxn1 0.51 3.20 4.01E-03 
Myzap 0.80 8.87 4.01E-03 
Begain 0.58 3.54 4.02E-03 
Stard4 1.23 7.22 4.02E-03 
Tlnrd1 1.19 9.19 4.02E-03 
Phlda1 0.78 5.81 4.07E-03 
Stom 1.22 8.10 4.15E-03 
Hhip 0.61 3.34 4.17E-03 
Map3k8 0.81 6.68 4.17E-03 
Fam126a 1.23 6.83 4.17E-03 
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Igsf3 0.67 4.02 4.22E-03 
Cyth4 0.54 2.97 4.23E-03 
Irx1 0.35 0.81 4.31E-03 
Gng2 0.81 6.80 4.37E-03 
BC028528 0.82 7.08 4.37E-03 
Gm15612 0.60 3.24 4.37E-03 
Slc38a3 0.43 1.85 4.38E-03 
L3mbtl3 1.24 6.60 4.38E-03 
Zfp664 1.20 8.11 4.46E-03 
Fam219a 0.79 6.18 4.51E-03 
Snrpe 1.36 4.83 4.53E-03 
Xpo1 1.21 7.77 4.53E-03 
Ccne2 1.36 5.00 4.64E-03 
Kif15 1.28 5.89 4.65E-03 
Colec12 0.73 5.39 4.68E-03 
Tmem159 0.72 4.59 4.68E-03 
Appl2 0.76 5.14 4.68E-03 
Psip1 1.26 6.20 4.70E-03 
Npdc1 0.79 6.44 4.70E-03 
Sptb 0.33 1.21 4.70E-03 
Arvcf 0.63 3.49 4.70E-03 
Tmem136 0.65 3.83 4.70E-03 
Lxn 1.26 6.63 4.74E-03 
Tagln2 1.18 9.51 4.76E-03 
Prdx6 0.80 6.19 4.77E-03 
Plekhg1 1.21 7.61 4.77E-03 
Pde8a 1.24 6.59 4.82E-03 
Plekhh2 0.46 1.99 4.89E-03 
Rhbdf2 0.81 6.70 4.89E-03 
Rasgrp2 0.75 5.00 4.90E-03 
Dlg5 0.80 6.26 4.90E-03 
Tcp1 1.20 7.68 4.90E-03 
Ldhb 0.18 -0.29 4.91E-03 
Pxdc1 0.79 6.03 4.94E-03 
Bmyc 0.53 2.80 4.95E-03 
Rasl11b 0.49 2.31 4.95E-03 
Ctla2b 1.42 5.10 4.95E-03 
Gtf2i 1.19 8.26 4.99E-03 
Nrbp2 0.61 3.35 5.00E-03 
Zfp260 1.25 6.02 5.00E-03 
Aqp5 0.40 1.27 5.02E-03 
Oit3 2.75 1.41 5.02E-03 
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Fen1 1.27 5.68 5.05E-03 
AU021092 0.61 3.58 5.08E-03 
Cdyl2 0.69 4.24 5.08E-03 
Ston2 0.68 4.53 5.08E-03 
Nlgn2 1.28 6.47 5.08E-03 
H3f3b 1.19 9.44 5.19E-03 
Daam2 0.43 2.22 5.20E-03 
Gaa 0.75 5.19 5.20E-03 
Atp13a2 0.82 7.64 5.20E-03 
Cyfip2 0.25 0.29 5.20E-03 
Ppt1 0.80 5.98 5.23E-03 
Glis3 0.63 3.60 5.23E-03 
Usp9x 1.21 7.38 5.34E-03 
Dhfr 1.34 4.95 5.50E-03 
Anxa6 0.84 8.46 5.50E-03 
Cdc42ep4 0.82 8.42 5.57E-03 
Bcar1 0.83 7.39 5.57E-03 
Aplp2 1.17 10.29 5.57E-03 
Snx18 0.78 5.60 5.62E-03 
Megf6 0.79 8.73 5.64E-03 
C3 0.35 0.89 5.74E-03 
Pard3b 0.75 5.35 5.75E-03 
Hnrnpu 1.17 9.59 5.76E-03 
Slco2b1 0.63 3.72 5.83E-03 
Plpp2 0.50 2.53 5.85E-03 
Sox4 1.19 8.15 5.85E-03 
Abcc4 1.43 4.36 5.85E-03 
Pnrc1 0.83 7.55 5.86E-03 
Ppp1r7 1.31 5.37 5.86E-03 
Ap3m1 1.28 5.45 5.86E-03 
Ctnnbip1 0.79 5.62 5.92E-03 
Col4a3 0.38 2.77 5.94E-03 
Fmnl1 0.51 2.44 5.95E-03 
Lin9 1.37 4.66 5.97E-03 
Ndnf 0.31 0.93 5.97E-03 
Flnc 1.62 3.41 5.98E-03 
Ifi27 0.67 3.96 5.98E-03 
AW549542 0.54 3.06 6.00E-03 
Ifit2 1.52 4.45 6.02E-03 
Stambpl1 0.37 1.30 6.02E-03 
Tmem252 1.22 6.89 6.06E-03 
Cd74 0.54 2.54 6.07E-03 
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Slc22a17 0.62 3.34 6.15E-03 
Car4 0.81 6.90 6.22E-03 
Npr2 0.61 3.20 6.24E-03 
Tmem246 0.58 3.21 6.29E-03 
Fbxw17 0.59 3.08 6.29E-03 
Pfkl 0.79 6.28 6.29E-03 
Tk1 1.34 5.57 6.43E-03 
Eid1 0.82 6.75 6.43E-03 
Ptprs 0.83 7.86 6.49E-03 
Pkhd1l1 1.89 3.00 6.50E-03 
Tor3a 1.24 6.43 6.55E-03 
Prr11 1.29 5.42 6.59E-03 
Cdc20 1.23 6.21 6.60E-03 
Apln 0.80 7.83 6.60E-03 
Nedd9 1.22 7.67 6.63E-03 
Afap1l1 0.85 9.42 6.68E-03 
Oasl1 1.90 3.92 6.73E-03 
Etl4 0.83 7.59 6.73E-03 
Ranbp2 1.19 8.28 6.77E-03 
4833423E24Rik 0.55 2.74 6.83E-03 
Fads3 0.64 3.48 6.83E-03 
Ninl 0.53 2.56 6.83E-03 
Dhcr7 1.35 4.69 6.83E-03 
Pgp 1.35 4.91 6.83E-03 
B4galt6 0.55 3.13 6.86E-03 
Ppp2r5b 0.78 5.86 6.86E-03 
Fam49a 0.63 3.42 6.96E-03 
Iqsec2 0.80 6.02 6.96E-03 
Mdfic 1.23 6.36 6.96E-03 
Rab11fip1 0.32 0.75 6.98E-03 
P3h3 0.72 4.78 7.07E-03 
Pla2g16 0.42 2.01 7.09E-03 
Adamts1 1.20 10.65 7.10E-03 
Arhgef6 0.59 3.39 7.13E-03 
Id3 1.20 7.65 7.13E-03 
Tle1 0.79 7.21 7.14E-03 
Akap12 0.85 9.14 7.14E-03 
Disc1 1.42 4.27 7.14E-03 
Gmps 1.30 5.17 7.14E-03 
Krt80 0.78 5.59 7.14E-03 
Rab43 1.23 6.29 7.14E-03 
Heph 0.80 6.39 7.14E-03 
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Lamp3 0.48 2.73 7.16E-03 
Hspa12a 0.64 3.62 7.16E-03 
Gnb5 0.58 2.91 7.24E-03 
Gulp1 0.74 4.92 7.24E-03 
Stmn1 1.25 6.30 7.27E-03 
Slc39a8 0.59 3.13 7.34E-03 
Ermp1 0.78 5.74 7.34E-03 
Tmem156 2.80 1.18 7.40E-03 
Gpc4 0.43 1.90 7.52E-03 
Zbtb34 0.79 5.60 7.64E-03 
Scn5a 0.56 2.70 7.72E-03 
Dzip3 1.39 4.37 7.72E-03 
Rbm38 0.72 4.38 7.72E-03 
Cldn12 0.76 5.04 7.72E-03 
Itga4 0.77 5.12 7.72E-03 
Agpat4 0.79 5.66 7.72E-03 
Mex3b 1.22 6.36 7.72E-03 
Cd200 0.81 7.74 7.72E-03 
Tpm1 0.83 7.05 7.72E-03 
Adgrf5 0.86 11.10 7.72E-03 
Hmgn3 0.53 2.45 7.74E-03 
Usp43 0.73 4.49 7.74E-03 
Trim65 1.62 3.22 7.75E-03 
Pamr1 0.44 1.67 7.75E-03 
Zfp24 1.28 5.41 7.75E-03 
Loxl3 0.68 3.96 7.76E-03 
Sirpa 0.68 5.53 7.82E-03 
Enpp5 0.66 3.64 7.92E-03 
Emp3 0.71 4.30 7.92E-03 
Pola1 1.28 5.45 7.95E-03 
Dapp1 0.50 2.26 7.97E-03 
Trf 1.27 5.95 8.11E-03 
Casp8 1.22 6.82 8.11E-03 
Klf9 1.31 5.59 8.12E-03 
Mastl 1.39 4.43 8.12E-03 
Cep295 1.26 5.87 8.13E-03 
Lrrc1 0.61 3.22 8.37E-03 
Dgka 0.78 5.36 8.37E-03 
Klhl2 0.78 5.64 8.37E-03 
Lyve1 1.17 10.36 8.40E-03 
Hbegf 0.78 5.36 8.42E-03 
Aif1l 0.54 2.78 8.43E-03 
  Mechanisms of angiogenesis in development & disease 
 228 
A230050P20Rik 0.65 4.40 8.43E-03 
Ect2 1.26 5.69 8.51E-03 
Baz1a 1.25 6.09 8.61E-03 
Hey1 1.24 6.82 8.61E-03 
Tmem2 0.85 9.84 8.73E-03 
Cpne2 0.66 4.55 8.80E-03 
Odf2 1.21 6.56 8.80E-03 
Rbbp7 1.19 7.30 8.80E-03 
Gm8203 1.19 7.93 8.80E-03 
Eif2s1 1.23 6.07 8.94E-03 
Flrt2 1.48 3.97 8.97E-03 
Gem 0.82 6.48 9.17E-03 
Fhdc1 0.52 2.57 9.19E-03 
Shtn1 0.50 2.26 9.19E-03 
Gnptg 0.70 4.09 9.20E-03 
Lrrc32 0.82 6.35 9.22E-03 
Fam184a 0.20 -0.41 9.27E-03 
Col16a1 0.48 1.56 9.33E-03 
Cdk17 1.19 7.25 9.33E-03 
Cxcl1 0.65 3.57 9.36E-03 
Ccna2 1.21 6.99 9.36E-03 
Fuca1 1.24 6.55 9.42E-03 
Svil 0.83 6.63 9.48E-03 
Synpo 0.81 6.12 9.48E-03 
Scg3 3.48 0.55 9.48E-03 
Plekho2 0.63 5.51 9.49E-03 
Prps2 0.66 3.75 9.49E-03 
Mmp28 0.79 5.61 9.55E-03 
Nedd4 1.15 10.60 9.55E-03 
Aida 1.24 6.04 9.55E-03 
Adgrl4 1.19 8.32 9.55E-03 
Smchd1 1.21 6.68 9.56E-03 
Kif20b 1.30 5.36 9.60E-03 
Rgl3 0.54 2.67 9.62E-03 
Uggt2 0.58 2.82 9.67E-03 
Polr2a 1.21 8.51 9.71E-03 
Selenoh 1.27 5.42 9.72E-03 
Ddhd2 0.75 4.69 9.73E-03 
Efhd2 0.69 4.48 9.75E-03 
4933412E12Rik 1.77 3.01 9.83E-03 
Scnn1g 0.36 0.35 9.84E-03 
P4htm 0.41 1.35 9.89E-03 
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Xpo4 1.31 4.85 0.0100 
Smad1 0.81 5.83 0.0100 
Syk 0.79 5.54 0.0101 
Cenpi 1.35 4.59 0.0102 
Rtf1 1.21 6.50 0.0102 
Smc3 1.21 7.18 0.0102 
Tnfsf9 0.30 0.58 0.0102 
Hopx 0.71 5.89 0.0103 
Nipal3 0.83 7.08 0.0104 
Vwa5a 0.78 5.94 0.0104 
Cldn5 0.87 10.57 0.0104 
Grb14 0.58 3.31 0.0104 
AI661453 0.42 1.56 0.0104 
Ltbp3 0.80 6.92 0.0105 
Anp32e 1.18 8.10 0.0105 
Clstn2 0.48 1.69 0.0105 
1700020L24Rik 0.74 4.77 0.0105 
Glg1 1.18 7.72 0.0105 
Hadh 0.80 5.61 0.0106 
Trpv2 0.38 1.06 0.0106 
Sema6a 0.85 7.97 0.0106 
Map1lc3a 0.81 5.72 0.0107 
Myl9 0.56 2.61 0.0107 
Siae 1.52 3.71 0.0107 
Tor1aip1 1.20 7.05 0.0108 
Zfp36l2 1.19 7.86 0.0108 
Lrrn3 0.48 2.00 0.0108 
Col1a1 0.54 4.33 0.0108 
Mrc1 0.74 4.43 0.0108 
Rab8a 1.24 5.91 0.0108 
Slc39a6 0.81 6.53 0.0108 
Atad2 1.20 7.03 0.0108 
Lsr 0.55 2.52 0.0109 
C1qtnf12 0.47 1.77 0.0109 
Fam19a1 0.29 0.36 0.0109 
Mif4gd 0.74 4.38 0.0110 
Col5a2 1.16 9.27 0.0110 
Asns 0.53 3.35 0.0110 
Osbpl6 0.47 1.75 0.0110 
Hcn4 0.26 1.17 0.0110 
2310022B05Rik 0.80 6.03 0.0110 
Txndc5 1.18 7.52 0.0110 
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Ip6k3 0.30 0.56 0.0110 
Fermt3 0.55 2.51 0.0111 
Slc12a2 1.26 6.70 0.0111 
Adamts10 0.84 7.51 0.0111 
Tagln 0.69 3.78 0.0112 
Nts 0.63 3.25 0.0112 
Plat 0.77 7.63 0.0112 
Tgfb1i1 0.84 7.52 0.0113 
Calm2 1.18 8.07 0.0113 
Suv39h1 1.27 5.33 0.0113 
Plin2 0.77 5.33 0.0113 
Fasn 1.20 6.73 0.0113 
Map7 0.69 3.94 0.0114 
Spred1 1.22 6.04 0.0114 
Cnot6l 1.21 6.33 0.0115 
Radil 0.39 1.38 0.0116 
Laptm4b 0.79 5.33 0.0116 
Eed 1.27 5.38 0.0116 
Noct 0.71 4.16 0.0117 
Socs3 0.83 9.53 0.0117 
Cd276 0.57 2.73 0.0117 
Lox 1.31 5.05 0.0117 
Map3k14 0.76 5.12 0.0117 
Ptprj 1.25 5.64 0.0117 
Heatr3 1.32 4.80 0.0118 
Zfp36l1 1.19 8.76 0.0118 
Lzts1 0.67 3.66 0.0118 
Sparcl1 1.35 9.44 0.0119 
Fam124a 0.77 5.01 0.0119 
Fstl1 1.16 9.84 0.0119 
Cnr2 0.53 2.33 0.0119 
Dkk2 1.57 3.38 0.0121 
Unc5a 0.74 4.34 0.0121 
Smim14 0.80 5.49 0.0121 
H2afy2 0.80 5.58 0.0121 
Hyal2 0.85 7.37 0.0121 
Ctps2 0.77 4.79 0.0121 
Parp1 1.20 6.66 0.0121 
Epn3 0.21 -0.74 0.0122 
Pabpc1 1.17 9.01 0.0122 
Sh3bgrl 1.27 7.39 0.0123 
Gcc1 0.73 5.65 0.0123 
  Mechanisms of angiogenesis in development & disease 
 231 
Il18r1 0.24 -0.51 0.0123 
Llgl1 1.18 7.12 0.0124 
Gramd1a 0.84 7.06 0.0125 
Lancl1 0.73 4.25 0.0125 
Mal2 0.38 1.50 0.0126 
Net1 0.77 5.77 0.0127 
Itpripl2 1.17 8.68 0.0128 
Enpep 0.60 2.52 0.0128 
Hs6st1 0.77 4.92 0.0128 
Peak1 1.21 6.28 0.0128 
Lamb3 0.41 0.86 0.0129 
Cthrc1 0.71 4.14 0.0129 
Knl1 1.26 5.25 0.0129 
Hsp90aa1 1.19 7.23 0.0129 
F11r 1.17 8.41 0.0129 
Rock2 1.17 8.19 0.0129 
Epas1 0.87 12.18 0.0129 
Gm20163 0.79 5.20 0.0130 
Zdhhc20 1.22 7.39 0.0131 
Pgm5 1.21 7.34 0.0131 
Vars 1.19 6.73 0.0132 
Klhl23 1.30 4.90 0.0132 
Elf1 1.20 6.96 0.0132 
B3gnt5 0.64 3.28 0.0133 
Gbp11 1.75 2.57 0.0133 
Rps6ka1 0.76 6.16 0.0133 
Lyz1 0.46 1.81 0.0134 
Lrrc40 1.32 4.77 0.0134 
Csrp2 1.18 7.22 0.0134 
Setd1b 1.22 6.22 0.0135 
9430041J12Rik 0.12 -2.64 0.0136 
Ivns1abp 1.17 8.31 0.0136 
Ifitm3 1.24 8.92 0.0136 
Krt7 0.50 2.31 0.0136 
Cdh13 1.43 3.82 0.0136 
Slit2 0.74 5.59 0.0136 
Arnt2 0.27 -0.03 0.0136 
Ppp1r14c 0.35 -0.15 0.0137 
Kbtbd11 0.57 2.72 0.0138 
Sftpd 0.38 1.43 0.0138 
Vps35 1.18 7.57 0.0138 
Klf5 0.29 0.13 0.0138 
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Mafk 0.84 7.29 0.0138 
Pck2 1.25 5.62 0.0138 
Slc35c2 0.72 4.07 0.0139 
Adamts12 0.48 2.07 0.0140 
Grp 1.39 4.54 0.0140 
Peli2 0.77 4.96 0.0140 
Kirrel 1.20 6.62 0.0140 
Itga3 0.85 7.76 0.0140 
Ushbp1 0.86 8.41 0.0140 
Hk2 0.34 0.67 0.0140 
Fhl1 0.82 7.44 0.0140 
Sbk1 0.72 4.06 0.0140 
Tacc3 1.24 6.02 0.0140 
Flt4 0.84 8.24 0.0140 
F2r 0.71 6.96 0.0141 
Zdhhc1 0.77 4.84 0.0141 
Nsl1 1.33 4.66 0.0142 
Zdhhc2 0.68 3.71 0.0142 
Erf 1.28 7.99 0.0142 
Sox18 1.18 8.00 0.0142 
Lama3 1.33 5.04 0.0142 
Nptx1 0.68 3.67 0.0143 
Prodh 0.69 3.94 0.0143 
Tppp 0.75 4.58 0.0143 
Clspn 1.24 5.59 0.0143 
Tnfsf15 0.21 -0.63 0.0143 
Dbf4 1.27 5.41 0.0144 
Serinc2 0.23 -0.33 0.0144 
Dhrs13 0.58 2.63 0.0145 
Klhl4 0.78 4.92 0.0145 
Gpc3 0.53 1.76 0.0146 
Ctsd 0.86 7.97 0.0149 
Slc38a4 0.38 1.02 0.0149 
Sulf1 1.22 5.95 0.0149 
Fahd2a 0.45 1.49 0.0149 
Tmem123 0.84 7.40 0.0150 
Snhg14 0.14 -1.65 0.0150 
Sh3kbp1 0.66 4.02 0.0151 
Pdk4 0.48 1.78 0.0151 
Gyg 0.76 5.20 0.0151 
Filip1l 1.24 7.35 0.0151 
St6galnac5 0.42 1.39 0.0151 
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Src 0.66 3.27 0.0151 
Hoxa4 0.61 3.03 0.0152 
Msmo1 1.31 4.78 0.0152 
Sorcs2 0.39 1.02 0.0152 
Gm10257 1.26 5.13 0.0153 
Serinc5 1.18 7.18 0.0153 
Lats2 0.86 7.96 0.0153 
Stat5a 0.75 4.35 0.0155 
Akr1c14 0.48 1.67 0.0155 
Fam3c 0.82 6.17 0.0155 
Cspg4 0.44 1.22 0.0157 
Aprt 0.73 4.55 0.0157 
Gstm1 0.81 6.16 0.0157 
Slc2a13 0.67 3.95 0.0157 
Atxn1 1.29 4.87 0.0157 
Tacc2 0.71 4.17 0.0158 
Csf2rb 0.19 -1.02 0.0158 
Reps1 0.84 6.45 0.0158 
Tpx2 1.24 6.63 0.0158 
Vps26a 1.22 6.04 0.0158 
Arap2 0.85 7.56 0.0159 
Mis12 1.26 5.25 0.0159 
Car8 0.81 5.49 0.0160 
Rnf152 1.55 3.51 0.0160 
Sms-ps 1.33 4.48 0.0161 
Psme4 1.17 7.19 0.0161 
Gprin3 0.58 2.66 0.0161 
Plk1 1.32 4.92 0.0162 
Tm7sf3 0.79 5.03 0.0162 
Zdhhc14 0.53 2.20 0.0162 
Fam167b 1.55 3.18 0.0163 
Nlrc3 0.64 3.23 0.0163 
Stard3nl 0.79 5.11 0.0163 
Mum1l1 0.53 2.46 0.0163 
Nid1 1.15 9.88 0.0163 
Mrgpre 0.54 2.41 0.0163 
Nup155 1.21 6.03 0.0163 
Hipk2 1.22 6.27 0.0163 
Itih5 0.44 1.30 0.0164 
Btnl9 0.53 2.12 0.0165 
Ctsc 0.68 5.81 0.0165 
Abcc1 0.78 5.01 0.0166 
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Suz12 1.18 7.15 0.0167 
Klhdc8a 0.47 1.82 0.0168 
Eif2s3x 1.45 3.80 0.0168 
Plekha5 0.78 5.27 0.0168 
Gxylt2 0.82 5.70 0.0168 
Gle1 1.22 5.79 0.0168 
Dock7 0.77 5.02 0.0169 
Arhgef9 0.69 3.72 0.0170 
Gramd1b 0.61 2.83 0.0171 
Spock2 0.66 3.52 0.0171 
C530008M17Rik 0.81 5.67 0.0171 
Sema3f 0.86 8.86 0.0172 
Tuba4a 0.41 1.11 0.0173 
Ptk2b 0.54 2.90 0.0173 
Scarb1 0.84 7.55 0.0174 
Stx7 0.84 6.52 0.0176 
3632451O06Rik 0.18 -1.09 0.0176 
Slfn5 1.16 9.28 0.0176 
Hba-a1 0.65 3.33 0.0177 
Fam129a 0.44 1.24 0.0180 
E2f7 1.22 5.87 0.0180 
Krba1 0.73 4.02 0.0181 
Hif1a 1.17 7.22 0.0181 
Naa50 1.19 6.53 0.0183 
Tifa 0.58 2.83 0.0183 
Slc52a3 0.56 2.31 0.0183 
Nkd1 0.86 8.04 0.0183 
Ttc12 0.65 3.39 0.0184 
Shd 0.35 0.56 0.0184 
Herc2 1.18 7.85 0.0184 
Rbm14 1.21 5.82 0.0185 
Clec12b 0.65 3.21 0.0186 
Fam83d 1.24 5.39 0.0187 
Anpep 0.54 2.39 0.0187 
Eps15l1 1.19 6.69 0.0187 
Magoh 1.23 5.49 0.0187 
LOC100503956 0.74 4.41 0.0189 
H13 0.84 6.70 0.0189 
Tmc7 0.64 3.19 0.0190 
Nacc2 0.70 3.65 0.0190 
Hyal1 1.38 4.20 0.0190 
Ankfy1 1.18 7.25 0.0190 
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Txlna 1.17 7.43 0.0190 
Gm9800 1.16 8.86 0.0190 
S100a10 0.85 6.95 0.0190 
Adcy3 0.65 3.50 0.0190 
Slfn4 3.00 0.35 0.0190 
Moxd1 1.34 4.22 0.0190 
Sh3bp1 0.45 1.50 0.0190 
Tbx4 0.56 2.29 0.0190 
Rai14 1.19 7.86 0.0190 
Sestd1 0.80 5.28 0.0191 
Fryl 1.18 7.56 0.0192 
Kdm5c 1.50 7.07 0.0192 
Clec14a 1.16 9.09 0.0193 
Sptbn5 0.55 2.19 0.0194 
Tgif1 1.36 4.69 0.0194 
Pclaf 1.25 5.92 0.0194 
Tmem204 0.85 7.65 0.0194 
Gmpr 0.51 2.14 0.0194 
Ces1d 0.49 0.41 0.0194 
Gadd45g 0.83 6.71 0.0195 
Robo2 0.50 1.81 0.0199 
Fam19a2 0.14 -1.94 0.0199 
Mafb 1.30 4.67 0.0199 
Mgp 1.24 5.63 0.0200 
Ncapd3 1.21 6.33 0.0200 
Ube2z 1.17 7.29 0.0200 
Klf6 1.16 8.65 0.0201 
Mmrn1 0.86 7.15 0.0202 
Plod2 0.77 4.75 0.0202 
Cep55 1.25 5.53 0.0202 
Slc1a1 0.36 1.56 0.0203 
Brwd3 1.31 4.51 0.0203 
Dennd2a 0.79 5.30 0.0203 
Map2 0.49 1.70 0.0203 
Sfr1 1.18 6.72 0.0203 
Cstb 0.63 3.53 0.0204 
Fntb 0.71 3.76 0.0205 
Shc1 1.18 6.90 0.0205 
Azin1 1.16 7.93 0.0205 
Abca5 0.44 1.23 0.0207 
Slc1a5 0.81 5.32 0.0207 
Anln 1.18 6.83 0.0207 
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Ssrp1 1.17 7.61 0.0208 
Iqck 0.43 1.21 0.0208 
Zim1 0.37 1.37 0.0208 
Atp2a2 1.15 8.38 0.0208 
Mcu 1.30 5.05 0.0208 
Dtx4 0.40 0.81 0.0209 
Svip 0.48 1.53 0.0209 
Atp1b1 0.41 0.64 0.0209 
Tmtc2 0.85 7.07 0.0209 
Phtf1 1.24 5.35 0.0210 
Rap1a 1.19 6.53 0.0212 
Adamtsl3 0.52 1.92 0.0212 
Mpnd 1.21 5.75 0.0212 
Dtna 0.33 0.17 0.0212 
Nup188 1.19 6.36 0.0212 
Cst3 0.85 6.94 0.0212 
Tmem150b 0.21 -0.82 0.0212 
Gnptab 0.78 4.76 0.0213 
Dagla 0.56 2.33 0.0213 
Ada 0.72 3.94 0.0214 
Tpm2 0.50 1.43 0.0214 
Krt19 0.28 0.33 0.0214 
Ecm1 0.58 6.58 0.0215 
Ccdc149 0.51 1.91 0.0216 
Steap3 0.42 1.28 0.0218 
Ctif 1.26 5.49 0.0218 
Wnt5a 0.42 0.91 0.0219 
Pcmtd1 0.82 5.86 0.0219 
Fbxl5 1.21 6.26 0.0219 
Adgrg1 1.31 4.47 0.0219 
Slc16a9 0.58 5.14 0.0220 
Trim30a 1.36 6.27 0.0220 
Ifnar1 1.18 7.80 0.0220 
Mansc1 0.77 4.74 0.0220 
Tmem189 0.79 5.42 0.0221 
Gas6 0.84 6.26 0.0221 
Ntn4 1.28 4.92 0.0221 
Txndc16 1.25 5.12 0.0222 
Dkk3 0.63 2.89 0.0224 
Blm 1.28 4.77 0.0224 
Celsr2 0.85 6.84 0.0224 
Pip4k2c 0.73 4.23 0.0224 
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Ddx60 1.29 5.36 0.0224 
Sep-11 1.18 7.95 0.0224 
Smpdl3a 0.83 5.98 0.0225 
Tuft1 0.19 -1.16 0.0225 
Sh3gl2 0.41 1.08 0.0225 
Aldh4a1 0.72 3.82 0.0225 
Ipo7 1.16 7.19 0.0226 
Gdi1 0.85 6.95 0.0226 
Zfpm1 1.17 6.95 0.0227 
Hfe 0.79 5.27 0.0227 
Coro7 0.80 4.96 0.0228 
B4galt2 0.75 4.34 0.0229 
Fam193b 0.85 6.94 0.0229 
Sap30 1.42 3.89 0.0229 
Cbx5 1.17 7.03 0.0231 
Col14a1 1.45 6.96 0.0232 
Mrc2 0.61 2.60 0.0232 
Dtx1 0.59 2.57 0.0233 
Iqgap2 0.55 2.27 0.0233 
Ano1 0.39 0.81 0.0234 
Prkcq 0.70 3.52 0.0235 
Rai2 0.44 1.39 0.0238 
Morc3 1.21 5.79 0.0238 
Vsir 0.85 7.00 0.0238 
Sdr39u1 0.80 5.06 0.0239 
Arxes2 0.32 0.27 0.0239 
Fbrsl1 0.84 6.37 0.0239 
Cfap57 0.29 -0.19 0.0239 
Tlr4 0.60 2.98 0.0241 
Slc7a6 0.76 4.85 0.0241 
Cdk5rap2 1.22 5.51 0.0241 
Mthfd2 1.42 3.89 0.0241 
E230016M11Rik 0.74 4.14 0.0241 
Tsx 6.95 -2.75 0.0241 
Gbp10 2.86 2.65 0.0242 
Gm9892 1.19 6.18 0.0242 
Peg10 1.36 4.73 0.0245 
Higd1b 0.40 0.90 0.0247 
Pfn2 0.60 2.67 0.0247 
Ndrg3 0.79 4.95 0.0247 
Ugcg 0.85 7.00 0.0247 
Mrpl55 1.43 3.72 0.0247 
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Rpl10a 0.74 3.98 0.0247 
Clu 0.77 5.32 0.0247 
B3gnt2 0.79 5.71 0.0247 
Dalrd3 0.81 5.30 0.0247 
Mgat2 1.18 6.38 0.0247 
Sidt2 0.85 6.54 0.0247 
Arid5b 1.18 6.69 0.0247 
Rif1 1.17 6.83 0.0247 
Mfsd6l 0.30 -0.12 0.0247 
Prkar1a 1.14 9.29 0.0247 
Renbp 0.66 3.16 0.0248 
Tmem181b-ps 0.80 5.12 0.0252 
H2-Ke6 0.75 4.25 0.0252 
Il17rc 0.69 4.23 0.0253 
Adh1 0.70 3.42 0.0253 
Stk38 1.19 6.50 0.0253 
Lrig3 0.76 4.56 0.0253 
Klhl13 0.79 5.46 0.0253 
Fyn 1.15 8.11 0.0256 
Pbdc1 1.43 4.14 0.0257 
Dlg4 0.73 4.01 0.0257 
Ednra 0.45 1.43 0.0260 
Cmah 2.17 1.71 0.0260 
Ptprk 0.86 7.82 0.0260 
Slc45a3 0.72 3.85 0.0260 
Cks1b 1.26 5.09 0.0261 
Sem1 1.20 6.09 0.0261 
Eme1 1.30 4.46 0.0262 
Pepd 0.72 4.00 0.0262 
Ogfr 1.17 6.93 0.0262 
Anapc1 1.15 8.06 0.0263 
Tom1l1 0.50 1.61 0.0263 
Arid3b 0.77 4.42 0.0263 
Crem 1.20 5.85 0.0264 
Ptpn13 0.41 0.62 0.0265 
BC034090 0.76 4.41 0.0265 
Cenpq 1.29 4.49 0.0266 
BC067074 0.32 0.15 0.0266 
Pla2g4b 0.63 2.97 0.0268 
Gm5637 1.21 5.80 0.0269 
Loxl1 0.54 1.56 0.0269 
Epdr1 0.50 1.59 0.0269 
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Pcdh18 0.70 3.67 0.0269 
Krt8 0.35 0.34 0.0269 
Tmx4 1.26 5.94 0.0269 
Psma6 1.19 6.27 0.0269 
Dock5 0.64 2.96 0.0269 
Dusp10 0.61 2.89 0.0269 
Bicd1 0.42 1.00 0.0269 
Pole 1.21 5.79 0.0271 
Fam111a 1.23 5.62 0.0271 
Galnt7 1.38 4.01 0.0272 
Gria3 0.49 1.52 0.0272 
Zmat3 0.74 4.42 0.0273 
Rflnb 0.85 7.01 0.0274 
Arhgef10l 0.45 1.24 0.0275 
Mapk8ip3 0.84 6.29 0.0275 
Slc8b1 0.76 4.30 0.0275 
Il4ra 0.83 8.18 0.0275 
Ptbp1 1.14 9.30 0.0275 
Chrd 0.38 0.72 0.0277 
Acvr2a 0.84 6.11 0.0277 
Phf1 0.82 5.30 0.0277 
Stab1 0.86 9.22 0.0279 
Kazn 0.81 5.32 0.0280 
Nup160 1.19 6.22 0.0280 
Smc2 1.16 7.06 0.0280 
Wfdc1 1.39 6.62 0.0281 
Spink5 0.24 -1.41 0.0281 
Cnnm4 0.72 3.73 0.0282 
Mthfr 0.81 5.41 0.0283 
Irx2 0.30 0.85 0.0283 
Masp1 0.47 1.33 0.0284 
Lsm12 1.39 3.82 0.0284 
Add2 0.55 2.59 0.0286 
Imp4 1.28 5.09 0.0286 
Chp2 0.46 1.22 0.0286 
Rnf122 0.83 6.11 0.0288 
Nhlrc2 0.84 6.44 0.0288 
Tmem9 0.79 4.82 0.0288 
Prpf40a 1.18 6.67 0.0288 
Btbd3 0.86 7.25 0.0289 
Sh2d4a 0.19 -1.62 0.0289 
Dnm3 0.62 2.75 0.0290 
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Plekhb2 0.72 4.06 0.0290 
Trp53i11 1.16 7.63 0.0290 
Prkab1 0.86 7.12 0.0291 
Ctnnal1 0.78 4.48 0.0291 
Bpgm 0.79 4.83 0.0291 
Gmip 0.75 4.05 0.0292 
Gm2a 0.61 2.66 0.0293 
Mustn1 0.67 3.18 0.0293 
Tram1l1 0.47 1.27 0.0293 
Comt 0.81 5.23 0.0293 
Pld3 0.78 4.95 0.0294 
Lmo2 0.87 7.56 0.0294 
Dnajc13 1.16 7.04 0.0294 
Lpp 1.17 7.97 0.0295 
Tnfrsf19 0.43 0.39 0.0296 
Ankrd13b 0.81 5.04 0.0296 
Slc46a3 1.41 3.61 0.0296 
Pygb 0.81 6.01 0.0296 
Ikzf4 0.29 -0.27 0.0297 
Tmco4 1.54 3.12 0.0297 
Nsmce1 1.23 5.27 0.0297 
Cldn18 0.39 3.00 0.0298 
Naa15 1.18 6.51 0.0299 
Pde4d 1.22 5.41 0.0300 
Sema6b 0.82 5.50 0.0300 
Smad5 1.15 8.01 0.0300 
Sumo3 1.18 6.51 0.0301 
Mob1a 1.18 6.44 0.0301 
Pnck 0.18 -1.56 0.0302 
Tmed2 1.20 5.74 0.0305 
Jmjd7 0.65 2.99 0.0305 
AI987944 1.47 3.22 0.0305 
Gypc 0.72 5.06 0.0305 
Rnd1 0.76 4.25 0.0305 
Ccdc88c 0.77 4.40 0.0305 
Tbkbp1 0.87 7.27 0.0305 
Nr4a1 0.86 8.79 0.0307 
Batf3 0.30 -0.24 0.0308 
9430069I07Rik 0.15 -1.98 0.0310 
Hoxa3 0.78 4.62 0.0310 
Mxra8 0.84 6.11 0.0310 
Celf2 0.63 2.72 0.0316 
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Mical1 0.76 4.35 0.0317 
Cd36 0.88 10.04 0.0317 
Gm10814 0.64 2.79 0.0318 
Camta1 0.73 3.80 0.0318 
Arhgap10 0.73 3.81 0.0318 
Abtb2 1.21 6.11 0.0318 
Dll1 0.83 7.44 0.0318 
Qsox1 0.85 6.82 0.0318 
Cracr2b 0.86 7.07 0.0318 
Ncaph2 1.16 7.14 0.0318 
Pcdh17 0.88 9.23 0.0318 
Mtmr9 1.22 5.67 0.0318 
Mast4 1.16 6.94 0.0318 
Prickle2 0.87 7.57 0.0318 
Alox12 1.50 3.90 0.0318 
Nuak2 0.79 4.94 0.0319 
Tagap1 1.32 4.15 0.0319 
Nfkbiz 0.87 8.17 0.0320 
Esco2 1.27 4.70 0.0321 
Prrg1 1.29 5.52 0.0321 
Vps4b 1.16 6.74 0.0321 
Aifm2 0.74 3.99 0.0321 
Bscl2 0.79 4.71 0.0322 
Hivep3 0.64 2.79 0.0323 
Mob3c 0.83 5.69 0.0323 
Abcb1a 1.16 7.40 0.0323 
Hmcn1 1.15 9.76 0.0323 
Fbxl19 1.19 5.83 0.0323 
Arap3 0.89 9.83 0.0323 
AW549877 1.19 6.11 0.0324 
Hoxa5 0.85 6.39 0.0324 
Col12a1 0.60 2.43 0.0325 
Fam110b 0.30 -0.26 0.0325 
Tnfaip2 1.31 4.71 0.0325 
Ralgds 0.86 6.81 0.0325 
Trappc13 1.22 5.52 0.0328 
Zscan18 0.47 1.20 0.0329 
Usp40 1.23 5.15 0.0329 
Stard10 0.46 1.16 0.0329 
Plxna1 0.86 8.30 0.0329 
St13 1.17 6.73 0.0332 
St3gal4 1.18 6.20 0.0332 
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Mink1 0.86 7.19 0.0332 
Rabgap1l 0.79 4.86 0.0333 
Arhgdib 0.77 4.32 0.0333 
Ppfibp1 0.87 7.61 0.0333 
Lgi3 0.54 1.40 0.0334 
Gnb4 0.84 5.91 0.0334 
Gltp 0.85 6.73 0.0334 
Cd93 1.12 11.48 0.0334 
Gm5144 1.52 2.95 0.0335 
Fam219aos 0.79 4.85 0.0335 
Nfix 1.16 6.97 0.0335 
Cd79b 0.18 -1.54 0.0335 
Insl3 0.64 2.72 0.0337 
Ago4 0.69 3.40 0.0337 
Kcne3 1.99 1.66 0.0339 
Egfem1 0.32 0.16 0.0339 
Hspg2 1.21 9.72 0.0339 
Dcp2 1.17 7.21 0.0339 
Dok4 0.87 7.38 0.0339 
Msrb2 0.66 2.98 0.0339 
Mxi1 1.22 5.44 0.0341 
Ddx11 1.32 4.19 0.0341 
Rftn1 0.81 5.58 0.0342 
Gm12696 1.19 5.85 0.0343 
Gadd45a 0.80 4.99 0.0345 
S100a16 0.88 8.05 0.0345 
Brsk1 0.39 0.78 0.0349 
St8sia4 1.17 7.11 0.0352 
Cggbp1 1.15 7.76 0.0353 
Crb3 0.18 -1.35 0.0353 
Ube2e2 0.63 2.68 0.0354 
Eif4h 1.13 8.63 0.0355 
Ing2 1.36 4.21 0.0356 
Ccnl2 0.86 7.44 0.0357 
Crim1 1.16 7.34 0.0357 
Adam9 0.80 5.37 0.0357 
Nploc4 1.18 6.25 0.0357 
Tmpo 1.13 8.93 0.0357 
St6gal1 0.85 6.15 0.0358 
Cldn7 0.31 0.14 0.0359 
Cpsf2 1.21 6.02 0.0359 
Tmbim1 0.86 6.37 0.0359 
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Rhod 0.44 1.05 0.0359 
Igf2os 1.76 2.26 0.0360 
Ank2 0.53 1.75 0.0360 
Sgk3 0.83 5.45 0.0360 
Rhpn1 0.25 -0.89 0.0360 
Cnrip1 0.69 3.50 0.0361 
Agt 0.38 0.05 0.0361 
Gtse1 1.29 4.38 0.0363 
Tmem141 0.32 -0.05 0.0364 
Nr4a3 0.60 2.90 0.0364 
Amot 0.83 5.33 0.0364 
Lpcat1 0.84 5.91 0.0364 
Kpna4 1.16 7.15 0.0364 
Ilk 0.87 7.26 0.0364 
Col6a3 0.72 3.33 0.0364 
Tmem57 1.17 6.42 0.0364 
Mitd1 1.29 4.71 0.0365 
Smndc1 1.18 6.10 0.0365 
Fam189a2 0.80 5.04 0.0366 
Akna 0.81 5.06 0.0366 
Selenom 0.75 4.07 0.0367 
Pde10a 1.60 2.66 0.0367 
Bend5 0.71 3.39 0.0367 
Efnb3 0.40 0.43 0.0367 
Abcg2 0.85 6.24 0.0367 
Ecm2 1.44 3.47 0.0367 
Supt16 1.16 6.67 0.0367 
Zfp36 0.88 9.60 0.0368 
Gas5 0.85 6.27 0.0368 
Atp9a 0.85 6.69 0.0369 
Brca1 1.25 5.15 0.0374 
Ajuba 0.81 5.07 0.0374 
Cd63 0.71 3.69 0.0375 
Foxd2os 1.37 3.79 0.0375 
Birc3 0.80 4.80 0.0376 
Fhod1 0.85 6.49 0.0376 
Kif26b 0.69 4.04 0.0376 
Phyh 0.54 1.85 0.0377 
Prkcd 0.71 3.44 0.0377 
Dapk2 0.46 1.11 0.0377 
Speg 0.38 0.50 0.0377 
Myom1 0.39 0.62 0.0377 
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Ciart 0.79 4.84 0.0377 
Yes1 1.16 7.92 0.0377 
Acvrl1 0.88 10.55 0.0377 
Lancl2 1.25 4.76 0.0377 
Dnajc8 1.15 7.01 0.0377 
Herc3 0.70 3.45 0.0378 
Rev3l 1.16 7.16 0.0379 
Setd6 0.58 2.10 0.0379 
Smim19 0.76 4.12 0.0380 
Amotl1 1.14 8.56 0.0380 
Sec24d 0.76 4.91 0.0381 
Zfp14 0.52 2.03 0.0382 
A730028G07Rik 0.57 2.11 0.0382 
Dolk 1.43 3.44 0.0382 
Slc35e1 1.16 6.82 0.0382 
Atp5sl 0.74 3.73 0.0382 
Wdr73 0.74 3.89 0.0382 
Thbs1 0.75 6.38 0.0384 
Samhd1 1.26 6.46 0.0384 
Car14 1.20 5.68 0.0384 
Ankrd17 1.14 7.36 0.0384 
2610507B11Rik 1.14 8.06 0.0384 
Scnn1a 0.54 1.91 0.0385 
Cyb561 0.85 6.71 0.0385 
Gprasp2 0.32 -0.24 0.0385 
Gfra2 0.43 0.77 0.0386 
Oxa1l 1.19 6.03 0.0386 
Dbn1 0.83 7.25 0.0386 
Mindy1 0.85 6.42 0.0386 
Dclre1a 1.37 3.65 0.0387 
Khdrbs3 0.30 -0.20 0.0387 
Tuba1b 1.14 7.80 0.0387 
Glmn 1.40 3.54 0.0387 
Ola1 0.76 4.45 0.0388 
Rgl1 0.87 7.30 0.0388 
Rnf8 1.25 4.67 0.0392 
Tomm40 1.19 5.65 0.0392 
Actg2 0.28 -1.00 0.0392 
Ndfip1 1.15 6.86 0.0392 
Jmjd6 0.85 6.27 0.0392 
Npnt 0.75 5.43 0.0392 
Pdha1 0.86 6.56 0.0393 
  Mechanisms of angiogenesis in development & disease 
 245 
Matn2 0.56 1.86 0.0394 
Hist3h2a 1.32 4.28 0.0394 
Plscr1 0.78 5.96 0.0394 
Kif1c 0.88 8.43 0.0394 
Myo5c 0.45 0.79 0.0395 
C330007P06Rik 1.23 5.34 0.0395 
Map3k15 0.82 5.04 0.0396 
Qrich1 1.16 6.55 0.0396 
Spon1 1.47 3.41 0.0396 
Erbb3 0.26 -0.88 0.0396 
Mycbp2 0.87 7.14 0.0396 
Lrrc59 1.15 7.68 0.0396 
Ccser1 0.67 2.93 0.0396 
Ddx58 1.21 7.05 0.0398 
Bcr 0.85 6.45 0.0398 
Ccdc120 0.55 2.04 0.0400 
Cyr61 0.85 7.80 0.0400 
Aspm 1.20 6.11 0.0402 
Mn1 1.28 4.55 0.0403 
Ehmt1 1.16 6.67 0.0403 
Casp4 0.61 2.88 0.0405 
Rnf157 1.28 4.31 0.0405 
Trim34a 1.26 4.76 0.0405 
Rnf187 1.14 7.80 0.0405 
Slc48a1 0.84 5.72 0.0406 
Ckap5 1.16 7.24 0.0406 
Fignl1 1.39 3.97 0.0406 
Zfp410 1.19 5.79 0.0406 
Zfr 1.15 7.10 0.0407 
Lpin1 0.70 3.42 0.0408 
Ralb 0.87 7.24 0.0409 
Ralgps2 0.75 4.08 0.0409 
Runx1t1 0.40 1.16 0.0411 
Ptpre 0.67 2.89 0.0411 
Cdc6 1.30 4.16 0.0411 
Sla2 1.21 5.20 0.0412 
Rttn 1.27 4.39 0.0414 
Cad 0.84 5.72 0.0414 
Ssbp4 0.87 7.27 0.0414 
Ppp1r3b 0.43 1.03 0.0414 
Scgb1a1 0.43 1.92 0.0415 
Fmnl2 0.85 6.19 0.0416 
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Yme1l1 1.15 6.86 0.0416 
Ccdc6 1.18 5.84 0.0416 
Ints6l 0.85 6.20 0.0417 
Ube2e1 0.80 4.75 0.0417 
Selenot 1.14 7.48 0.0417 
Ankrd33b 0.87 7.30 0.0418 
Cx3cl1 0.58 4.77 0.0419 
Asb13 0.69 3.62 0.0419 
Garnl3 0.77 4.28 0.0424 
Cdk1 1.17 6.42 0.0424 
Ackr4 0.59 2.42 0.0424 
Thoc2 1.16 6.91 0.0424 
Chst14 0.80 4.74 0.0426 
4930453N24Rik 1.29 4.39 0.0427 
Nod2 0.79 4.67 0.0427 
P3h4 0.81 4.98 0.0427 
Chtf8 1.15 6.96 0.0427 
Map1b 0.86 6.50 0.0428 
Trim59 1.23 5.21 0.0428 
Kremen1 0.85 6.19 0.0429 
Lipa 1.17 6.13 0.0430 
Acss1 0.35 -0.08 0.0431 
Rab20 0.30 -0.41 0.0431 
Arfip2 1.17 6.07 0.0431 
Prpf19 1.15 7.05 0.0432 
Dctn2 0.88 7.53 0.0432 
Bex4 0.23 -0.98 0.0433 
Gm14322 0.35 0.05 0.0435 
Mapk11 0.82 5.29 0.0435 
Muc1 0.53 1.76 0.0436 
Tmem65 0.86 6.56 0.0436 
Stx3 0.86 6.67 0.0436 
G3bp2 1.14 7.42 0.0436 
Sox13 0.88 8.29 0.0436 
Acer3 1.23 5.57 0.0437 
Cd37 0.54 1.73 0.0438 
Shc4 1.99 1.36 0.0441 
Dmxl2 0.76 4.04 0.0441 
Ppm1b 1.22 4.96 0.0441 
F8 1.65 2.30 0.0441 
Ptprm 0.89 9.70 0.0443 
F2rl3 1.84 1.82 0.0444 
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Col24a1 0.30 -0.51 0.0444 
Hist1h2bc 1.30 4.21 0.0446 
Spc24 1.26 4.52 0.0447 
2600006K01Rik 0.19 -1.92 0.0447 
Mgat4a 0.67 3.05 0.0447 
Cdk7 1.22 5.03 0.0447 
Srsf1 1.14 8.19 0.0447 
Slc25a24 0.86 6.20 0.0450 
4930592A05Rik 0.55 1.65 0.0451 
Sowahc 0.82 5.54 0.0451 
Mcm7 1.18 6.17 0.0452 
Nsmf 0.86 6.19 0.0452 
Kat2b 1.16 6.92 0.0452 
Tubb2a 1.14 7.59 0.0453 
Msi2 1.16 6.92 0.0455 
Htra2 0.81 4.85 0.0455 
Eif1ad 1.20 5.52 0.0455 
Plk4 1.19 5.67 0.0455 
E330009J07Rik 0.52 1.70 0.0456 
Lgals4 0.62 2.44 0.0456 
Tsn 1.16 6.36 0.0456 
Zfas1 0.82 5.11 0.0457 
Prkd1 0.78 4.91 0.0457 
Kdelc2 0.83 5.31 0.0457 
Gkap1 1.21 5.29 0.0457 
Adar 1.15 7.43 0.0458 
Fam174b 0.79 4.63 0.0459 
Sardh 0.82 4.96 0.0459 
Fam149a 0.80 4.70 0.0460 
Col6a2 0.63 3.87 0.0462 
Trappc10 0.85 6.14 0.0462 
Smu1 1.17 6.09 0.0463 
Ubn2 1.27 6.27 0.0465 
Npm1 1.18 6.08 0.0466 
Tbc1d8 0.81 5.97 0.0466 
Eif2ak2 1.21 6.60 0.0468 
Ccdc184 0.38 0.36 0.0468 
Rarb 0.69 3.09 0.0469 
Zfp811 0.20 -1.65 0.0469 
Maea 1.16 6.81 0.0470 
Kpnb1 1.13 8.68 0.0470 
Lama1 0.76 6.44 0.0472 
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Rnf150 0.30 -0.28 0.0472 
Naa30 1.20 5.82 0.0472 
Prosc 0.80 4.73 0.0474 
Dnajc1 0.86 6.13 0.0474 
Slc25a23 0.70 3.35 0.0476 
Cyp1b1 1.51 2.71 0.0477 
Fam57b 0.53 1.54 0.0480 
Ctnnb1 1.11 10.62 0.0480 
Pdlim1 0.86 6.43 0.0482 
Ezr 0.86 6.27 0.0482 
Tax1bp1 1.14 8.27 0.0483 
Il15ra 0.63 2.72 0.0483 
Reln 0.86 6.19 0.0483 
Foxc2 1.57 2.46 0.0484 
Tdrp 0.76 4.02 0.0484 
Iffo1 0.83 5.17 0.0484 
Man2a2 0.86 6.22 0.0484 
Ptgr1 0.57 1.87 0.0484 
Col27a1 0.55 1.59 0.0488 
Gprasp1 0.79 4.41 0.0490 
Wdr36 1.24 5.07 0.0490 
Arf6 1.13 8.12 0.0491 
Wdr19 1.43 3.40 0.0492 
Rangap1 1.15 6.66 0.0495 
Dpy19l3 1.20 5.49 0.0496 
Gm8008 0.25 -0.77 0.0496 
Pabpc4l 0.59 2.11 0.0497 
Bmp6 0.82 7.78 0.0497 
4930579G24Rik 1.45 3.15 0.0498 
Mfhas1 0.87 6.46 0.0498 





Table 8.2. Downregulated genes for KEGG pathway analysis shown in Figure 4.2a 
N refers to total number of genes in the pathway that are present in the filtered RNA-sequencing data, N Down refers to the number of genes that are 
downregulated from the total genes related to the pathway. P.down refers to the FDR for downregulated genes in the pathway in Hbo1iEC/iEC lung ECs 
 
Pathway N N Down P.Down Downregulated genes 
ECM-receptor 
interaction 
68 20 0.000 Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Col1a1, Itga3, Itgb5, Lama1, Lamc3, Itga4, 
Thbs1, Sdc4, Npnt, Tnc, Cd36, Reln, Itga9, Col4a5 
Protein digestion and 
absorption 
55 13 0.000 Col4a4, Col4a3, Col6a3, Atp1b1, Col6a2, Col1a1, Slc1a1, Col5a1, Col24a1, Col27a1, 
Slc1a5, Col12a1, Col4a5 
PI3K-Akt signaling 
pathway 
269 35 0.000 Sgk3, Irs1, Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Erbb3, Flt4, Pik3r6, Col1a1, 
Itga3, Syk, F2r, Gng2, Osmr, Nr4a1, Itgb5, Lama1, Fgf1, Ppp2r5b, Lamc3, Itga4, Thbs1, 
Gnb4, Tnc, Tlr4, Reln, Il4ra, Vegfc, Jak3, Gnb5, Itga9, Col4a5 
Lysosome 110 18 0.000 Gnptab, Cd63, Gm2a, Gaa, Galc, Lgmn, Cltb, Ctsl, Laptm4b, Lamp3, Gnptg, Ctsz, Ctso, 
Ppt1, Napsa, Ctsc, Gga2, Ctsd 
Focal adhesion 173 24 0.001 Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Flt4, Col1a1, Itga3, Itgb5, Lama1, Lamc3, 
Itga4, Thbs1, Myl9, Src, Tnc, Reln, Ilk, Vegfc, Bcar1, Birc3, Itga9, Col4a5 
Cytokine-cytokine 
receptor interaction 
134 20 0.001 Il18r1, Inhbb, Bmp6, Tnfrsf19, Osmr, Lifr, Csf2rb, Acvrl1, Il1rap, Tnfsf9, Il15ra, Acvr2a, 
Tnfsf15, Cxcl15, Cxcl1, Il17rc, Il4ra, Cx3cl1, Ackr4, Il13ra1 




Pathways in cancer 431 47 0.001 Col4a4, Col4a3, Ralb, Lamc2, Lamb3, Bcr, Flt4, Itga3, Stat5a, Axin2, Adcy3, Gadd45g, 
Dapk1, F2r, Rarb, Gng2, Wnt5a, Csf2rb, Dll1, Lama1, Epas1, Fgf1, Pmaip1, Rasgrp2, 
Il15ra, Ralgds, Lamc3, Gnb4, Gstm1, Runx1t1, Dvl1, Gnai1, Gadd45a, Rasgrp4, Arnt2, 
Il4ra, Vegfc, Jak3, Ednra, Hhip, Cdh1, Agt, Birc3, Dapk2, Gnb5, Il13ra1, Col4a5 
Axon guidance 160 22 0.001 Sema4c, Epha4, Efnb3, Unc5a, Wnt5a, Sema5a, Plxnb2, Rnd1, Robo2, Sema6b, Sema6a, 
Ssh3, Rhod, Myl9, Src, Sema6c, Gnai1, Slit2, Plxna1, Ilk, Sema7a, Sema3f 
Cell adhesion molecules 
(CAMs) 




116 17 0.002 Ralb, Dnm3, Plpp2, Dgka, Pik3r6, Pld2, Adcy3, Syk, F2r, Ptk2b, Cyth4, Agpat4, Ralgds, 
Pla2g4b, Agpat5, Agt, Mras 
Neuroactive ligand-
receptor interaction 




44 9 0.002 Pfkl, Pfkp, Pfkm, Acss1, Adh1, Bpgm, Hk2, Ldhb, Pdha1 
Ether lipid metabolism 30 7 0.003 Plpp2, Pld2, Gdpd1, Lpcat1, Pla2g16, Pla2g4b, Pld3 





Table 8.3. Top 100 Gene Ontology terms (biological processes) as shown in Figure 4.2b 
N refers to total number of genes in the pathway that are present in the filtered RNA-sequencing data, N Down refers to the number of genes that are 
downregulated from the total genes related to the term. P.down refers to the FDR for downregulated genes for the term in Hbo1iEC/iEC lung ECs 
Term N Down Proportion 
Down 
P.Down -10log(p-value) 
signaling 3650 391 10.7 4.41E-27 263.6 
cell communication 3687 393 10.7 8.46E-27 260.7 
biological adhesion 947 149 15.7 5.85E-24 232.3 
cell adhesion 938 148 15.8 6.38E-24 232.0 
signal transduction 3371 349 10.4 1.03E-20 199.9 
multicellular organismal process 4551 437 9.6 1.46E-20 198.4 
response to stimulus 5332 491 9.2 4.88E-20 193.1 
biological regulation 7604 642 8.4 1.63E-19 187.9 
regulation of multicellular organismal process 2243 253 11.3 5.90E-19 182.3 
regulation of localization 2028 233 11.5 2.62E-18 175.8 
localization 4231 403 9.5 9.75E-18 170.1 
anatomical structure development 3959 380 9.6 5.43E-17 162.7 
system development 3240 325 10.0 8.14E-17 160.9 
anatomical structure morphogenesis 1979 224 11.3 8.93E-17 160.5 
developmental process 4215 398 9.4 9.21E-17 160.4 
regulation of cell adhesion 524 89 17.0 1.44E-16 158.4 
cell migration 1076 144 13.4 1.46E-16 158.4 
cellular response to stimulus 4456 414 9.3 2.29E-16 156.4 
locomotion 1296 163 12.6 3.76E-16 154.2 
cell motility 1160 150 12.9 6.50E-16 151.9 
localization of cell 1160 150 12.9 6.50E-16 151.9 
 
 252 
regulation of biological process 7214 600 8.3 2.35E-15 146.3 
movement of cell or subcellular component 1450 174 12.0 2.93E-15 145.3 
multicellular organism development 3639 346 9.5 1.79E-14 137.5 
regulation of signaling 2346 246 10.5 1.89E-14 137.2 
regulation of response to external stimulus 512 83 16.2 2.50E-14 136.0 
regulation of cellular process 6785 567 8.4 2.58E-14 135.9 
inflammatory response 402 71 17.7 2.68E-14 135.7 
regulation of developmental process 1964 213 10.8 6.70E-14 131.7 
regulation of biological quality 2721 273 10.0 9.36E-14 130.3 
system process 1010 130 12.9 1.10E-13 129.6 
regulation of cell communication 2327 241 10.4 1.60E-13 127.9 
cell surface receptor signaling pathway 1691 189 11.2 1.60E-13 127.9 
cell differentiation 2827 277 9.8 1.03E-12 119.9 
response to chemical 2560 255 10.0 2.09E-12 116.8 
cellular developmental process 2982 287 9.6 2.87E-12 115.4 
regulation of anatomical structure morphogenesis 827 109 13.2 3.06E-12 115.1 
regulation of cellular component movement 800 106 13.3 4.53E-12 113.4 
regulation of response to stimulus 2701 264 9.8 6.15E-12 112.1 
animal organ development 2337 235 10.1 8.49E-12 110.7 
chemotaxis 367 62 16.9 9.05E-12 110.4 
negative regulation of multicellular organismal process 930 117 12.6 1.01E-11 110.0 
taxis 369 62 16.8 1.15E-11 109.4 
positive regulation of cell adhesion 310 55 17.7 1.99E-11 107.0 
negative regulation of response to external stimulus 225 45 20.0 2.28E-11 106.4 
regulation of cell migration 708 95 13.4 3.19E-11 105.0 
 
 253 
regulation of multicellular organismal development 1550 169 10.9 3.37E-11 104.7 
regulation of cell motility 737 97 13.2 5.86E-11 102.3 
regulation of locomotion 791 102 12.9 5.98E-11 102.2 
regulation of transport 1323 149 11.3 5.98E-11 102.2 
regulation of signal transduction 2072 210 10.1 8.03E-11 101.0 
cell-cell adhesion 513 75 14.6 8.26E-11 100.8 
response to external stimulus 1400 155 11.1 8.38E-11 100.8 
cell-substrate adhesion 270 49 18.1 1.12E-10 99.5 
transport 3079 287 9.3 1.24E-10 99.1 
positive regulation of multicellular organismal process 1337 149 11.1 1.30E-10 98.9 
defense response 859 107 12.5 1.55E-10 98.1 
cell morphogenesis involved in differentiation 594 82 13.8 1.94E-10 97.1 
regulation of cell differentiation 1382 152 11.0 2.16E-10 96.7 
cellular process 10218 765 7.5 4.80E-10 93.2 
negative regulation of biological process 3919 346 8.8 5.28E-10 92.8 
establishment of localization 3187 291 9.1 8.78E-10 90.6 
supramolecular fiber organization 551 76 13.8 9.65E-10 90.2 
regulation of peptide secretion 335 54 16.1 1.20E-09 89.2 
cell morphogenesis 813 100 12.3 1.31E-09 88.8 
actin filament-based process 597 80 13.4 1.36E-09 88.7 
secretion 784 96 12.2 3.65E-09 84.4 
actin cytoskeleton organization 536 73 13.6 3.67E-09 84.4 
regulation of protein secretion 317 51 16.1 3.75E-09 84.3 
regulation of catalytic activity 1382 147 10.6 4.60E-09 83.4 
cell-cell signaling 958 111 11.6 4.83E-09 83.2 
 
 254 
peptide secretion 417 61 14.6 4.99E-09 83.0 
negative regulation of cellular process 3552 314 8.8 5.20E-09 82.8 
intracellular signal transduction 1933 191 9.9 5.96E-09 82.2 
regulation of hydrolase activity 714 89 12.5 5.98E-09 82.2 
regulation of inflammatory response 212 39 18.4 6.07E-09 82.2 
positive regulation of biological process 4351 370 8.5 1.07E-08 79.7 
cell development 1648 167 10.1 1.18E-08 79.3 
regulation of molecular function 1887 186 9.9 1.21E-08 79.2 
regulation of secretion 564 74 13.1 1.45E-08 78.4 
tissue development 1372 144 10.5 1.63E-08 77.9 
cellular component morphogenesis 889 103 11.6 1.84E-08 77.3 
positive regulation of response to stimulus 1507 154 10.2 2.86E-08 75.4 
protein secretion 396 57 14.4 2.88E-08 75.4 
myeloid leukocyte activation 116 26 22.4 3.43E-08 74.6 
circulatory system process 321 49 15.3 4.28E-08 73.7 
regulation of peptidase activity 264 43 16.3 4.39E-08 73.6 
positive regulation of macrophage cytokine production 8 7 87.5 4.39E-08 73.6 
blood circulation 312 48 15.4 4.60E-08 73.4 
regulation of cell morphogenesis 422 59 14.0 4.74E-08 73.2 
actin filament organization 332 50 15.1 4.85E-08 73.1 
regulation of system process 393 56 14.2 5.43E-08 72.7 
biological_process 13079 919 7.0 5.87E-08 72.3 
anatomical structure formation involved in morphogenesis 877 100 11.4 6.74E-08 71.7 
regulation of secretion by cell 532 69 13.0 7.17E-08 71.4 
cellular response to chemical stimulus 1921 185 9.6 7.56E-08 71.2 
 
 255 
regulation of neuron projection development 470 63 13.4 8.11E-08 70.9 
positive regulation of signaling 1225 129 10.5 8.49E-08 70.7 
positive regulation of developmental process 1105 119 10.8 8.61E-08 70.7 




Table 8.4. Up- and downregulated genes in Hbo1iEC/iEC lung ECs used to construct barcode plots 




Fn1, Itga2, Itga1, Lama3, Hspg2, Comp Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Col1a1, Itga3, 




Fn1, Fyn, Rock2, Itga2, Itga1, Lama3, Shc4, Shc1, Rap1a, 
Pik3r3, Flnc, Ccnd1, Comp, Ctnnb1 
Col4a4, Col4a3, Col6a3, Lamc2, Lamb3, Col6a2, Flt4, Col1a1, 
Itga3, Itgb5, Lama1, Lamc3, Itga4, Thbs1, Myl9, Src, Tnc, Reln, 




F11r, Nlgn2, H2-T22, Vcam1, Glg1 Cldn7, Nrcam, Cldn5, Alcam, Ptprm, Itga4, Sdc4, Cdh4, Ptprf, 
Sdc3, Cdh1, Jam3, Cd276, Cldn18, Itga9 
 
 
